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The role of enthesitis in the pathogenesis of psoriatic arthritis has been 
increasingly recognised in the last twenty years.  High resolution imaging 
techniques and histology have shown that the distal interphalangeal (DIP) 
joint extensor tendon is directly anchored to the nail.  More recently, it has 
become apparent that a significant proportion of asymptomatic psoriasis 
patients have subclinical enthesitis at sites such as the Achilles tendon.  
This thesis explored the hypothesis that nail disease without clinical 
arthritis was associated with DIP joint enthesopathy and that nail disease 
equated with remote systemic enthesopathy.   
Imaging studies utilising magnetic resonance imaging (MRI) of the DIP joint 
confirmed the relationship between enthesitis and nail disease in psoriatic 
arthritis, and found subtle enthesitis and osteitis in psoriasis patients.  High 
resolution ultrasound that has an intrinsically greater resolution than MRI 
showed extensor tendon enthesopathy of the DIP to be common in 
psoriasis patients with nail disease, but not those without nail disease.  It 
was also shown that nail disease in psoriasis patients without arthritis was 
associated with sonographically-determined remote enthesopathy in the 
lower limbs.  In a small pilot study (N=9), despite clinical improvements 
MRI showed ongoing inflammation in and around the DIP joint after six 
months treatment with a TNF inhibitor.    
The long term outlook of DIP joint psoriatic arthritis was studied, with a 
review of a cohort of patients at a mean of nine years after a baseline MRI 
scan.  This demonstrated joint space narrowing in the majority of patients.  
The development of arthritis mutilans or ankylosis was seen in a minority, 
but without a close correlation with baseline MRI findings. 
Collectively these findings show a link between nail disease in psoriasis 
patients and both local and systemic subclinical enthesopathy.   
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The seronegative spondyloarthropathies (SpA) are a group of inflammatory 
arthritides which include psoriatic arthritis (PsA), ankylosing spondylitis 
(AS), reactive arthritis, enteropathic arthritis and undifferentiated SpA.  
Psoriatic arthritis was first described as a clinical entity distinct from 
rheumatoid arthritis (RA) by the late Professor Verna Wright in the 1950s 
(Wright 1978).  Psoriasis is a common skin condition occurring in 
approximately 2% of the population (Stern et al. 2004; Gelfand et al. 
2005b).  Approximately 20 – 40% of psoriasis patients develop PsA and 
currently there is no means to predict in an individual psoriasis patient 
whether they will go on to develop PsA. 
 
Recent descriptions of inflammation at ligament and tendon insertions, or 
enthesitis, being a primary pathology in the spondyloarthropathies has led 
to increased interest in understanding the disease processes.  The finding 
of enthesitis in areas such as the Achilles tendon in psoriasis patients 
without arthritis or arthralgia also supports the concept that psoriasis is 
‘more than skin deep’ – in other words that patients with psoriasis have 
multi-organ involvement (Scarpa et al. 2006a; Gisondi et al. 2008).  This 
includes increased cardiovascular risk, obesity, lipid abnormalities and 
psychological morbidity.  However, the significance of the enthesitis in 
patients with psoriasis is still not clear. 
 
Historically it has been noted that nail disease is more strongly associated 
with PsA than psoriasis (Wright 1956).  Imaging studies in PsA have shown 
the nail to be closely associated with the entheses of ligaments and 
tendons around the distal interphalangeal (DIP) joint (Tan et al. 2007).  
Little is known about the pathogenesis of nail disease in psoriasis patients.  
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Historically it has been suggested that some nail lesions may relate to 
psoriatic plaques in the nail bed (Zaias 1990).  The recent finding that nail 
disease in PsA is associated with DIP joint arthritis and enthesitis raises 
the question as to whether the same processes are true in psoriasis.  
Certainly a substantial proportion of psoriasis patients report nail pain (de 
Jong et al. 1996), but the origin of the pain is not yet understood.  Detailed 
imaging of these structures may allow us to understand the pathogenesis 
of nail disease in both PsA and psoriasis, and to study whether nail disease 
in psoriasis is related to local DIP joint enthesitis. 
 
Modern treatment options for PsA include non-steroidal anti-inflammatory 
drugs, disease modifying drugs and TNF antagonists.  These treatments 
are largely borrowed from rheumatoid arthritis, and primary outcomes 
assessed in clinical trials tend to assess articular disease.  Nonetheless, 
efficacy has been shown in enthesitis and nail disease, both as secondary 
outcomes (Ash et al. 2012a).  Indeed improvements in nail disease can be 
dramatic, and perhaps surprising when they occur in patients with severely 
damaged DIP joints where you might imagine the nail matrix is also 
damaged beyond repair. 
 
In common with spinal and sacroiliac joint disease, DIP joint disease in PsA 
is associated with a diffuse pattern of bone marrow oedema (BMO) when 
seen on magnetic resonance imaging (MRI) (Tan et al. 2006a).  This BMO 
has been shown at other sites such as the sacroiliac joint to represent an 
osteitis (Bollow et al. 2000; Marzo-Ortega et al. 2007b) and to be 
associated with the development of future radiographic AS (Bennett et al. 
2008).  It is however unknown whether osteitis in the DIP joint progresses 
to arthritis mutilans and whether it is also linked to nail disease.  
 
This thesis aims to study the relationship between enthesopathy and nail 
disease in detail, to improve our understanding of the pathogenesis of nail 
disease in psoriasis patients and to assess whether nail disease might be a 
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clinical marker for those patients who have imaging evidence of subclinical 
enthesitis.  Both MRI and ultrasound (US) will be used in order to study 
both the peripheral entheses and the microenvironment of the DIP joint. 
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The structure of this thesis can be summarised as follows: 
 
Chapter Two  Review of the literature 
This chapter overviews psoriasis and psoriatic arthritis, including the 
epidemiology, pathogenesis and treatment of the different forms of the 
disease.  The pathogenesis of nail disease is explored, and imaging 
methods and techniques used in the assessment of psoriatic disease are 
reviewed. 
 
Chapter Three Aims and objectives 
This chapter sets out the research questions and hypotheses for the thesis. 
 
Chapter Four Ultrasound imaging of the peripheral entheses in 
psoriasis patients 
In this chapter the relationship between subclinical ultrasound enthesitis 
and nail disease is assessed in psoriasis patients. 
 
Chapter Five   Comparison of the ultrasound appearances of 
peripheral enthesitis in psoriasis and psoriatic 
arthritis patients and healthy controls 
The characteristics of ultrasound-determined enthesopathy are here 
compared between psoriasis patients, those with PsA and healthy controls. 
 
Chapter Six  High resolution magnetic resonance imaging of the 
distal interphalangeal joint and nail in psoriasis 
and psoriatic arthritis 
Studying the DIP joint in detail, the relationship between nail disease and 
local enthesopathy and bone changes is explored using MRI. 
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Chapter Seven Ultrasound imaging of the nail and distal 
interphalangeal joint and nail in psoriasis and 
psoriatic arthritis 
In this chapter the ability of ultrasound to assess the nail plate and matrix is 
assessed, in comparison to clinical assessment. 
 
Chapter Eight Imaging of psoriatic nail disease pre and post TNF 
inhibitor therapy 
The known clinical response of nail disease to TNF inhibitors is examined 
further, using MRI to study changes in the bone and entheses before and 
during treatment. 
 
Chapter Nine  An assessment of high resolution magnetic 
resonance imaging of distal interphalangeal joint 
psoriatic arthritis for predicting radiographic joint 
destruction at nine years 
This chapter reviews the long term outcomes of a cohort of patients who 
underwent high resolution MRI for active DIPJ arthritis, assessing their 
radiographic progression over time. 
 
Chapter Ten  Discussion and future directions 
The results presented in all chapters are reviewed and discussed in the 
context of new literature and data available.  Future avenues for research 
are explored, in particular the prediction of which psoriasis patients will 
later develop psoriatic arthritis. 
 
Chapter Eleven Conclusions 








2.1.1. Epidemiology  
 
Psoriasis is a common skin disease, occurring in approximately 2% of the 
population (Stern et al. 2004; Gelfand et al. 2005b).  Although initial clinical 
presentations vary, the majority of patients go on to develop chronic plaque 
psoriasis.  The severity of psoriasis in an individual can fluctuate.  Flares of 
psoriasis have been linked to streptococcal infections (especially guttate 
psoriasis), stress, hormonal changes and medications such as lithium, 
beta-blockers and anti-malarials (Fry 1988; Gudjonsson et al. 2007).  
Psoriasis is found throughout the world, with prevalence estimates ranging 
from 0% in Samoan and South American Indian populations, to 4.8% in 
Norway (a patient-reported estimate) (Gudjonsson et al. 2007).  Rates for 
psoriasis are equal in males and females (Fry 1988).  It is rare in infants, 
presents in most individuals between the teenage years and the age of 30 
but can occur at any age (Fry 1988; Gudjonsson et al. 2007).  Patients 
presenting at an early age with psoriasis are more likely to have severe 
disease, a positive family history and psoriasis-associated HLA subtypes 
(Gudjonsson et al. 2007). 
   
2.1.2. Pathology  
 
Psoriasis most commonly occurs as raised erythematous skin plaques with 
clearly demarcated borders and a scaly surface.  The underlying 
pathological changes are abnormal proliferation and differentiation of 
keratinocytes, with T cell infiltrates in the dermis and epidermis.  Within the 
- 25 - 
 
 
psoriatic plaque, superficial dermal microvessels are elongated, tortuous 
and widened, while uninvolved skin in the same subject does not show 
these changes (Hern et al. 2007). 
Psoriasis is part of a disease spectrum, with several phenotypes of 
psoriasis being described as well as associations with a particular form of 
arthritis (Psoriatic Arthritis, PsA) and co-morbidities including obesity and 
increased cardiovascular risk.  This has led to the term ‘psoriatic disease’ 
to explain the varied features that different patients may present with 
(Figure 1) (Scarpa et al. 2006a). 
 
Figure 1.  The spectrum of psoriatic disease 
 
2.1.3. Burden of disease  
 
Psoriasis may have a major impact on a patient’s life, affecting their quality 
of life, employment and self esteem (Wu et al. 2009; Magin et al. 2010).  
The application of treatments also takes significant time (Devaux et al. 
2012).  Relationships are frequently affected, with psoriasis patients 
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describing a marked impact on their sexual relationships and intimacy 
(Magin et al. 2010).  When psoriasis is severe (such as with erythroderma 
or widespread plaque disease) it may result in hospitalisations and severe 
systemic illness (Condon et al. 1994).  In a Canadian study, the mean 
annual cost of psoriasis was $7999 per patient, with direct healthcare-
associated costs accounting for 57% of this and lost productivity the 
remainder (Levy et al. 2012).  Costs were higher in patients with more 
severe disease. 
 
2.1.4. Systemic manifestations of psoriasis 
 
Several large studies have now demonstrated a relationship between 
psoriasis and an increased risk of the metabolic syndrome, hypertension, 
hypercholesterolaemia, obesity and depression (Cohen et al. 2010; Schmitt 
et al. 2010; Love et al. 2011).  Obesity is more prevalent in patients with 
psoriasis but is also noted to be present prior to the development of 
psoriasis as an independent risk factor (Herron et al. 2005; Setty et al. 
2007; Wolk et al. 2009).  There has also been demonstration of an 
association between body mass index and psoriasis severity, with 
reductions in the PASI with weight loss (Huang et al. 2010; Hossler et al. 
2011).  A recent study using positron emission tomography (PET) found 
that psoriasis patients had significant uptake not just in the musculoskeletal 
system but also the liver, in keeping with the known association with fatty 
liver disease (Miele et al. 2009; Mehta et al. 2011; Tsai et al. 2011).  
Psychological morbidity is common, including depression, anxiety and an 
increased rate of suicide (Magin et al. 2009; Kurd et al. 2010; Han et al. 
2011),  
 
2.1.5 Clinical assessment 
 
Clinical assessment of psoriasis should take into account the phenotypic 
type of psoriasis (such as plaque, guttate, palmar-plantar).  The distribution 
of lesions is important, partly because of the prognostic implications of 
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lesions in certain areas for the development of PsA (Wilson et al. 2009a) 
but also because psoriasis in body areas such as the face and genitals 
may have more functional and psychological impact than psoriasis in other 
areas.  
Several tools are available for the documentation of psoriasis severity and 
distribution.  The simplest is the Body Surface Area (BSA) which only 
assesses the percentage of the body surface area currently affected by 
psoriasis, without grading the severity of lesions.  This uses the ‘rule of 
nines’ made popular in the assessment of burns (Wallace 1951).  Using 
this method, the arms are approximately 20% of the BSA, the legs 40%, 
the trunk 30% and the head 10%.  A simple way to assess this has been 
developed, where the surface of the patient’s own hand (palm and fingers) 
is used to equate to approximately 1% of the BSA.  This allows more rapid 
estimation of plaques.  This method may however overestimate the BSA as 
a study has found that the size of the hand equates to between 0.51 and 
0.91% of the BSA (Long et al. 1992).  An international reliability exercise 
found moderate inter-rater reliability when assessed by both 
rheumatologists and dermatologists (Chandran et al. 2009).  Using the 
BSA, the FDA defines severe psoriasis as a BSA of more than 20%. 
The Psoriasis Area and Severity Index (PASI) is the most commonly used 
tool (Fredriksson et al. 1978).  In this method, the trunk, arms, legs and 
scalp are each assessed.  For each area, relative percentage involvement 
with psoriasis gives scores between 0 and 6.  Severity is then assessed as 
erythema, induration and desquamation, each graded using a scale from 0 
– 4 on a semi-quantitative basis.  The scores are then calculated together, 
but using a weighting to account for the relative BSA of each body area.  
The PASI has the advantage that it is relatively rapid to calculate, thus 
making it a feasible tool for clinical use.  It also assesses severity both in 
terms of the body surface area involved as well as the severity of the 
plaques themselves.  Given the weighting of the BSA in the PASI, 
limitations in the accuracy of BSA involvement do also affect the PASI.  
The other difficulty is the accuracy at either end of the spectrum of severity.  
With mild psoriasis, the PASI score is less accurate and is therefore 
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generally not used when the BSA is less than 3%.  Also, although the 
maximum possible score is 72, even with very severe widespread psoriasis 
it is unusual to score more than 40 and therefore the distribution of 
common scores is skewed. (Setty et al. 2007; Berth-Jones et al. 2008).   
The international reliability exercise performed by the Group for Research 
and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) members 
demonstrated substantial agreement between raters for the PASI 
(Chandran et al. 2009).  Substantial inter-rater and intra-rater reliability 
were also seen in a comparison study with other assessment methods 
(Berth-Jones et al. 2008).  Using the PASI, psoriasis severity may be 
divided into mild disease (PASI <3), moderate (PASI 3 – 10) or severe 
psoriasis (PASI >10). 
Given that other factors such as the location of the psoriasis plaques may 
impact on how severe the patient perceives their psoriasis to be, the 
National Psoriasis Foundation have also suggested definitions of mild, 
moderate and severe psoriasis which take into account the impact on the 
patient (Krueger et al. 2000). 
A simpler scale, the physician’s global assessment has also been 
described.  Here severity is scored as ‘clear’, ‘almost clear’, ‘mild’, ‘mild to 
moderate’, ‘moderate’, ‘moderate to severe’ and ‘severe’.  This can be a 
more subjective measure with some raters taking severity and distribution 
into account and others simply scoring severity of the plaques.  It is a static 
score; scoring current severity without reference to previous disease 
activity.  Moderate agreement between raters was demonstrated with this 
tool (Berth-Jones et al. 2008). This assessment method has been 
recognised by the FDA. 
A number of other assessment methods have been described but are not 
in frequent use (Mazzotti et al. 2003; Shikiar et al. 2003; Langley et al. 
2004; Berth-Jones et al. 2008).  One other important issue is that all of 
these assessment methods were developed only for the assessment of 
plaque psoriasis and therefore they have not been validated for the 
assessment of other psoriasis sub-types. 
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The effect of psoriasis on quality of life is most frequently assessed using 
the Dermatology Life Quality Index (DLQI) (Finlay et al. 1994).  This was 
developed in Cardiff for use in all skin diseases and includes ten questions, 
in which raters are asked to score how much their skin problem has 
affected their life from ‘not at all’ to ‘very much’.  This includes questions on 
how the skin disease restricts activities of daily life, symptoms such as 
itching as well embarrassment and the impact on relationships.  The DLQI 
has been used extensively in clinical trials and is included as a criterion to 
assess eligibility for TNF inhibitor therapy for psoriasis in the UK.  Good 
internal validity, construct validity, content validity and sensitivity to change 
have been demonstrated (Mazzotti et al. 2003; Shikiar et al. 2003).  A 
Rasch analysis found good internal reliability in psoriasis but poor 
responsiveness to change in patients with mild disease (Bronsard et al. 
2010).  The analysis did identify some problems with the questions and 
response thresholds.   
The Psoriasis Disability Index (PDI) was the first questionnaire designed 
specifically for psoriasis patients (Finlay et al. 1987).  The questionnaire 
has subsequently been validated and used in a variety of studies (Bronsard 
et al. 2010).  One of the limitations of this tool is that it is more focussed on 
symptoms, with less assessment of the quality of life.  A significant floor 
effect and lack of sensitivity have been noted in further studies (Nijsten et 
al. 2005; Fernandez-Penas et al. 2012). 
 
2.2  Psoriatic arthritis 
 
Although an association between psoriasis and arthritis was reported in 
1818 (Alibert 1818), it was Verna Wright who first described an association 
between a particular form of arthritis (PsA) and psoriasis (Wright 1956).   
The discovery that the majority of patients with PsA were negative for 
rheumatoid factor also cemented the distinction between PsA and RA 
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(Blumberg et al. 1964).  Clinical and radiographic differences help to 
differentiate PsA from osteoarthritis (OA) and RA (Table 1). 
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Table 1.  Clinical and radiographic differences between PsA, RA and OA 
 
 Psoriatic Arthritis Rheumatoid Arthritis Osteoarthritis 
Clinical 
features 
Pattern of joint 
involvement 





- may affect DIP joints 
 
- symmetrical polyarthritis sparing 
DIP joints 
- large joint disease 
- nodal disease predominantly 












- rheumatoid nodules 
- vasculitis 
- pulmonary involvement 
- none 
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 Psoriatic Arthritis Rheumatoid Arthritis Osteoarthritis 
Radiographic  
features 
- soft tissue swelling 
- joint space loss  
- bone proliferation  
- distal tuft resorption   
- marginal erosions  
- "pencil-in-cup"   
- osteolysis 
- ankylosis 
- soft tissue swelling  
- joint space narrowing  
- erosions (periarticular)  
- joint subluxation and 
malalignment 
- ulnar deviation of the fingers at 
the metacarpophalangeal joints  
- In very late RA, fusion or joint 
ankylosis may occur 
- joint space narrowing 
- osteophyte formation  
- subchondral sclerosis  
- subchondral cyst formation  
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2.2.1 Epidemiology  
 
Psoriatic arthritis has a prevalence of 0.1% in the general population, with a 
fairly equal prevalence in both sexes (Shbeeb et al. 2000; Wilson et al. 
2009b).  Estimates for the prevalence of PsA in patients with psoriasis 
vary, in part depending on the population studied but also the method used 
to identify PsA (Zachariae 2003; Gelfand et al. 2005a; Wilson et al. 2009b).  
In the majority of patients, the onset of arthritis follows the onset of 
psoriasis, often by many years.  Approximately 20% patients have a 
contemporaneous onset of psoriasis and arthritis and 20% develop arthritis 
as the first presentation (Gladman et al. 1987b; Jones et al. 1994).   
The risk of developing psoriatic arthritis has been shown to increase with 
the duration and the severity of the psoriasis (Gelfand et al. 2005a).  The 
presence of nail disease, scalp psoriasis and intergluteal psoriasis are also 
associated with PsA (Wilson et al. 2009a), but there are still no definitive 




The pathogenesis of PsA has been historically made more difficult to study 
because of the wide heterogeneity of clinical manifestations.  It is also 
difficult to conceptualise a common pathogenic mechanism for a disease 
which may cause erosions and bone lysis in some areas, and new bone 
formation in others.   
Psoriatic arthritis was initially presumed to be a synovial based pathology 
similar to RA.  Evidence for an autoimmune pathogenesis suggests that 
inflammation is driven by T cells reacting to either skin or synovial antigens 
(Haroon et al. 2012).  The synovium itself shows some differences from RA 
synovium, with similar numbers of macrophages, fibroblasts and cytokines, 
but significantly lower numbers of T cells (van Kuijk et al. 2006). 
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In the last decade however, it has been shown that enthesitis, or 
inflammation at insertions such as ligament or tendon attachments to bone, 
forms a unifying concept for PsA and the spondyloarthropathies 
(McGonagle et al. 1998a; McGonagle et al. 1999).   Enthesitis has been 
demonstrated to be a common clinically hidden finding in inflamed synovial 
joints (McGonagle et al. 1998b).   Osteitis is frequently seen adjacent to 
active enthesitis (McGonagle et al. 2002). An MRI study including 13 
patients with PsA found diffuse inflammation extending beyond the joint 
capsule in nine patients, including into the surrounding soft tissues and 
ligaments.  In one patient, the abnormalities were predominantly extra-
capsular, raising the possibility for the first time that the primary area of 
inflammation may not be synovial (Jevtic et al. 1995).  Data from an 
ultrasound study also suggests that PsA patients may have enthesitis in 
the absence of synovitis (Frediani et al. 2001).  The importance of these 
findings was acknowledged by the development of an MRI enthesitis 
scoring index to define treatment responses to biological therapy with the 
anti-TNF drugs in both the axial and peripheral skeleton (McGonagle et al. 
2000; Marzo-Ortega et al. 2005).  In dactylitis, imaging has shown 
widespread inflammation, with flexor tenosynovitis, bone marrow oedema, 
synovitis and soft tissue oedema (Coates et al. 2008a).   
The entheseal hypothesis suggests a biomechanical link between skin and 
joint disease, with inflammation localised to sites of tissue microdamage 
(McGonagle et al. 1999; McGonagle et al. 2000).   This is supported by the 
fact that both mechanical problems and degenerative disease may present 
a similar pattern on MRI to PsA (Kiuru et al. 2005; Tan et al. 2006a; 
Bennett et al. 2009).   Enthesis sites have also demonstrated microdamage 
and local inflammatory changes in healthy subjects (Benjamin et al. 2007a; 
McGonagle et al. 2009b; Aydin et al. 2010a).  Environmental influences are 
important with both Moll and Wright and the Toronto cohort amongst others 
reporting an association between the development of arthritis and trauma 
(Moll et al. 1973; Eder et al. 2011b). 
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2.2.3 Burden of disease 
 
Psoriatic arthritis is a heterogenous disease, but while some forms may be 
mild in their disease course, other patients will develop marked deformities 
and disability.  One prospective study found that 20% of patients developed 
joint damage and disability over time (Gladman et al. 1987b).  In patients 
with at least 5 year follow-up data available, the proportion of patients with 
at least 5 damaged joints increased from 19% to 41% (Gladman et al. 
1990).  A separate prospective study involving 180 patients found that 57% 
of patients had erosive disease on radiographs (Torre Alonso et al. 1991).  
In a comparison of 47 RA and PsA patients matched for disease duration, 
although greater levels of peripheral joint damage were seen in RA, the 
levels of functional disability and quality of life were the same in the two 
diseases (Sokoll et al. 2001).  Significant loss of productivity is seen, 
relating to sick leave, reduced working hours and time on benefits 




A detailed review of the genetics of psoriasis and PsA is beyond the scope 
of this thesis.  However, recent advances in genetic knowledge do shed 
some light on the role of the immune system in the development of PsA.  
The major histocompatibility complex (MHC) has been implicated most 
strongly, in particular HLA-Cw6 and the HLA-Cw*0602 allele.  This is 
associated with early onset psoriasis (Allen et al. 2005; Nair et al. 2006; 
Queiro et al. 2012b).  It is less associated with PsA than with psoriasis (Ho 
et al. 2007; Ho et al. 2008) and Cw6 negative patients are more likely to 
have scalp and nail psoriasis (Gudjonsson et al. 2002; Fan et al. 2007).  
Multiple genes in the IL23 pathway (thus with a role in the adaptive immune 
system) have been identified as being associated with PsA and psoriasis 
(Cargill et al. 2007).  IL12B has also been implicated (Liu et al. 2008).  A 
further GWAS study confirmed these associations as well as finding new 
associations within the NFκB pathway (TNF-α induced protein 3 (TNFAIP3) 
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and TNFAIP3 interacting protein 1 (TNIP1)) which are associated with 
general autoimmunity and the innate immune response (Nair et al. 2009).  
Within psoriasis patients, additional genes have been identified with a role 
in the barrier function of the skin (LCE3B and LCE3C) (Filer et al. 2008).  
Although there is clearly significant overlap in the genetics of psoriasis and 
PsA, some differences have been shown.  A higher rate of HLA B27 
carriage is seen in PsA patients with axial disease and of B38 and B39 in 
those with peripheral arthritis (Duffin et al. 2008).  IL13 also appears more 
strongly related to PsA than psoriasis (Bowes et al. 2011; Eder et al. 
2011a).  Despite these advances, the major part of the heritability of 
psoriatic disease is still unexplained. 
 
2.2.5 Diagnosis and classification 
 
The diagnosis of PsA is a clinical one, based on history, examination and 
the phenotype of disease.  To aid in research by producing a 
homogeneous population for study, a number of classification criteria have 
been developed.  The first of these were the Moll and Wright criteria, which 
have now largely been superseded by the ClASsification of Psoriatic 
ARthritis (CASPAR) criteria.  A number of other criteria have been 
proposed but not reached widespread use. 
The Moll and Wright criteria are simple and quick to use – requiring just 
three items; the presence of psoriasis, the finding of an inflammatory 
arthritis and (usually) a negative rheumatoid factor (Moll et al. 1973).  
These were probably developed more as diagnostic criteria.  The term 
inflammatory arthritis was deliberately broad, in order to encompass spinal 
disease.  Moll and Wright recognised that a proportion of patients may 
present with what phenotypically appears to be PsA, but have a positive 
rheumatoid factor and therefore a negative rheumatoid factor was not an 
absolute requirement.  This may however allow RA patients with co-
existent psoriasis to be classified as PsA.  These criteria are fairly broad, 
and do not include some particular features of PsA such as dactylitis which 
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may be useful in identifying patients and improving specificity.  One 
limitation of the Moll and Wright criteria is that skin psoriasis is an absolute 
requirement, but there is a proportion of patients who may either develop 
psoriasis later, or never have psoriasis.  The sensitivity in early PsA has 
also been shown to be lower than with the CASPAR criteria (Coates et al. 
2012). 
A modification of the Moll and Wright criteria was proposed by Gladman, 
largely to reduce the likelihood of RA patients with co-existent psoriasis 
being included.  This involved the addition of a number of exclusion criteria 
suggestive of RA (Gladman et al. 1987a).  Other criteria have been 
described by Bennett, Vasey and Espinoza, McGonagle, ESSG and 
Fournié (Bennett 1979; Vasey et al. 1984; Dougados et al. 1991; Fournié et 
al. 1999; McGonagle et al. 1999).  These criteria have not been widely 
used or validated, although during the development process of the 
CASPAR criteria, a comparison was made of these existing criteria in 
cohorts of RA and PsA patients (Taylor et al. 2004b).  This found that the 
most feasible and accurate were the Gladman modification of the Moll and 
Wright, the Vasey and Espinoza and the McGonagle criteria. 
The CASPAR criteria were developed by an international group of experts 
(Table 2) (Taylor et al. 2006).  The development process commenced with 
the recruitment of cohorts in a number of centres, each recruiting both 
cases (physician diagnosis) and controls.  The controls were recruited on 
the basis of having another form of inflammatory arthritis, and at least half 
of the controls were required to have RA.  Both patients and controls 
underwent a detailed clinical and laboratory assessment.  New 
classification criteria were derived using Classification and Regression 
Trees (CART) analysis to find the most discriminant items and the addition 
of some items found to be independently predictive using logistic 
regression.  In the initial analysis the sensitivity was 91.4% with a specificity 
of 98.7%.  With these criteria, it is now possible to be classified as having 
PsA in the absence of skin psoriasis, also in the presence of a positive 
rheumatoid factor if enough other criteria are satisfied.  
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Table 2.  The CASPAR criteria 
(Taylor et al. 2006) 
Inflammatory articular disease (joint, spine or entheseal) (mandatory) 
Plus, 3 or more points from the following: 
Evidence of current psoriasis, a personal history of psoriasis or 
a family history of psoriasis 
- Current psoriasis is defined as psoriatic skin or scalp 
disease present today as judged by a rheumatologist or 
dermatologist 
- A personal history of psoriasis is defined as a history of 
psoriasis that may be obtained from a patient, family 
physician, dermatologist, rheumatologist, or other 
qualified health care provider 
- A family history of psoriasis is defined as a history of 
psoriasis in a first or second degree relative according 









Typical psoriatic nail dystrophy including onycholysis, pitting 
and hyperkeratosis observed on current physical examination 
Score 1 
A negative test for the presence of rheumatoid factor by any 
method except latex but preferably by enzyme-linked 
immunosorbent assay or nephelometry, according to the local 
laboratory reference range 
Score 1 
Either current dactylitis, defined as swelling of an entire digit, 
or a history of dactylitis recorded by a rheumatologist 
Score 1 
Radiographic evidence of juxta-articular new bone formation, 
appearing as ill-defined ossification near joint margins (but 
excluding osteophyte formation) on plain radiographs of the 
hand or foot 
Score 1 
 
The CASPAR criteria have subsequently been validated in a number of 
other settings.  In a Chinese cohort of PsA and other arthritis patients the 
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sensitivity was 98.2% and the specificity was 99.5% (Leung et al. 2010).  A 
retrospective analysis of an existing research cohort found the criteria to be 
feasible to apply, with a sensitivity of 99.7% and a specificity of 99.1% 
(Tillett et al. 2012a).  In a family medicine clinic in Toronto, the sensitivity 
was 100% with a specificity of 98.8 (Chandran et al. 2008). 
A significant problem with the CASPAR criteria is the initial stem which 
requires the assessor to be confident of the finding of inflammatory articular 
disease.  This is very difficult to define further, although the GRAPPA group 
are working on this (Garg et al. 2012).  It makes it more difficult for non-
rheumatologists (such as dermatologists) to use the criteria as they may 
find this assessment difficult.   
One other concern was that the mean duration of disease in the initial 
cohort was 12.5 years and thus the criteria may not perform as well in early 
disease, but in fact the sensitivity of the criteria was 99.1% in an early 
disease cohort (mean disease duration of 1.1 year) in a tertiary care centre 
(Chandran et al. 2007).  As this was a tertiary care centre this may be an 
over-estimation.  A further validation in an early arthritis cohort (<24 months 
disease duration) found a sensitivity of 87.4% and a specificity of 99.1%.  
In the Leiden early arthritis clinic, the sensitivity of the CASPAR criteria was 
88.7%, with a specificity of 95.6%. 
In addition to the criteria developed for PsA itself, as PsA is one of the 
spondyloarthropathies patients may be classified using the ASAS 
peripheral SpA classification criteria (Rudwaleit et al. 2011).  Patients 
would meet these criteria in the presence of arthritis, enthesitis or dactylitis 
along with at least one or two other SpA features.  The disadvantage of 
using these criteria in PsA research is that the cohort identified will be more 
heterogeneous and may include patients with reactive arthritis or 




- 40 - 
 
 
2.2.6 Subtypes of psoriatic arthritis 
 
In the original descriptions of psoriatic arthritis by Moll and Wright, a 
number of subtypes of disease were described (Moll et al. 1973).  The five 
subgroups described are: 
 
- DIP predominant arthritis 
- Arthritis mutilans (with or without sacroiliitis) 
- Symmetrical polyarthritis similar to RA but without a positive 
rheumatoid factor 
- Asymmetrical oligoarthritis 
- Axial disease-predominant 
 
There is ongoing discussion as to whether these are in fact separate 
entities or a spectrum of manifestations and this may become clearer with 
further research, with full examination (clinical, laboratory, imaging, 
genetics) of cohorts of patients.  Moll and Wright did emphasize in the 
original description that there may be no clear division between the 
subgroups. 
Oligoarthritis may be more common in early PsA and some groups have 
described progression from one subgroup to another over the course of 
disease, in particular oligoarthritis to polyarthritis (Gladman et al. 1987a; 
Helliwell et al. 1991; Jones et al. 1994; Marsal et al. 1999; Khan et al. 
2003; Veerapen 2007).  The largest subgroup is generally polyarthritis, 
although this may be as it is more readily identified and thus diagnosed 
(Haroon et al. 2013), or this may be because in most cohorts, patients have 
established disease rather than early arthritis.  This is in contrast to the 
original description by Moll, where only 15% had polyarticular disease, but 
has been a consistent finding in more recent reports.  In the Toronto 
cohort, an association was noted between DIP disease and dactylitis, and 
between radiographic damage and DIP disease or polyarthritis (Gladman 
et al. 1987a). 
- 41 - 
 
 
2.2.7 Clinical assessment – joint counts, enthesitis, clinical 
assessment, dactylitis 
 
The majority of tools for the assessment of PsA were developed for use in 
RA and some although in common use have not been validated for the 
assessment of PsA.  In this section, available tools will be described and 
compared, along with their development and validation as appropriate. 
The assessment of the peripheral joints is performed by assessing for 
swelling and / or tenderness of each joint in turn.  In PsA, the most 
common joint count is the 68 tender and 66 swollen (this includes the DIP 
joints and assesses the hips for tenderness only).  The 28 joint count used 
in RA is not ideal in PsA as it may underestimate disease, in particular 
oligoarthritis and arthritis affecting the lower limbs (Fransen et al. 2006). 
A reliability exercise involving both dermatologists and rheumatologists 
found the overall ICC for the tender joint count to be 0.78 (substantial 
agreement) and for the swollen joint count 0.24 (fair agreement) (Chandran 
et al. 2009).  There was better agreement amongst rheumatologists for the 
swollen joint count (ICC 0.42) than dermatologists (ICC 0.31).  A separate 
reliability exercise found an ICC of 0.78 for the tender joint count and 0.50 
for the swollen joint count (Gladman et al. 2007a).  In clinical trials, joint 
assessments are frequently performed by other members of the multi-
disciplinary team and an assessment of reliability here has again shown 
poor reliability, particularly amongst inexperienced raters (Tillett et al. 
2012b).  Responsiveness to change has been demonstrated in a number 
of clinical trials. 
 
Although there are differences in the axial disease seen in PsA compared 
to AS, the majority of measures used to assess axial disease in clinical 
practice were developed for AS.  The tools most frequently used are the 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath 
Ankylosing Spondylitis Functional Index (BASFI) and the Bath Ankylosing 
Spondylitis Metrology Index (BASMI) (Calin et al. 1994; Garrett et al. 1994; 
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Jenkinson et al. 1994).  The BASDAI is a six point questionnaire for 
completion by patients and assesses pain and stiffness.  It has been tested 
in PsA and although it correlates well to patient-reported disease state, it 
does not differentiate well between axial disease and peripheral disease 
(Taylor et al. 2004a).  The BASFI is a ten point self-completed 
questionnaire and assesses function.  It has also been reported to correlate 
well to patient-reported outcomes but not differentiate well between spinal 
disease and peripheral arthritis (Leung et al. 2008).  Other measures of 
function may therefore be preferred.  The BASMI is a tool composed of a 
number of measurements of spinal mobility, which are then compared 
against expected values to create a score.  Some of the measurements in 
the BASMI have demonstrated excellent inter-observer agreement while 
others show poor agreement (Gladman et al. 2004). 
 
Enthesitis (inflammation at insertions such as ligament or tendon 
attachments to bone) is a characteristic feature of the 
spondyloarthropathies.  It is assessed clinically by noting tenderness or 
swelling at the enthesis.  A number of different scoring systems 
incorporating variable number of enthesis sites have been described.  The 
majority of these scoring systems were developed primarily for AS patients 
but have since been used in PsA.  The commonly used scores will be 
reviewed here (see also Table 3). 
The first enthesitis scoring system was described by Mander in 1987 
(Mander et al. 1987).  This was developed in AS patients and initially 
assessed both sites known to be frequently involved in AS but also 
potential other sites.  In a pilot assessment in six AS patients, sites that 
were not tender in any patient at any timepoint were discounted.  This left 
66 sites in the Mander Enthesitis Index (MEI).  Some of these sites were 
grouped and the highest score taken forward.  This included the nuchal 
crests, costochondral joints and the cervical, thoracic and lumbar spinous 
processes.  Each enthesis was graded for the degree of tenderness from 0 
(non tender) to 3 (wince or withdraw), giving a total score of 90.  The index 
was then tested by one observer on one cohort of patients and compared 
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to other existing methods of disease activity assessment, and on another 
cohort of patients with weekly assessments on and off medication by three 
observers.  The index took three minutes to complete per person in the 
original study.  A correlation was seen between pain and stiffness scores 
and the MEI and it appeared sensitive to change in therapy.  The principal 
limitation of the MEI is the complexity in terms of both number of sites to 
assess and the grading of the degree of tenderness, which may be 
subjective. 
The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) was 
developed as part of a simplification process from the MEI (Heuft-
Dorenbosch et al. 2003).  Data from the OASIS cohort was used, in which 
an enthesitis assessment was performed using the MEI.  An analysis was 
performed to find the enthesis sites most frequently recorded as being 
tender (reduced MEI), and then enthesis sites were excluded if they were 
difficult to localise or neighboured other sites already included (concise 
index).  Both of these indices were then also calculated using a 
dichotomous result for tenderness in place of the semi-quantitative scale.  
Further analysis found the concise index without grading of tenderness to 
perform the best and this was termed the MASES index.  The INSPIRE 
study found moderate agreement between assessors (ICC 0.56) with better 
performance in AS than PsA patients (Gladman et al. 2007a).  A 
comparative study using ultrasound in AS patients has shown a correlation 
between the MASES and both the total sonographic score and the 
sonographic score for acute enthesitis (Hamdi et al. 2011).  One limitation 
of the MASES is a floor effect due to the reduced number of sites assessed 
and thus it may miss patients with low level enthesitis elsewhere. 
The development of the Spondyloarthritis Research Consortium of Canada 
(SPARCC) enthesitis index proceeded along different lines, being based on 
sites noted in ultrasound and MRI studies to be common sites for enthesitis 
(Maksymowych et al. 2009).  This literature suggested 8 possible sites, 
each assessed bilaterally: the greater trochanter, quadriceps tendon 
insertion into the patella, patellar ligament insertion into the patella and 
tibial tuberosity, Achilles tendon insertion, plantar fascia insertion, medial 
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and lateral epicondyles and the supraspinatus insertion.  Tenderness was 
assessed as present or absent.  Validation of the index was performed on 
two cohorts of AS patients in Canada, to assess its performance against 
the OMERACT filter criteria of trust, discrimination and feasibility.  This 
confirmed the SPARCC index to be feasible and with reasonable reliability 
in AS patients.  The INSPIRE study found excellent agreement between 
assessors, with an ICC of 0.81 (Gladman et al. 2007a).  In AS patients, a 
correlation has been demonstrated between the SPARCC enthesitis index 
and the total sonographic enthesitis score (Hamdi et al. 2011). 
The Major enthesitis index was derived for use in AS clinical trials (Braun et 
al. 2002) and includes 12 entheseal sites.  Substantial agreement (ICC 
0.70) was seen between observers when assessing PsA patients in the 
INSPIRE study (Gladman et al. 2007a). 
The Gladman Index was described by a group from SPARCC in ten 
patients with PsA, using enthesis sites included in the MASES (Gladman et 
al. 2004).  These were the rotator cuff insertion at the shoulder, tibial 
tuberosity at the knee, Achilles tendon, and plantar fascia insertions in the 
calcaneus.  Fair to moderate reliability between ten assessors was 
demonstrated, with good agreement at the plantar fascia and tibial 
tuberosity.  A large effect size has been seen with treatment (Healy et al. 
2008b).  
The Leeds Enthesitis Index (LEI) was developed specifically for use in PsA 
(Healy et al. 2008b).  It was developed in a cohort of PsA patients with 
active disease (including enthesitis) who were embarking on a new 
therapy.  A clinical assessment was recorded at each time point, including 
the existing enthesitis indices.  An iterative process of data reduction was 
performed, to find the entheses which were noted to be tender the most 
frequently.   At each step, patients who had reported that enthesis as 
tender were excluded, until 80% patients were accounted for.  The 
corresponding contralateral entheses were also included in the index.  This 
gave a simple enthesitis index of just six sites and thus is the quickest 
measure to use.  Data from the cohort showed significant change from 
baseline with treatment with a good effect size, and a minimal floor effect.  
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It correlated well with other disease activity measures.  A validation study 
using ultrasound found a poor relationship between clinical and ultrasound 
findings at sites included in the LEI, with 26% sites having US evidence of 
inflammation but no clinical tenderness, and 20% sites having a normal 
ultrasound but clinical tenderness (Ibrahim et al. 2010).  The INSPIRE 
study found excellent agreement between assessors, with an ICC of 0.81 
(Gladman et al. 2007a). 
Validation of these scores is difficult because of the necessity of showing 
‘truth’ without a gold standard for confirming the presence of enthesitis.  
The correlation between clinical enthesitis and imaging enthesitis is still 
debated and biopsy, while this would confirm the presence of inflammation, 
is not considered feasible by patients or clinicians.  There is still no 
consensus as to the best method to be used for assessment.  The LEI has 
the advantage of being simple and quick, as well as having been 
developed specifically for PsA, but may miss enthesitis in other areas. 
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Sites assessed Validated 
in PsA? 
MEI (Mander et al. 
1987) 
66 Nuchal crests, manubriosternal joint, costochondral joints, greater 
tuberosity and medial and lateral epicondyles of the humerus, iliac 
crests, anterior superior iliac spines, greater trochanter, medial and 
lateral femur condyles, Achilles tendon and plantar fascia calcaneal 
insertion, cervical, thoracic, and lumbar spinous processes, ischial 
tuberosities, posterior superior iliac spines 
No 
MASES (Heuft-
Dorenbosch et al. 
2003) 
13 1st costochondral joint, 7th costochondral joint, posterior superior iliac 
spine, anterior superior iliac spines, iliac crest, 5th lumbar spinous 
process, proximal insertion of Achilles tendon 
No 
SPARCC (Maksymowych et 
al. 2009) 
16 Greater trochanter, quadriceps tendon insertion into the patella, 
patellar ligament insertion into the patella and tibial tuberosity, Achilles 
tendon insertion, plantar fascia insertion, medial and lateral 
epicondyles and the supraspinatus insertion 
No 







Sites assessed Validated 
in PsA? 
Major (Braun et al. 
2002) 
12 Femur medial and lateral epicondyles, iliac crests, greater trochanter, 
calcaneal insertion of Achilles tendon, calcaneal insertion of plantar 
fascia 
No 
Gladman (Gladman et al. 
2004) 
8 Rotator cuff insertion at the shoulder, tibial tuberosity at the knee, 
Achilles tendon, and plantar fascia insertions in the calcaneus 
Yes 
LEI (Healy et al. 
2008b) 
6 Lateral epicondyle, medial femoral condyle, Achilles tendon insertion Yes 
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Dactylitis is described as a ‘sausage’ finger or toe, where swelling of the 
whole digit occurs.   This has been shown on imaging to include 
inflammation and swelling within the joints, tendon sheaths, as well as 
other soft tissues and skin (Coates et al. 2008a).  It may be assessed 
simply by the number of dactylitic digits, and these may also be rated as 
swollen and tender (thought to represent the more acute phase) or as 
simply swollen, which may represent the more chronic phase.  A reliability 
exercise using clinicians with an interest in PsA found a moderate 
agreement between assessors for a simple dactylitis count (reliability 
coefficient 0.57) (Gladman et al. 2004) and this has been used as an 
outcome measure in clinical trials.  However, data from another reliability 
exercise show that while rheumatologists with an interest in PsA 
demonstrate substantial agreement (ICC 0.69), dermatologists with an 
interest in psoriasis showed no agreement (ICC 0.08) and thus experience 
or training may be needed for this measure to perform well (Chandran et al. 
2009). 
The only objective measure of dactylitis uses the Leeds dactylometer.  
Using this, the presence of dactylitis may be confirmed by demonstrating at 
least a 10% difference between the circumference of a dactylitic digit 
compared to the corresponding digit on the other hand or foot (Helliwell et 
al. 2005).  The Leeds Dactylitis Index (LDI) uses the dactylometer to 
measure the circumference of the dactylitic digit and the corresponding 
contralateral digit (or the use of a normative value if that digit was also 
dactylitic) and then this is calculated together with a subjective semi-
quantitative score for tenderness (Helliwell et al. 2005).  As part of the 
development process for the LDI, it was demonstrated that inexperienced 
observers had poor inter- and intra-observer agreement in judging the 
subjective presence of both tender and non-tender dactylitis (without using 
the dactylometer).  A reliability exercise of the LDI in 20 patients found an 
ICC of 0.70, showing substantial agreement (Gladman et al. 2007a).  In a 
cohort of patients changing treatment, both the LDI and the LDI basic 
(tenderness scored simply as present or absent) performed well, with an 
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effect size of 0.99 and 0.90 respectively (Healy et al. 2007).   Limitations of 
the LDI are the time involved and the requirement of a dactylometer. 
 
The assessment of nail disease will be reviewed in section 2.5.4. 
 
While all of these assessments are important, patient reported outcomes 
such as visual analogue scales are also relevant and these may give a 
better understanding of the impact of disease on the patient.  Physicians 
may also under-estimate the severity of disease when compared to patient 
assessments (Dandorfer et al. 2012). 
 
2.2.8  Screening for psoriatic arthritis in psoriasis patients  
 
Given that the majority of PsA patients develop psoriasis first, and then the 
arthritis a number of years later, many patients are under the care of 
dermatologists or general practitioners at the time of development of PsA.  
It is clear that a significant proportion of psoriasis patients, whether under 
secondary care dermatology or not, have undiagnosed psoriatic arthritis 
(Khraishi et al. 2012; Haroon et al. 2013).  This may be because the patient 
has not reported their symptoms to the physician, or because their 
symptoms were attributed to other causes.  Various screening tools have 
been developed in the last few years to assist other physicians caring for 
psoriasis patients to identify PsA better.  While a rheumatologist assessing 
every psoriasis patient would be a theoretical option for screening, in 
practice this is rarely possible.  Screening tools are therefore useful to sub-
select patients with a higher risk of PsA for review by a rheumatologist.  
These include the Psoriatic and Arthritic Questionnaire (PAQ), the 
Psoriasis Epidemiology Screening Tool (PEST), the Psoriatic Arthritis 
Screening and Evaluation tool (PASE), the Toronto Psoriatic Arthritis 
Screen (ToPAS) and the Early ARthritis for Psoriatic patients questionnaire 
(EARP). 
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The PAQ was originally developed in Canada as a twelve item 
questionnaire but published only in abstract form, and was subsequently 
studied in Sweden as a ten item questionnaire, modifying it to make it more 
applicable to a community cohort (Alenius et al. 2002b).  This was 
administered to 202 community and hospital based patients with psoriasis.  
A ROC analysis found a score of four or greater to be the best cut-off, with 
a sensitivity of 60% and a specificity of 62%.   
The PEST questionnaire was developed in Yorkshire from a cohort of 
patients with psoriasis in the community (Ibrahim et al. 2009).  Patients 
identified by their general practitioner as having psoriasis were invited to 
complete a questionnaire, and a sample of those underwent a clinical 
assessment at the rheumatology clinic.  The questionnaire was also 
completed by a cohort of patients with PsA.  This questionnaire included 
items from the PAQ as well as additional questions.  A manikin was also 
included for patients to label joints which had caused discomfort.  168 
patients returned a questionnaire by post and of these, 89 were examined.  
A logistic regression analysis was used to reduce the questionnaire to the 
five best performing questions.  In this initial cohort, with a cut-off score of 
≥3 the sensitivity was 92% and the specificity was 78%.  The advantage of 
the PEST questionnaire is that it is simple and short and hence requires 
less time to complete.  A recent hospital-based study however found a 
much lower sensitivity of 27.5% and a specificity of 98% amongst 
dermatology patients with psoriasis, and a sensitivity of 86% amongst PsA 
patients (Haroon et al. 2013).   A significant proportion of psoriasis patients 
were on treatments which may suppress arthritis, but perhaps more 
importantly the PEST questionnaire performed well in polyarticular PsA 
patients but poorly in other subtypes of PsA.   
The PASE questionnaire was developed in the United States by a group of 
rheumatologists and dermatologists, using a Delphi method (Husni et al. 
2007).  It is a self-administered questionnaire with 15 questions.  This 
includes two sections, one assessing function and one assessing 
symptoms. Each item is scored on a scale from 1 (strongly disagree) to 5 
(strongly agree).  This gives a maximum possible function score of 40 and 
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symptom score of 35, leading to a total score which can be between 15 
and 75.  This was then validated in 69 tertiary referral psoriasis patients, 
comparing the results against the gold standard of physician diagnosis for 
psoriasis and for psoriatic arthritis, by a dermatologist and a rheumatologist 
correspondingly.  The PsA diagnosis took into account the Moll and Wright 
criteria.  Osteoarthritis was also present in 35% of the patients.  Psoriatic 
arthritis was diagnosed in 25% of the patients.  Using a cut-off PASE score 
of 47 gave a sensitivity of 82% and a specificity of 73% for the diagnosis of 
PsA.  Further validation was performed in 194 patients with psoriasis or 
PsA, with or without other rheumatic diseases such as osteoarthritis 
(Dominguez et al. 2009).  This included analyses for the test-re-test 
reliability and the sensitivity to change with a change in treatment.  In this 
group the optimal cut-off score was 44, which gave a sensitivity and 
specificity each of 76%.  The Intraclass Correlation Coefficient (ICC) for the 
total PASE score was 0.90, indicating acceptable reliability.  Another sub-
group analysis found reasonable sensitivity to a change in disease state. 
Given that this questionnaire (unlike the others) assesses symptoms and 
function, in patients with fluctuating symptoms it may be less sensitive.    
The ToPAS questionnaire was developed and validated by the group in 
Toronto (Gladman et al. 2009).  The twelve questions were devised by an 
expert group of rheumatologists and dermatologists, based on features that 
they considered to be seen frequently in PsA patients.  After initial testing 
for ease of use, it was shown to differentiate well between PsA patients 
and those with other rheumatic diseases.  Subsequently the questionnaire 
was validated on PsA patients, patients in a tertiary care psoriasis clinic, 
patients from a general rheumatology clinic (with those with PsA excluded), 
patients from a general dermatology clinic and also a family medicine clinic.  
A total of 688 patients completed the questionnaires.  This is a wider range 
of patient populations than has been studied with the other questionnaires.  
After completing the questionnaire all patients were assessed by a 
rheumatologist to confirm or refute a diagnosis of PsA.  Logistic regression 
and receiver operating curves (ROC) were used to assess the responses 
to the questionnaire.  A sensitivity of 89 – 93% and a specificity of 86 – 
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100% were seen in the different patient populations.  The advantages of 
the ToPAS are that it has been validated in a variety of settings rather than 
psoriasis patients alone, and that it includes images to help patients more 
reliably answer the question as to whether they have psoriasis.  While the 
PASE asks regarding current symptoms, the ToPAS assessed any history 
of symptoms to better classify patients who may have had intermittent 
symptoms.  There is also no assessment of function in the ToPAS as it was 
designed primarily for case identification. 
The EARP was designed by a group in Verona for use in patients with early 
psoriasis, with the aim of being simple and quick to use (Tinazzi et al. 
2012).  The questionnaire may be self-administered and includes ten 
questions.  Initial validation in a cohort of 228 patients demonstrated a 




2.3  Imaging in psoriatic arthritis 
 
A number of imaging modalities have been used in PsA.  These include 
radiographs, ultrasound, MRI, CT, PET and bone scintigraphy.  In this 
section, the commonly used modalities will be reviewed, including typical 
features seen and the advantages and disadvantages of each method.  
The imaging of enthesitis will be covered separately in section 2.4.1. 
 
2.3.1 Radiographs in psoriatic arthritis 
 
Radiographs have historically been used to assess for joint damage in 
PsA, among other arthritides.  They are quick to perform, are easy to score 
as part of multicentre studies, and are acceptable to patients.  Radiographs 
do involve a small dose of radiation, less so for radiographs of the hands 
and feet but a significant dose is involved in a lumbar spine film, for 
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example.  They only give information as to bony changes (which may take 
some time to develop) or significant soft tissue swelling but are not able to 
assess soft tissues such as tendons or ligaments, or assess for current 
inflammation. 
The typical radiographic features seen in PsA were described by Verna 
Wright in 1961 and have subsequently been described further in other 
cohorts (Wright 1961).  In the peripheral joints these features include some 
consistent with bone proliferation (bony ankylosis, juxta-articular bone 
proliferation, periostitis and spur formation) and others suggestive of bone 
destruction (erosions, joint osteolysis, pencil-in-cup, tuft osteolysis).  In the 
axial skeleton, syndesmophytes and sacroilitis may be seen.  Plain film 
evidence of enthesopathy is relatively rare, and in one study was seen no 
more frequently in PsA than it was in RA (Helliwell et al. 2007).  This may 
reflect that the enthesis structure is largely soft tissue which is not 
visualised on radiographs, and thus only severe or chronic disease may be 
seen. 
Radiographs may be useful to differentiate between different forms of 
arthritis, according to the pattern of joints involved and the types of 
abnormality seen.  Juxta-articular bony proliferation may be particularly 
discriminative and is included in the CASPAR criteria for this reason, 
although it is only seen in around 50% PsA patients (Taylor et al. 2006; 
Ichikawa et al. 2012). 
Radiographs have been used in the majority of the trials of anti-TNF 
medications in PsA, showing substantial reductions in radiographic 
progression with these medications (Kavanaugh et al. 2006; Mease et al. 
2006b; Gladman et al. 2007b; van der Heijde et al. 2007).  Scoring systems 
for the peripheral joints have been well described, the majority of which 
were originally designed for the assessment of RA (Table 4). 
The modified Steinbrocker score was devised in Toronto to provide more 
detail than in the original Steinbrocker (which merely recorded the score for 
the worst joint) (Rahman et al. 1998b).  This method includes the DIPs, 
PIPs, MCPs, wrists, MTPs and great toe IPJs. Each joint is scored on a 0-4 
- 54 - 
 
 
scale, from normal to soft tissue swelling, erosion and complete joint 
destruction.  Validation was performed on a set of films from 68 PsA 
patients, with x-rays taken at least two years apart.  This showed excellent 
interobserver reliability, with an ICC of 0.86 and similar responsiveness to 
change when compared to the modified Larsen score.  This scoring 
method has not been used in RCTs but has been used for radiographic 
scoring in a number of publications on the Toronto PsA cohort (Abu-Shakra 
et al. 1995; Rahman et al. 1998a). 
The modified Larsen method (for PsA) includes the MCPs, PIPs, DIPs, 
wrists, MTPs and the 1st MTP and IPJ (Rahman et al. 1998b).  Each joint is 
graded from 0 – 5, again ranging from normal, through degrees of erosion 
to total joint destruction.  The final score is the mean of each individual joint 
score.  Validation was performed in the same exercise as the modified 
Steinbrocker on a set of films from 68 PsA patients, with x-rays taken at 
least two years apart.  This found excellent inter-observer reliability with an 
ICC of 0.87. 
The PsA modified Sharp score was devised from the original Sharp score 
(Sharp et al. 1985) in order to monitor radiographic progression in a 
number of clinical trials of TNF inhibitors in PsA (Mease et al. 2004).  This 
included a larger number of joints than the other methods, with a detailed 
scoring system of erosions and joint space narrowing, with a number of 
other PsA-specific features also recorded.  Erosions were scored from 0 – 
5 but with additional scores of 6 or 7 recorded if present but not added to 
the total score (for pencil-in-cup and gross osteolysis).  Joint space 
narrowing was scored from 0 - 4 with widening recorded separately.  
Additional note was made of shaft periostitis, juxta-articular periostitis, 
periostitis in the wrist, and tuft resorption.  In the original study inter-reader 
ICC values were between 0.81 and 0.88. 
Another modification of the Sharp score for PsA patients was described by 
van der Heijde (van der Heijde 2000).  The DIP joints of the hands are 
assessed in addition to those assessed in the original Sharp scoring 
system.  Again a large number of joints are assessed.  Erosions are scored 
per joint with a maximum erosion score of 5 in the hands and 10 in the feet.  
- 55 - 
 
 
Joint space narrowing is scored from 0-4, with a score of 4 representing 
bony ankylosis.  Pencil-in-cup and gross osteolysis are scored separately, 
but if present that joint would score maximum for both erosions and joint 
space narrowing.  This score has been used in a number of RCTs, showing 
moderate to excellent agreement between readers (Kavanaugh et al. 2006; 
Kavanaugh et al. 2012b). 
The Ratingen score was developed for use in PsA (Wassenberg et al. 
2001).  It requires radiographs of the hands (including the wrist) and the 
feet and scores a total of 40 joints.  Joints included are 8 DIPs, 2 IPJ of the 
thumb, 8 PIPs, 10 MCPs, 2 wrists, 2 IPJs of the great toe and the 2nd to 5th 
MTPs.  Each joint is scored for destruction (scored from 0-5) and 
proliferation (scored from 0-4).  Initial validation was performed on 20 PsA 
patients, each with radiographs from baseline and an average of three 
years.  Sets of radiographs were scored in chronological order by two 
readers and good reliability was shown, with a minimum detectable change 
of around 5% of the total score. 
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Each DIP, PIP, MCP and wrist, MTPs and 1st 
IPJ of great toe 
160 Soft tissue swelling, 
erosion, joint destruction 









MCPs, PIPs, DIPs, wrists and the 1st MTP and 
IPJ 
5 Soft tissue swelling, 
erosion, joint destruction 
(in a single score) 
Ratingen (Wassenberg 





DIPs, PIPs, MCPs, wrists, IPJ thumb and 
great toe, MTPs 
360 Destruction and 
proliferation 




















Erosions:  2nd – 5th DIPs, all MCPs, the IPJ of 
the thumb, 7 bones in the wrist, all MTPs and 
the IPJ of the great toe 
JSN: 2nd – 5th DIPs, all MCPs, 6 joints in the 
wrist and all MTPs  
Erosion 270 
JSN 200 
Erosion, JSN and 
widening, shaft 
periostitis, juxta-articular 
periostitis, periostitis in 













Erosions: all DIPs/IPs, MCPs, two 1st  
metacarpal bones, two radius and ulnar 
bones, two multangular units (trapezium and 
trapezoid combined), all MTPs and the IPJs of 
the great toes 
JSN: all DIPs/IPs, MCPs, two 3rd, 4th and 5th 
CMCJs, two multangular-navicular joints, two 
capitate-navicular-lunate joints, two 




Erosion, JSN, ankylosis, 
pencil-in-cup, gross 
osteolysis 
JSN: joint space narrowing
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For axial disease, scoring systems are largely derived from AS, but both 
the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) and 
Bath Ankylosing Spondylitis Radiology Index (BASRI) have been validated 
in a cohort of patients with PsA (Lubrano et al. 2009b).  A modification of 
these specific to axial PsA has also been described, termed the Psoriatic 
Arthritis Spondylitis Radiology Index (PASRI) (Lubrano et al. 2009a).  This 
also scores the posterior elements of the spine.   
Radiographs are quick to perform and useful for assessing chronic bony 
changes, with well validated scoring systems published. 
 
2.3.2 Magnetic resonance imaging in psoriatic arthritis   
 
Magnetic resonance imaging uses a strong magnetic field to alter the axis 
of protons within the body.  Radiofrequency sources are then used to 
cause the nuclei to resonate and the radio wave signals that this generates 
are detected and used to create the images.  The duration that it takes for 
the tissues to relax after the radiofrequency source is switched off is 
different for different tissues (based on their fat and water content) and 
allows differentiation between the tissues. 
Magnetic resonance imaging has shown great promise for the imaging of 
PsA.  Unlike conventional radiography, MRI is also able to demonstrate 
soft tissues including cartilage, synovium, tendons and ligaments.  Unlike 
ultrasonography, MR is able to reveal bony changes such as osteitis and 
image the spine.  It is therefore useful for imaging arthritis, enthesitis, 
dactylitis, and axial disease.  Other advantages include the lack of radiation 
and the ability to standardise sequences and score imaging at distant sites 
for multi-centre studies.  Some tissues and sequences require intravenous 
contrast administration, which is not possible in all patients.  MRI remains 
expensive, time consuming and at times, uncomfortable for patients.  
Movement artefact may also degrade image quality.  For peripheral arthritis 
and enthesitis, MRI remains a research tool, but for spinal imaging it has a 
place in clinical care.  MR imaging of enthesitis in PsA will be covered in 
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detail in section 2.4.1.2 and MRI studies of the DIP joint and nail will be 
covered in section 2.5.5.1. 
Typical features of peripheral joint arthritis are similar to those seen in 
rheumatoid arthritis.  Synovitis, joint effusion, bone marrow oedema and 
erosions are common, as is soft tissue involvement and tenosynovitis 
(Tehranzadeh et al. 2008).  Bone proliferation and periosteal enhancement 
may also be seen (Ghanem et al. 2007).  Peripheral joint arthritis may 
appear as high signal on T2 weighted images and contrast enhancement 
on T1 weighted post contrast images.  Unlike in rheumatoid arthritis where 
the main changes occur within the synovial joint, active joints in PsA may 
have quite extensive surrounding inflammation, affecting the joint capsule, 
surrounding tendons and ligaments and the soft tissue (Jevtic et al. 1995).  
MRI is more sensitive than radiographs for detecting both inflammation and 
damage in PsA (Wiell et al. 2007).  Bone marrow oedema lesions are 
important as they predict the later development or erosions (Savnik et al. 
2002).  A cross-sectional study of erosive PsA including arthritis mutilans 
also found an association between bone oedema and current radiographic 
damage (Tan et al. 2009). 
In a comparative study with RA, periostitis and synovitis of the PIP joints 
occurred more frequently in PsA.  Erosions were more frequent in RA 
compared to PsA and there was no different in the frequency of bone 
marrow oedema or tenosynovitis (Schoellnast et al. 2006).  A separate 
study found the only differences on imaging between RA and PsA were the 
DIP involvement in PsA along with bony proliferation (Wiell et al. 2007).  In 
early arthritis (symptom duration < 1 year), the presence of enthesitis or 
diaphyseal bone oedema differentiated PsA from RA, both with a specificity 
of 100% and sensitivities of 71% and 65% respectively (Narvaez et al. 
2012).  In contrast, Marzo-Ortega et al. found that MRI of the MCP joints 
was not able to differentiate reliably between early RA and PsA (<24 
months duration), although a small subgroup of PsA patients had 
extracapsular enhancement and bone marrow oedema (Marzo-Ortega et 
al. 2009).   
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In another study assessing the sensitivity and specificity of clinical 
examination of the MCP joint, an association was seen between clinical 
tenderness and MRI synovitis (Stone et al. 2009).  Stress pain (pain at the 
extreme of passive extension) showed an association with bone oedema.  
No association was seen between clinical swelling and underlying MRI 
findings, suggesting that tenderness may be more discriminative than 
swelling.  Clinical examination was not as sensitive as MRI in detecting 
synovial pathology. 
An MRI study of dactylitic digits has shown widespread changes, with 
synovitis and soft tissue oedema the most common findings, but 
tenosynovitis and bone marrow oedema also noted (Healy et al. 2008a).  
The degree of bone marrow oedema varied from patient to patient.  Soft 
tissue oedema was seen to be circumferential rather than localised to any 
particular structure. 
Little data are available on the imaging of spinal disease in PsA.  A study of 
103 patients with PsA (not selected on the basis of axial symptoms) in 
whom 68 agreed to undergo an MR scan found clinical features of 
sacroiliitis in 35% and MRI features in 38% patients (Williamson et al. 
2004b).  The correlation between clinical and MRI features was low, with a 
positive predictive value of clinical assessment in predicting MRI sacroiliitis 
of 42%.  The best clinical predictor of MRI sacroiliitis was restricted spinal 
movements on examination.  HLA B27 was not significantly associated with 
MRI findings. 
To meet the criterion of ‘truth’ in the OMERACT filter, it is important that 
what is believed to represent inflammation on MRI does indeed represent 
histological inflammation.  For sacroilitis this was demonstrated in a biopsy 
study in patients with spondyloarthropathies including PsA (Bollow et al. 
2000).  T cells and macrophages were the most common inflammatory 
cells seen in actively inflamed sacroiliac joints and a correlation was seen 
between cellularity and the degree of MRI sacroiliitis.  For synovitis, no 
data is available in PsA but two studies in RA have confirmed a correlation 
between MRI appearances and histological inflammation (Konig et al. 
1990; Gaffney et al. 1995). 
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Until the development of a validated scoring system for PsA, a variety of 
methods have been used.  A scoring system for the MR appearances of 
dactylitis was documented in one observational study (Healy et al. 2008a).  
At each joint level, eight features were recorded as present (score 1) or 
absent; synovitis, bone oedema, subcutaneous oedema, flexor 
tenosynovitis, extensor tenosynovitis, plantar / volar plate enhancement, 
collateral ligament enhancement and erosions.  For the thumb and great 
toe, sesamoiditis was also scored.  The maximum score was 17 for the 
thumb or great toe and 24 for all other digits.  With change in treatment, 
reductions in the MRI score were seen, but on an individual digit level, 
correlations were not seen between clinical findings and the MRI score.  In 
an adalimumab study, MRI scans were performed of the most active wrist 
or knee joint (Anandarajah et al. 2010).  These were scored for bone 
marrow oedema (score 0-5), bone erosions (score 0-5), synovitis (score 
0.3) and effusion (score 0.5).  Bone marrow oedema and erosions were 
scored at 13 sites in the wrist and at three sites in the knee.  Synovitis and 
effusion were scored at three sites in the wrist and one in the knee.  Scans 
were scored by consensus and therefore no inter-observer reliability data is 
available.  The RCT for abatacept used a modification of the Rheumatoid 
Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) designed for RA.  
A trend to improvement in erosion, synovitis and effusion scores was seen 
(Mease et al. 2011). 
Improvements in MRI-determined bone marrow oedema have been shown 
in patients with PsA receiving treatment with adalimumab (Anandarajah et 
al. 2010).  Surprisingly though, the erosion score increased over 24 weeks 
of treatment and although synovitis improved in nine joints, it worsened in 
eight and was static in three.  In an open label study with infliximab in PsA, 
in order to reduce concerns over placebo response in subjective patient-
reported outcome measures, MRI was performed in eight patients.  A 
reduction in Gadolinium uptake was seen in all patients at ten weeks 
(Antoni et al. 2002).  For a study using etanercept, bone marrow oedema 
volume in a target joint was chosen as the MRI outcome measure 
(Anandarajah et al. 2008).  The overall BMO volume decreased in nine 
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patients and increased in four after six months treatment but the majority of 
patients (even those with an overall improvement) had new or worsening 
areas of bone oedema on the six month scans.  A study using infliximab 
found significant reductions in both synovitis and bone marrow oedema on 
MRI scans of the affected hand or knee after 20 weeks treatment, with 7/9 
patients having complete resolution of bone marrow oedema (Marzo-
Ortega et al. 2007a).   
The development of a PsA-specific scoring method for MRI scans of the 
hands was first described in 2007 as a modification of the RAMRIS 
(McQueen et al. 2007).  This was initially termed the Psoriatic Arthritis 
Magnetic Resonance Imaging Scoring system (PAMRIS) but was later 
renamed the PsAMRIS.  The framework was taken from the RAMRIS but 
with the addition of features specific to PsA.  In initial development, 
moderate to very good interreader reliability was seen for bone marrow 
oedema and erosions, but reliability was lower for synovitis (particularly in 
the DIP joints), extra-capsular inflammation and tendinopathy (McQueen et 
al. 2007).   The scoring system was refined and definitions were proposed 
for key pathologies (Ostergaard et al. 2009).  This was then tested in a 
cross-sectional and a longitudinal study (McQueen et al. 2009).  While 
reliability was good for some features, peri-articular inflammation and DIP 
disease scores were less reliable.  A multi-reader exercise was then 
performed in a group of patients commencing treatment and followed for 12 
months (Boyesen et al. 2011).  Generally, reliability was good, and 
sensitivity to change in synovitis, flexor tenosynovitis and periarticular 
inflammation was demonstrated.  The PsAMRIS has since been used in a 
treatment study involving zolendronic acid (McQueen et al. 2011). 
Dynamic contrast-enhanced MRI is a newer technique in development 
which assesses enhancement to study vascularity but is currently showing 
inconclusive results in its ability to differentiate synovitis between RA, OA 
and PsA (Cimmino et al. 2005; Schwenzer et al. 2010; Schraml et al. 2011; 
Cimmino et al. 2012).  One study has been published on whole body MR, 
which gives a good overview of multiple joint areas including the spine in 
one scan (Weckbach et al. 2011).  Enthesitis was the most common 
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finding, followed by synovitis and bone marrow oedema.  The most 
common sites for enthesitis were around the spine and pelvis.  MRI was 
more sensitive than clinical examination in detecting enthesitis and 
synovitis.  In 73% patients the treatment was changed as a result of the 
findings on MR.  Three patients who underwent a second scan after a 
change in treatment had improvements noted on imaging.   
Magnetic resonance imaging has an important place in research into PsA, 
with its potential to study the multiple facets of the disease, but remains 
limited by cost, accessibility and discriminative ability from widespread use 
in clinical practice. 
 
2.3.3 Ultrasound in psoriatic arthritis 
 
Ultrasound uses high frequency sound waves to generate images.  These 
sound waves are transmitted into the body by the probe, and some are 
reflected back when there is a boundary between different types of tissue 
(water, fat, bone).  The time taken for these reflections or echoes to return 
back to the probe is used to calculate the distance involved and produce an 
image.  Resolution is determined by the pulse length, probe frequency and 
frame rate.  Higher frequency probes give greater lateral resolution but 
lower depth penetration.   
Ultrasound has increasingly been used in rheumatology clinical practice 
and research over the part twenty years.  Key advantages include the ease 
of use, lack of radiation, acceptability to patients, low cost, widespread 
availability, high sensitivity and the ability to study many joints in one 
assessment.  Disadvantages include the fact that ultrasound is very 
operator dependent and also as it is a real-time imaging modality, this limits 
its use in multicentre studies as images cannot be scored centrally.  
Modern scanners with high frequency transducers now have very good 
resolution for detecting very small structures or abnormalities such as 
erosions.  The majority of data on rheumatology ultrasound comes from the 
RA literature, showing that power Doppler (PD) ultrasound identifies 
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vascular abnormalities known to be associated with inflammation, and that 
these relate to both later damage and response to treatment (Naredo et al. 
2008; Kurosaka et al. 2010; Hammer et al. 2011).  There has been 
increasing interest in the use of ultrasound in PsA partly because of the 
ability to study not just synovitis but also enthesitis and dactylitis.  
Ultrasound also has a greater sensitivity to detect inflammation than clinical 
examination (Milosavljevic et al. 2005; Delle Sedie et al. 2010; Delle Sedie 
et al. 2011). 
Typical features include synovitis, erosions, tenosynovitis, enthesitis and 
soft tissue oedema.  In the peripheral joints ultrasound features include 
joint effusion, synovial proliferation, intra-articular PD signal (suggesting 
active inflammation) and bone erosion (Gutierrez et al. 2010).  Tendon 
involvement may demonstrate tenosynovitis, areas of hypoechogenicity or 
tendon tears (Gutierrez et al. 2010).  In dactylitic digits, synovitis, 
tenosynovitis and soft tissue oedema may all occur (Kane et al. 1999; 
Gutierrez et al. 2010).  In an earlier dactylitis study, only flexor 
tenosynovitis was demonstrated on ultrasound, without soft tissue or joint 
involvement (Olivieri et al. 1996). 
A comparative study of MCP disease in RA and PsA using ultrasound 
found peritenon extensor inflammation and extra-articular PD signal to be 
characteristic of PsA and to help differentiate these diseases (Gutierrez et 
al. 2011b).  These findings were confirmed in another study where RA and 
PsA fingers were compared, again detecting synovitis, tenosynovitis and 
erosions but observing extra-articular abnormalities to be characteristic of 
PsA and not seen in RA (Fournié et al. 2006).  The most common seen 
here were enthesophytes, enthesopathy, periosteal reaction and soft tissue 
thickening.  Ultrasound may be useful in helping confirm a diagnosis of PsA 
in psoriasis patients with articular symptoms (De Simone et al. 2011). In a 
study of early PsA patients (<1 year symptoms), no radiographic 
abnormalities were seen, but ultrasound confirmed an effusion in the target 
joint in every patient (Bonifati et al. 2012).   Ultrasound has been shown to 
have good specificity in PsA, with greater sensitivity in detecting erosions 
than x-rays (Wiell et al. 2007).  Ultrasound was more sensitive than clinical 
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examination in detecting synovitis.  In a study comparing different imaging 
modalities for assessing the peripheral joints in PsA patients, ultrasound 
had a lower sensitivity in detecting synovitis and joint effusion than MRI, 
but better sensitivity than MRI in detecting erosions (Weiner et al. 2008).  
This study was limited by not using PD ultrasound as part of the 
assessment.  In one of the earlier studies, ultrasound showed good 
correlation with the clinical course in PsA patients undergoing 
synovectomy, showing promise as an objective measure for monitoring 
treatment (Fiocco et al. 1996). 
There are currently no validated widely used scoring systems for the 
ultrasound assessment of joints or dactylitis in PsA, although OMERACT 
has set out definitions of pathological findings in order to help standardise 
descriptions (Wakefield et al. 2005).  A composite scoring system called 
the Five Targets PD for Psoriatic Disease (5TPD) is in development and 
preliminary data has recently been published (Gutierrez et al. 2012).  This 
measures PD signal at five targets (skin, nails, joints, tendons and 
enthesitis, with a semiquantitative score of 0-3 at each target, giving a 
maximum possible score of 15.  In the preliminary study, all clinically 
involved areas were assessed, and the maximum score for each target 
was recorded.  Reductions in the 5TPD were seen with treatment.  
Validated scoring systems are needed and this score may offer some 
promise.  One of the difficulties with the heterogeneous nature of PsA is 
that composite scores may make it more difficult to study treatment efficacy 
on different aspects of the disease.  In a treatment study using 
adalimumab, ultrasound assessment was used as an outcome 
assessment, with the most clinically involved joint being scanned, and 
abnormalities as per the OMERACT definitions being recorded and scored 
on a semiquantitative basis (Teoli et al. 2012).  With this method, 
significant improvements in effusion, synovial proliferation and PD signal 
were seen.  Several other studies have used similar semiquantitative 
measurements or measurements of synovial thickness (Fiocco et al. 2005; 
Milosavljevic et al. 2005; De Agustin et al. 2012). 
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Ultrasound is a widely used technique in studying PsA, currently used more 
in research than in clinical practice.  The most significant ongoing limitation 
is the lack of well validated and widely accepted scoring systems. 
 
2.4 Enthesitis  
 
2.4.1 Enthesitis in psoriatic arthritis  
 
As described earlier enthesitis, or inflammation at insertions such as 
ligament or tendon attachments to bone, is a characteristic feature of PsA.  
It may be assessed clinically but a number of imaging modalities have also 
been used.   
 
2.4.1.1 Ultrasound imaging of enthesitis in psoriatic arthritis 
One of the earliest descriptions of the ultrasound appearances of 
enthesopathy suggested that oedema at the tendon insertion was the most 
common feature, and that it was frequently missed on clinical examination 
(Lehtinen et al. 1994).  Typical features are tendon thickening, 
calcifications, enthesophytes (generally the most common finding), 
erosions, bony irregularities, PD signal at the enthesis, PD signal in the 
tendon, bursitis, tendon hypoechogenicity or loss of the normal fibrillar 
tendon structure (Balint et al. 2002; Gutierrez et al. 2010; Iagnocco et al. 
2012). 
In 2005 the OMERACT group published a consensus definition for the 
ultrasound definition of enthesopathy: ‘Abnormally hypoechoic (loss of 
normal fibrillar architecture) and/or thickened tendon or ligament at its bony 
attachment (may occasionally contain hyperechoic foci consistent with 
calcification), seen in 2 perpendicular planes that may exhibit Doppler 
signal and/or bony changes including enthesophytes, erosions, or 
irregularity’ (Wakefield et al. 2005). 
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Enthesitis can occur in multiple areas around the body.  The most common 
sites are in the lower limb, but it can also occur in the upper limb and 
enthesitis of the deltoid proximal insertion has been demonstrated in 17% 
PsA patients with current shoulder pain (Falsetti et al. 2002). 
With increasing interest in the different areas of the enthesis organ, it has 
been shown that ultrasound has the capability to visualise the entheseal 
fibrocartilage (a structure of around 0.5mm thickness), with evidence of 
loss of the fibrocartilage at sites of entheseal erosion (Aydin et al. 2010a).  
Surprisingly one study has shown that erosions as seen on ultrasound may 
not be a permanent structural alteration, as 25% had disappeared after six 
months follow-up, and 50% had resolved after 12 months (de Miguel et al. 
2011a).  The authors suggested that this may be due to new bone 
formation as part of the SpA pathological processes. 
Little data are available on the prevalence and characteristics of enthesitis 
amongst the subtypes of PsA.  SAPHO (synovitis, acne, pustulosis, 
hyperostosis) syndrome has been described as a subtype of SpA.  In a 
small study, US evidence of enthesopathy (largely subclinical) was 
significantly more common in SAPHO patients than controls, and was only 
seen in the subgroup of patients with palmoplantar pustulosis or 
palmoplantar pustular psoriasis as the skin lesion, not in patients with only 
acne or hidradenitis suppurativa, suggesting that these subgroups may be 
phenotypically important (Queiro et al. 2012a). 
One of the key problems of ultrasound assessment of enthesitis is where to 
draw a line between ‘normal’ and ‘disease’ in view of the high prevalence of 
abnormalities in healthy controls.  Particularly in the lower limbs these 
findings may be mechanical.  Herein lies the importance of recruiting 
appropriate controls to studies in order not to over-call minor changes 
which are in fact within the normal range. 
The majority of studies have found that clinical examination underestimates 
the prevalence of enthesitis in PsA, suggesting that subclinical enthesitis is 
common.  The study by Balint et al. assessing enthesopathy in the lower 
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limbs in SpA patients found clinical enthesitis in 22% of the sites examined, 
and US abnormalities in 56% sites.  In comparison to ultrasound, they 
found clinical examination to have a sensitivity of 23% and a specificity of 
80% in detecting enthesitis (Balint et al. 2002).  Data on quadriceps tendon 
enthesitis also found an underestimation by clinical examination, with 45% 
PsA patients having ultrasound evidence of enthesitis, but of these, only 
45% had clinical enthesitis (Frediani et al. 2001).  When assessing all the 
entheses at the knee, ultrasound was shown to be more sensitive overall 
than clinical assessment in detecting joint inflammation and enthesitis.  
However, in 14 patients, clinical examination suggested enthesitis while 
ultrasound was normal (Delle Sedie et al. 2010).  One key difference in this 
study is that enthesophytes were not included in the scoring system as 
they were felt to be common and non-specific.  A study in patients with 
longstanding PsA found subclinical enthesitis in 13% of the sites assessed 
(Marchesoni et al. 2012).  In SpA patients, 30% entheses assessed had 
subclinical enthesitis seen on ultrasound (D'Agostino et al. 2003).  A study 
validating the Leeds Enthesitis Index found a very poor correlation between 
clinical and ultrasound findings (Ibrahim et al. 2010).  In AS, abnormalities 
were found frequently in both the upper and lower limbs (Spadaro et al. 
2011).  The study found a high prevalence of both subclinical enthesitis but 
also sites which were clinically tender but with a normal ultrasound. 
In contrast, in a study of patients with early PsA, only 4% non-tender 
entheses had a positive ultrasound (definited as a grey scale score >1 or a 
PD score >0), suggesting a very low level of subclinical enthesitis 
(Freeston et al. 2012).  Those areas of subclinical enthesitis also tended to 
be in the lower limb and the authors suggested a potential role of 
mechanical stress here.  A grey scale score of 1 was considered as normal 
as this can occur in normal subjects, and this may potentially explain the 
discrepancy between this and other studies.  The study also found that 
13% entheses had a positive finding on clinical examination but a normal 
ultrasound, suggesting that clinical examination was overestimating the 
degree of enthesitis.  In a quarter of these, the tender enthesis was 
adjacent to a tender joint, suggesting that this may have influenced the 
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clinical finding.  In the control group (n=10), only 1% entheses had a 
positive low grade PD signal but grey scale findings were common, with 
50% patients having a bony spur at the calcaneum and 10% having 
intratendinous calcification in the inferior patellar tendon. 
Although US features of enthesopathy were more severe in PsA than RA 
patients overall, on a patient level it was not possible to differentiate the 
two diseases using an ultrasound of the entheses (Iagnocco et al. 2012).  
At the quadriceps tendon insertion, differences were noted between PsA 
and RA patients, with more PsA than RA patients having ultrasound 
evidence of enthesitis (45% vs 7.5%) but RA patients being more likely to 
have a joint effusion (95% vs 60%).  Isolated enthesitis (without joint 
effusion) was only seen in PsA patients. RA patients were more likely to 
have inflammatory features (oedema, tendon thickening and 
hypoechogenicity) while features of new bone formation were almost 
exclusively seen in PsA (Frediani et al. 2001).  In the finger, entheseal 
abnormalities were seen in a subset of PsA patients (enthesophytes  in 
3/25 and distal phalanx enthesopathy in 4/25) while no enthesopathy was 
seen in RA patients (0/25) thus this did allow differentiation between the 
diseases, albeit with a low sensitivity (Fournié et al. 2006).  At the MCP 
joint, the presence of peritenon extensor tendon inflammation potentially 
differentiated PsA and RA patients, occurring in 65.8% vs 0% (Gutierrez et 
al. 2011b).  Interestingly when assessing the entheses at the heel, the 
frequency of enthesophytes was similar in OA and PsA (Falsetti et al. 
2003).  Inflammatory features were more common in PsA and RA than OA.  
Achilles enthesitis was seen in 8% PsA patients but not in OA or control 
subjects.  Plantar fasciitis was not significantly more common in PsA than 
RA.  The value of PD ultrasound in the diagnosis of SpA at an early stage 
was evaluated in a French cohort (D'Agostino et al. 2011).  A finding of at 
least one vascularised enthesis using PD ultrasound gave a sensitivity of 
76.5% and a specificity of 81.3% for the diagnosis of SpA.  The Achilles 
tendon and lateral epicondyle were more frequently involved in SpA than 
non-SpA patients.  A similar study in Spain found a significantly higher 
mean ultrasound enthesitis score in early SpA patients compared to 
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undifferentiated early SpA and controls (de Miguel et al. 2011b).  No 
difference was seen in the overall US score or the pattern of abnormalities 
between patients with axial or peripheral disease.  An US score of >20 had 
a sensitivity of 53.1%, a specificity of 83.3% and a positive likelihood radio 
of 3.26 for a diagnosis of SpA.  The differential diagnosis of PsA and 
fibromyalgia can be difficult clinically, as enthesitis is manifest as tender 
points, and fibromyalgia is characterised by tender points.  These can be 
situated quite close together, for example at the elbow.  A study performed 
to address whether ultrasound may help in making this distinction was 
performed in Italy (Marchesoni et al. 2012).  Interestingly, although all 
features of enthesopathy were significantly more common in PsA, the 
fibromyalgia patients also had frequent abnormalities on US (enthesopathy 
in 80% patients, inflammatory lesions 23% and entheseal PD signal 23%).  
The quadriceps tendon and Achilles tendon were the most frequently 
abnormal.  Erosions were only seen in PsA patients.  Fibromyalgia patients 
were more likely to have clinically tender but ultrasonographically normal 
sites than PsA patients (37% vs 8%).  A finding of US-detected 
abnormalities in at least three entheses predicted a diagnosis of PsA with a 
sensitivity of 72% and a specificity of 76%. 
 
Several different ultrasound scoring systems have been described for 
enthesitis which include features such as thickening, hypoechoic change, 
bone erosion and new bone formation (see Table 5).  The Madrid 
Sonographic Entheseal Index (MASEI) was proposed in 2009 after 
development in a cohort of SpA patients (de Miguel et al. 2009).  The 
maximum total score is 136.  An enthesis in the upper limb was included, in 
order to reduce the influence of mechanical factors.  In comparing healthy 
controls and SpA patients, a score of ≥18 had a sensitivity of 83.3%, a 
specificity of 82.8% and a positive likelihood ratio of 4.87 in predicting a 
diagnosis of SpA.  The GUESS score was proposed by Balint, with 
substantial to excellent intraobserver agreement demonstrated in the initial 
study (Balint et al. 2002).  The disadvantages of the GUESS score are that 
it studies the lower limbs only, and does not include a PD assessment.  
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The ultrasound score proposed by Naredo showed excellent intraobserver 
reliability and responsiveness to change with treatment (Naredo et al. 
2010).  Morphological abnormalities, PD signal and bursitis scores all 
reduced with treatment, suggesting that these are indeed inflammatory 
features, while calcific deposits and cortical abnormalities were confirmed 
as more in keeping with structural damage.  An ultrasound assessment of 
the same entheses as in the MASES clinical enthesitis index unusually 
found that clinical examination revealed more positive findings than 
ultrasound (Kiris et al. 2006).  This scoring system includes more entheses 
around the axial skeleton than the others.  Highly vascularised entheses 
were more likely to be tender.  A scoring system for the Achilles tendon 
was proposed in order to demonstrate the validity of ultrasound in 
assessing entheses (Filippucci et al. 2009).  Moderate to excellent 
interobserver and intraobserver agreement was seen for the overall score 
and all individual features except calcaneal bone irregularities, which were 
therefore then not included in the total score.  The Sonographic Enthesitis 
Index (SEI) was developed in AS patients (Alcalde et al. 2007).  All the 
healthy controls had an SEI score of 0.  Of the AS patients, 41/44 had 
abnormalities seen on entheseal ultrasound.  Good interobserver reliability 
was seen.  A modification was subsequently proposed to the SEI to add a 
PD assessment (Hamdi et al. 2011).  With this, the Doppler score 
correlated well with disease activity measures and the total score 
correlated well with clinical enthesitis indices.  The GUESS score has been 
the most widely used. 
 
One of the key problems of ultrasound assessment is the fact it is operator 
dependent.  A process to improve reliability was recently reported by 
D’Agostino (D'Agostino M et al. 2009).  The first step was to assess the 
interobserver and intraobserver reliability of five sonographers.  Consensus 
definitions and guidelines were then produced within the group regarding 
scanning technique, a scoring system and definitions of abnormalities.  
Reliability was then reassessed.  After a further year, reliability was again 
re-assessed.  Marked improvements were seen in the reliability of 
ultrasound assessments and scoring for Doppler findings. 
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in PsA, AS 
or SpA 






(Balint et al. 
2002) 
SpA  Quadriceps tendon into 
superior border of 
patella 
 Superior patellar 
tendon insertion 
 Inferior patellar tendon 
insertion 
 Achilles tendon 
 Plantar fascia 
No Four aspects scored at each enthesis: tendon thickness (> 
stated normal thickness for each site), erosions, 
enthesophyes and bursitis (where applicable – not scored at 
plantar fascia or superior patellar tendon insertion) 
When present, scored as one point for each abnormality at 
each site, giving maximum score of 36  
Soft tissue score (entheseal thickness and bursitis) and bone 




(Falsetti et al. 
2003) 
 
PsA  Achilles tendon 
 Plantar fascia 
No Abnormalities graded as 0-3 
Enthesophytes, enthesitis (hypoechogenicity and thickening), 
bursitis, erosions, panniculitis 







in PsA, AS 
or SpA 













SpA  Common extensor 
origin at the elbow 
 Common flexor origin 
at the elbow 
 Gluteus insertion at the 
greater trochanter 
 Pubis enthesis 
 Quadriceps tendon into 
patella 
 Superior patellar 
tendon insertion 
 Achilles tendon 
 Plantar fascia 
 Tibialis anterior 
insertion 
Yes Stage 0 
Stage 1 
 
Stage 2a  
 
 








Vascularisation at the cortical junction without 
abnormal findings in B mode 
Vascularisation associated with swelling 
and/or decreased echogenicity at the cortical 
junction in B mode 
Same as stage 2a, plus erosions of cortical 
bone and/or calcifications of enthesis, and 
optional surrounding bursitis 
Abnormal findings in B mode as in stage 2a, 
but without vascularisation 
Abnormal findings in B mode as in stage 3a, 
but without vascularisation 
 







in PsA, AS 
or SpA 






(Kiris et al. 
2006) 
AS  5th lumbar spinous 
process 
 1st and 7th 
costochondral joints 
 Posterior superior iliac 
spine 
 Anterior superior iliac 
spine 
 Iliac crest 







Yes  Focal changes (hypoechogenicity within the tendon) 
 Calcification of the tendon 
 Cortical reactive changes (reabsorption, new bone 
formation, irregularity) 
 Bursitis 
The above scored as present or absent (0-1) 
Vascularisation (scored 0-3) 
 







in PsA, AS 
or SpA 






(Alcalde et al. 
2007) 
AS  Quadriceps tendon into 
superior border of 
patella 
 Superior patellar 
tendon insertion 
 Inferior patellar tendon 
insertion 
 Achilles tendon 
 Plantar fascia 
 
No Separate scores for inflammation and chronic change 
Inflammation: entheseal thickening, hypoechogenicity, 
peritendinous oedema, bursitis (where applicable) 
Chronic change: tears, loss of thickness, intratendinous 
calcification, bone erosion 
Each feature scored as present (1) or absent (0) 







SpA Achilles tendon (3 sites: 
proximal and distal 




Bone spurs (semiquantitative scoring for size 0-3) 
Hypoechoic thickening or loss of fibrillar architecture 







in PsA, AS 
or SpA 








SpA Achilles tendon Yes Lesions scored: tendon hypoechogenicity, tendon thickening, 
intra-tendinous calcifications, enthesophytes, bony erosions, 
bony cortex irregularities, presence of Doppler signal at the 
level of the bony attachment, presence of intratendinous 
Doppler signal, bursal enlargement, tendon tears (partial or 
full thickness) 
Each item scored dichotomously as present / absent (1/0) 
















in PsA, AS 
or SpA 






(de Miguel et 
al. 2009) 
SpA  Distal brachial triceps 
tendon 
 Quadriceps tendon into 
superior border of 
patella 
 Superior patellar 
tendon insertion 
 Inferior patellar tendon 
insertion 
 Achilles tendon 
 Plantar fascia 
Yes Lesions scored at each site: calcifications, bursae, erosions, 
power Doppler signal in the bursa or tendon at the enthesis, 
thickness and structure 
Score for calcification: irregularity of the cortical bone, 
enthesophytes and ossifications  
Thickness measured at the point of maximal thickness at the 
insertion (> stated normal thickness for each site) 
Abnormal structure defined as loss of fibrillar pattern, 
hypoechonicity or fusiform swelling at the enthesis 
Each item scored as 0 (absent) or 1 (present) except 
calcifications (scored 0-3), erosion (0 or 3 if present) and 












in PsA, AS 
or SpA 











 Common extensor 
origin at the elbow 
 Quadriceps tendon into 
superior border of 
patella 
 Superior patellar 
tendon insertion 
 Achilles tendon 
 Plantar fascia 
Yes Morphologic abnormalities: increased thickness or 
hypoechogenicity of enthesis insertion (score 1) 
Structural abnormalities: calcifications and /or enthesophytes 
(score 1), erosions (score 1) 



















in PsA, AS 
or SpA 








SpA Achilles tendon only Yes Based on OMERACT definition of enthesopathy 
Separate scores for inflammation and tissue damage 
Inflammation score: tendon hypoechogenicity, tendon 
thickening, entheseal hypoechogenicity, bursal effusion, PD 
signal at the tendon level, PD signal at entheseal level, PD 
signal at bursal level 
Scores calculated as either presence / absence (maximum 
total 7) or semiquantitative (score 0-2) (maximum total 14) 
Tissue damage score: intratendinous calcification, entheseal 
calcification, enthesophytes and bone erosions 
Scores calculated as either presence / absence (maximum 












in PsA, AS 
or SpA 






(Naredo et al. 
2010) 
SpA  Common extensor 
origin at the elbow 
 Common flexor origin 
at the elbow 
 Quadriceps tendon into 
superior border of 
patella 
 Superior patellar 
tendon insertion 
 Inferior patellar tendon 
insertion 
 Achilles tendon 
 Plantar fascia 
Yes Lesions scored as present or absent: morphologic 
abnormalities (hypoechogenicity, thickening), entheseal 
calcific deposits, entheseal cortical abnormalities (erosion, 
enthesophytes), adjacent bursitis, intraenthesis PD signal at 
















in PsA, AS 
or SpA 






(Ibrahim et al. 
2010) 
PsA  Common extensor 
origin at the elbow 
 Medial femoral condyle 
 Achilles tendon 
Yes Lesions scored as present (1) or absent (0): 
Inflammation features: entheseal vascularisation (with PD), 
bursitis, entheseal thickening and perientheseal soft tissue 
oedema 
Damage score: erosions, enthesophytes,  
Modification 
of the SEI 
 
(Hamdi et al. 
2011) 
AS  Quadriceps tendon into 
superior border of 
patella 
 Superior patellar 
tendon insertion 
 Inferior patellar tendon 
insertion 
 Achilles tendon 
 Plantar fascia 
 
 
Yes As for the SEI with the addition of PD findings (scored 0 or 1) 
Total score range 0-76 







in PsA, AS 
or SpA 








PsA  Common extensor 
origin at the elbow 
 Inferior patellar tendon 
insertion 
 Achilles tendon 
 Plantar fascia 
 
Yes Based on OMERACT US group recommendations 
Findings divided into ‘active inflammation’ and ‘structural 
change’. 
GS and PD each scored semiquantitatively (range 0–3) 
GS score designated as a composite score of 
tendon/aponeurosis thickening and hypoechogenicity (loss of 
fibrillar pattern).  Highest score for either parameter used as 
the final GS score 
GS score of ≤1 considered as normal 
Adjacent bursal effusion scored 0–3 where present  
Erosion, bony spur, and intratendinous calcification (all 
features of structural change), recorded as present or absent 
Erosions only scored if identified in two planes and located 
within the area into which the tendon or aponeurosis typically 
inserts 
 







in PsA, AS 
or SpA 








PsA  Common extensor 
origin at the elbow 
 Gluteus insertion at the 
greater trochanter 
 Quadriceps tendon into 
superior border of 
patella 
 Superior patellar 
tendon insertion 
 Inferior patellar tendon 
insertion 
 Achilles tendon 
 Plantar fascia 
Yes Based on the OMERACT definition of enthesopathy 
Features included: hypoechogenicity, thickening, 
calcifications, enthesophytes, erosions, bony irregularities, 
PD signal at the enthesis, PD signal in the tendon, bursitis 
and tendon lesions 
Items scored on a semiquantitative (0-3) or dichotomous 
basis (0-1) 
















in PsA, AS 
or SpA 








PsA  Common extensor 
origin at the elbow 
 Gluteus insertion at the 
greater trochanter 
 Quadriceps tendon into 
superior border of 
patella 
 Superior patellar 
tendon insertion 
 Inferior patellar tendon 
insertion 
 Achilles tendon 
 Plantar fascia 
Yes Based on OMERACT definition of enthesopathy 
Scored for tendon hypoechogenicity, tendon thickening, 
intratendinous calcification, enthesophytes, erosions, bone 
cortex irregularities and PD signal at the bony insertion 
Semiquantitative scoring (0-3) except cortex abnormalities 
(present or absent) 
Active inflammation: hypoechogenicity, PD signal at the 
enthesis 
Previous inflammation: erosions 
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A number of studies have used ultrasound scans of the entheses to 
monitor treatment response in SpA patients.  With sulphasalazine 
treatment in SpA patients, no improvement was seen in ultrasound 
parameters of enthesopathy over six months treatment (Lehtinen et al. 
1995).   A larger study of RA and AS patients commencing treatment with 
sulphasalazine monitored treatment response using the GUESS score and 
also found no improvement in US scores with treatment (Genc et al. 2007).  
Two SpA patients with refractory heel pain treated with infliximab had 
marked improvements both clinically and noted with ultrasound over 14 
weeks (D'Agostino et al. 2002).  A significant reduction in the morphology 
score, intraenthesis PD score, perienthesis PD score and bursitis score for 
a number of enthesis sites was seen in SpA patients after six months of 
treatment with TNF inhibitors (Naredo et al. 2010).  The calcific abnormality 
score and cortical abnormality score (both more related to chronic damage) 
both increased during the study.  Another study assessed only the Achilles 
enthesis, using the scoring system previously described by Filippucci 
(Filippucci et al. 2009), but recording the inflammatory features only as the 
damage features were not expected to change with treatment (Aydin et al. 
2010b).  These scores were summated to give a score for PD findings, a 
grey scale score and a total score.  Scans were performed on 43 AS 
patients prior to and after two months of TNF inhibitor therapy.  Significant 
reductions were seen in the grey scale and total scores, the PD score 
reduced but the difference was not statistically significant.  The score least 
affected by the treatment was the tendon thickness.  
 
2.4.1.2 Magnetic resonance imaging of enthesitis in psoriatic arthritis 
 
The majority of studies on the imaging of enthesitis have used 
ultrasonography but descriptions of the MR appearances of enthesitis are 
available.  One key advantage of MRI over ultrasound in the assessment of 
enthesitis is the ability to detect bone marrow oedema at the insertion.  
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Enthesitis is not included in the PsAMRIS scoring system and no other 
validated scoring systems are available for enthesitis. 
One of the earliest descriptions of the key role of enthesitis was by 
McGonagle and colleagues (McGonagle et al. 1998b).  Ten SpA (including 
three PsA patients) and ten RA patients underwent MRI scanning of a 
swollen knee of recent onset.  Three SpA patients and one RA patient had 
clinical evidence of enthesitis.  All ten SpA patients had evidence of focal 
peri-entheseal high signal outside of the joint, while four of the ten RA 
patients also showed this.    Focal bone marrow oedema at the enthesis 
was seen in six SpA patients and no RA patients.  These findings led to the 
hypothesis that enthesitis is the common pathogenic mechanism shared in 
the spondyloarthropathies, and that it may occur as a primary pathology 
rather then secondary to synovitis. 
Emad and colleagues described features of PsA on MRI scans of the knee 
joint (Emad et al. 2010).  They found enthesitis to be a common finding at a 
number of sites around the knee, with bone oedema at the entheseal 
insertions.   In a second study comparing patients with undifferentiated 
arthritis, RA and SpA including PsA, enthesitis was seen in 100% SpA 
patients, none of the RA patients and only 3/25 undifferentiated arthritis 
patients (Emad et al. 2009).  The commonest sites were at the medial 
collateral ligament and the patellar tendon.  In the hands, Jevtic used MRI 
and demonstrated characteristic features of enthesitis in PsA patients, with 
extra-capsular inflammation and thickening of the collateral ligaments 
(Jevtic et al. 1995).  At the MCP joint, MRI was able to detect a 
characteristic pattern of extracapsular soft tissue enhancement suggestive 
of entheseal disease, but this was only seen in a small subgroup of 
patients (Marzo-Ortega et al. 2009).  When compared to ultrasound at the 
finger, MRI was less sensitive at detecting insertional changes of the flexor 
and extensor tendons and capsular / extracapsular changes (Wiell et al. 
2007). 
In a cohort of SpA patients, MRI was performed of the heel (Feydy et al. 
2012).  Abnormalities were surprisingly common in both controls and SpA 
patients without heel pain (67% and 53% respectively) but were more 
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common in patients with current heel pain (81%).  In control subjects (with 
mechanical back pain), enthesophytes of the plantar fascia were seen in 
31%, enthesophytes of the Achilles in 17% and thickening of the Achilles in 
21%.  The only feature specific (94%) to SpA patients was oedema of the 
calcaneum but sensitivity was only 22%.  Another study using ultrashort 
echo time imaging of the Achilles tendon found that quantitative 
measurements could be made, which were significantly different in SpA 
patients compared to healthy controls (Hodgson et al. 2012). 
Whole body MRI was able to demonstrate widespread enthesitis in PsA 
patients, seen in 67% patients in the hips, 60% around the lumbar spine 
(particularly the interspinal ligaments) and 33% in the feet (Weckbach et al. 
2011).  MRI was more sensitive in detecting enthesitis than clinical 
examination, although in three patients clinical examination suggested 
enthesitis but MR was normal. 
 
2.4.2 Subclinical enthesitis in psoriasis 
 
Subclinical musculoskeletal inflammation, especially osteitis and periostitis, 
has been recognised since the 1970s in patients with psoriasis but no 
arthritis.  Following the publication of the enthesitis theory of disease and 
the discovery that enthesitis is linked to osteitis, various groups have begun 
to look at the prevalence of enthesitis in patients with psoriasis but no 
arthritis.   It is now been fairly well established that subclinical entheseal 
involvement is common in patients with psoriasis but without arthritis (see 
Table 6).   The long term significance and predictive value of this is not yet 
known, especially as the prevalence of enthesitis in some reports is greater 
than the prevalence of PsA amongst psoriasis patients.  The only available 
data on the predictive value of subclinical enthesitis in psoriasis patients 
comes from an Italian cohort, where the mean baseline GUESS score was 
significantly higher in patients who went on to develop PsA or OA than in 
those who remained asymptomatic after 3.5 years (Tinazzi et al. 2011).  
Looking at those developing PsA alone (without including OA) there was no 
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significant difference, but this was a small cohort (n=28).  There are also 
little data available comparing the characteristics of enthesitis in psoriasis 
and PsA patients.  Subclinical enthesitis has also been demonstrated in 
inflammatory bowel disease (Bandinelli et al. 2011), anterior uveitis 
(Munoz-Fernandez et al. 2009), scleroderma (Schanz et al. 2013), 
Behçet’s (Ozkan et al. 2012) and renal dialysis patients (Gutierrez et al. 
2011c). 
Recently, positron emission tomography-computed tomography (PET-CT) 
has been used in psoriasis and PsA patients.  In six patients with psoriasis 
(including one with PsA), three had no subclinical musculoskeletal 
involvement, the PsA patient had inflammation in joints, entheses, and 
muscles and two asymptomatic psoriasis patients had enthesitis and 
synovitis (Mehta et al. 2011).  Increased uptake in the aorta and liver were 
also noted compared to controls.  A second study found subclinical arthritis 
in 3/5 psoriasis patients but no PET-CT uptake in the joints of twenty 
control subjects (Takata et al. 2011).  Intriguingly, a reduction in uptake 
was then seen after treatment with a TNF inhibitor. 
Looking at the control cohorts, variable proportions are noted to have 
enthesitis also, depending on the imaging modality and scoring system 
used.  With the GUESS score, 5% (2/40) of the controls for the 
inflammatory bowel disease study had an enthesophyte at the Achilles 
(Bandinelli et al. 2011).  Also using the GUESS score, Gisondi found a 
correlation of the GUESS score with age, body mass index and waist 
circumference in the control cohort as well as the psoriasis patients 
(Gisondi et al. 2008).  In the controls they saw no bursitis or erosions but 
enthesophytes were common (seen in 40% controls at the superior pole of 
the patella).  Gutierrez also used the GUESS score and found evidence of 
enthesopathy in 8.4% of the sites assessed, predominantly entheseal 
thickness and enthesophytes, and commonest in the quadriceps enthesis 
and the Achilles (Gutierrez et al. 2011a).  The 33 controls for the dialysis 
study were also assessed using the GUESS score, again entheseal 
thickness and enthesophytes were the most common finding, with a 
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positive finding in 16% enthesis sites and in 82% controls assessed 
(Gutierrez et al. 2011c).  No PD signal was seen in the controls.  Using the 
MASEI ultrasound score, 20 patients with non inflammatory eye diseases 
and 21 healthy controls were scanned (Munoz-Fernandez et al. 2009).  
10% of the eye controls and 19% of the healthy controls had a score equal 
to or greater than the previously set positive MASEI cut-off score of 18.  
The most common lesion in either of the control groups was calcification or 
bone proliferation, seen most frequently at the Achilles.  A high prevalence 
of subclinical synovitis and enthesopathy was seen in the study by Naredo 
(Naredo et al. 2011).  US abnormalities were seen in 56.5% of the 46 
controls, with both synovitis and enthesopathy seen in 15.2%.  The Achilles 
tendon was the most common site of enthesopathy.   In keeping with other 
studies, no controls had PD signal detected.  These high rates are even 
after excluding the MTP joints from study because of the known high rate 
of synovitis in healthy controls 
With MRI of the knee, no evidence of enthesitis or bone marrow oedema 
was seen  in 20 controls (Emad et al. 2010).  Likewise, with an MR of the 
foot, no abnormalities were seen in the control group (Erdem et al. 2008). 
Two studies looked for factors predicting subclinical disease and found 
either no correlation between either demographic factors or the severity of 
skin psoriasis and subclinical disease, or only a correlation between 
increasing age and subclinical enthesopathy (Naredo et al. 2011; Emad et 
al. 2012).  
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Table 6.  Studies assessing subclinical enthesitis and arthritis in psoriasis patients 
Reference  Modality  No. of  
psoriasis 
patients  
Control group  Findings in psoriasis patients Findings in controls 
(De Filippis 
et al. 2005) 
US 24 None 33% patients had evidence of enthesopathy: 





MRI 6  20 healthy 
controls 
5/6 showed enthesitis at the patellar tendon 
insertion, 1/6 at the medial patellofemoral 
ligament and 1/6 had bone marrow oedema  
No entheseal 
changes, bone 




MRI 48 20 MR evidence of enthesitis seen in 94% 
patients, soft tissue oedema in 54% knees 
scanned, bone marrow oedema in 21%, 
bone marrow oedema at the enthesis in 3% 
and erosions in 28% 
Bone marrow 
oedema seen in 
10%, cartilage 
lesions in 5%, no 
enthesitis seen 
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Reference  Modality  No. of  
psoriasis 
patients  
Control group  Findings in psoriasis patients Findings in controls 
(Erdem et 
al. 2008) 
MRI 26 10 healthy 
controls 
92% patients with psoriasis had abnormal 
MRI of the foot (arthritis, enthesopathy, bone 
marrow oedema) 
No abnormalities 









US and    
x-ray  
30  30 controls: other 
dermatology 
diagnoses 
Mean GUESS score 7.9 - significantly higher 
than in controls (p<0.0001).  Thickness of 
lower limb entheses and number of 
enthesophytes also higher.  





US 45 45 healthy 
controls 
Mean GUESS score significantly higher than 
in controls (p<0.0001).  Increased entheseal 
thickness in 16% entheses, enthesophytes in 
15%, PD signal seen in 0.9%. 
 
US enthesopathy in 
8.4% entheses, no 
erosions or PD signal 
seen 
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Reference  Modality  No. of  
psoriasis 
patients  











Generalised periarticular uptake seen in all 
psoriasis patients.  86% of 168 joints 
scanned were abnormal  
 





US 162 60 (outpatients 
with  other skin 
diseases) 
77% psoriasis patients had ultrasound 
abnormalities.  Synovitis and enthesitis 
significantly more common than in controls.  
Entheseal or peri-entheseal PD signal seen 
in 11%.  Subclinical synovitis most common 
in the knee, enthesitis at the Achilles  
57% controls had 
ultrasound 




MRI and  
x-ray  
25  12 healthy 
controls 
MRI abnormal in 68% psoriasis patients and 
x-ray in 32%.  Subchondral changes in 36% 
patients on MRI 
 
Only one joint cyst 
seen  
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Reference  Modality  No. of  
psoriasis 
patients  
Control group  Findings in psoriasis patients Findings in controls 




50 25 controls: 




35 of 50 patients (70%) with no clinical 
evidence for arthritis had a positive bone 
scan 
 
16% controls had a 
positive bone scan 
GUESS:  Glasgow Ultrasound Enthesitis Scoring System.  US: ultrasound.  N/A: not applicable 
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Nail disease is more common in PsA than in psoriasis (Gladman et al. 
1987b; Jiaravuthisan et al. 2007; Love et al. 2007).  It is recognised that the 
presence of nail disease in patients with psoriasis but without arthritis is 
predictive of future PsA development (Wilson et al. 2009a).  The presence 
of nail disease has also been noted to be higher in patients with more 
severe psoriasis, those with a psoriasis history of more than five years 
duration and patients aged more than 50 (Tham et al. 1988).  In that study 
a correlation was also seen between the presence of nail disease, scalp 
and periungual psoriasis, and the presence of arthritis.  It is not yet clear 
whether the pathological changes causing nail disease are the same in 
both psoriasis and psoriatic arthritis.  An association between nail disease 
and DIP joint disease has long been reported (Green 1968; Jones et al. 
1994; Cohen et al. 1999; Kane et al. 2003; Scarpa et al. 2004; Williamson 
et al. 2004a).  A small study in Japan found an association between nail 
fold psoriasis, DIP involvement and nail disease, but did not find an 
association between nail disease and the severity of the skin disease 
(Maejima et al. 2010).  In 305 patients with nail psoriasis, nail disease was 
most commonly seen in the dominant thumb nail, raising the possibility that 
trauma may be involved in the pathogenesis (Rich et al. 2008).  Another 
study found the highest prevalence in the fourth finger and the great toes 
(Brazzelli et al. 2012). 
 
2.5.2 Pathology  
The nails have an important function in protecting the tip of the finger and 
improving dexterity.  The nail plate sits on the nail bed and is formed by the 
nail matrix (Figure 2 and 3).  The nail bed has tiny longitudinal ridges, 
running from the lunula to the tip of the nail, these help attach the nail plate 
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to the nail bed and also contain blood vessels which are responsible for 
splinter haemorrhages (Zaias 1990). 




Figure 3.  Diagrammatic representation of a cross section of the distal 
phalanx 
 
Various types of psoriatic nail disease are recognised, and more than one 
type frequently co-exists in the same patient and even in the same nail.  
Nail changes may be divided into those abnormalities generally thought to 
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be associated with the nail plate and those with the nail matrix (Table 7 and 
Figure 4 and 5). 
Table 7.  Nail changes seen in psoriasis 
Nail Plate Nail Matrix 
Oil drop discolouration Leuconychia 
Splinter haemorrhages Red spots in the lunula 
Subungual hyperkeratosis Pitting 
Onycholysis Nail crumbling 
 
Onycholysis is a lifting up or separation of the nail plate from the nail bed.  
It may be visibly separated, or otherwise may be noted by a well 
demarcated area extending up from the nail tip a variable distance, where 
the nail appears as pale or yellow in place of the usual colour. 
Oil drop discolouration appears as clearly demarcated discoloured patches 
within the nail, usually pale or yellow but they may be brown.  They are 
thought to be a localised form of onycholysis; separation of the nail plate 
from the nail bed, with a build up of air, cells and fluid within. 
Splinter haemorrhages appear as narrow linear dark abnormalities, 
typically towards the tip of the nail.  They can occur secondary to trauma, 
and also occur in other medical disorders including endocarditis and 
systemic vasculitis.  They are thought to represent blood from tiny bleeds 
between the nail plate and bed, which track up and down linear grooves in 
the nail bed. 
Subungual hyperkeratosis is thickening of the nail bed, thought to 
represent psoriatic plaques under the nail, where the proliferating cells are 
unable to desquamate and therefore build up as a thick collection.  Red 
spots may appear in the lunula when inflammation occurs within the nail 
matrix (Jiaravuthisan et al. 2007). 
Pitting is seen as tiny localised superficial depressions within the nail plate.  
They may occur in clusters or in a linear pattern, longitudinally along the 
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nail.  They are thought to originate in a psoriatic lesion in the nail matrix; 
defective keratinisation occurs and then as the nail grows, the more 
superficial cells slough off leaving a depression (Zaias 1990).  Nail 
crumbling resembles pitting on a larger scale, where the production of the 
nail plate is defective, the nail is therefore fragile and may disintegrate. 
Leuconychia appears as bright white patches within the nail.  It is fairly 
common in healthy subjects.  It is an abnormality within the nail plate itself, 
which may reflect calcification. 
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Figure 4.  Nail plate lesions 
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Figure 5. Nail matrix lesions 
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Some of these abnormalities may also be found in healthy individuals 
without psoriasis.  One small study found pitting and splinter haemorrhages 
in more than half the healthy subjects, although few had more than two of 
either feature (Robertson et al. 1974).  Leuconychia was also seen very 
frequently.  A study by Verna Wright compared the changes seen in psoriatic 
patients to those in other medical inpatients in order to assess the 
discriminative power for a diagnosis of psoriatic nail disease (Eastmond et 
al. 1979).  They reported five conclusions.  Onycholysis (in the absence of a 
history of trauma) suggested a psoriatic cause.  The presence of at least two 
features from onycholysis, horizontal ridging and nail pitting in the same 
patient suggest a psoriatic cause.  The presence of nail pitting alone is not 
sufficient for the nail disease to be attributed to psoriasis.  The presence of 
more than twenty pits is suggesting of a psoriatic cause, and more than sixty 
are unlikely to be seen in a non-psoriatic cause.  
In a cross-sectional study in Singapore, pitting and onycholysis were the 
most common abnormalities seen in their psoriasis patients (Tham et al. 
1988).  This was replicated in a cross-sectional study in Italy (Brazzelli et al. 
2012) and was also stated in one of the original papers by Wright (Eastmond 
et al. 1979). 
Recently it has emerged that the nail is functionally integrated into the 
enthesis network around the DIP joint (McGonagle 2009).  This offers a 
novel explanation for the link between arthritis and skin disease.  It also 
raises the possibility that nail pain in psoriasis without arthritis is in fact a 
manifestation of enthesitis (see section 2.5.5.1 for further details). 
A small case control study comparing psoriasis patients and controls, 
without diabetes, hypertension or a smoking history assessed the nailfold 
vessel resistance index (NVRI) in the proximal nail plate using Doppler 
ultrasound (Husein El-Ahmed et al. 2012).  The patients were receiving a 
variety of systemic therapies for their psoriasis.  Sixteen out of 23 psoriasis 
patients had nail disease.  A significant increase in the NVRI was seen in the 
psoriasis patients with nail disease, compared to those without nail disease 
and compared to controls also.  The authors suggest that this may relate to 
microvascular changes and endothelial dysfunction involved in the 
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pathogenesis of psoriasis itself, and the nail changes.  One group were able 
to describe a typical pattern of changes seen on capillaroscopy in psoriasis 
patients, and the presence of this pattern correlated with the presence of 
periungual psoriatic lesions, onycholysis and pitting (Ohtsuka et al. 1994).  
An later assessment of nail fold capillaroscopy in patients with psoriasis and 
PsA was not able to replicate this but did find reduced capillary bed density 
in patients with either nail disease or DIP arthritis compared to controls, 
suggesting a possible role of microvascular disease in the pathogenesis 
(Bhushan et al. 2000). 
The presence of the HLA-Cw*0602 allele differentiates different subtypes of 
psoriasis, with nail disease being more common in patients who are HLA-
Cw*0602 negative (Gudjonsson et al. 2006). 
Alterations of the microenvironment of the nail by psoriatic nail disease may 
also predispose to co-existent fungal nail disease, which can be seen in 
around half of the psoriatic nails (Natarajan et al. 2010).  This may reduce 
the accuracy of clinical assessment of the nails, particularly the toenails. 
 
2.5.3 Burden of disease 
 
One of the first descriptions of the impact of psoriatic nail disease was by de 
Jong (de Jong et al. 1996).  In a large postal questionnaire study, 1728 
patients were surveyed regarding their psoriasis.  Nail pain was reported by 
51.8% patients and cosmetic problems by 93.3%.  Functional impact was 
also commonly reported; 59% in activities of daily living, 56% for 
housekeeping and 48% for carrying out their work.  Major restrictions at work 
were reported by 14% patients.   
A large cross-sectional study in Germany found that psoriasis patients with 
nail disease had higher DLQI scores and required more time off work than 
those with normal nails (Augustin et al. 2010).  However, a number of 
confounding factors may be influencing these results, as patients with nail 
disease also had higher PASI scores, were more likely to have had inpatient 
treatment and were more likely to have co-existent PsA.  These results were 
echoed in a later German study (Radtke et al. 2011).  Patients with nail 
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disease had a higher DLQI score and poorer general health as measured by 
the EQ5-D visual analogue score.  Satisfaction with treatment was lower and 
patients required more time off work. 
A retrospective study in France found that the presence of nail disease in 
psoriasis patients was associated with a higher DLQI score, suggesting 
again that nail disease does have an impact on quality of life (Lin et al. 
2011).  In another cohort, a correlation was seen between nail disease 
severity (measured using the psoriasis nail severity score [PNSS]) and 
functional impairment (measured using the HAQ), also with anxiety and 
depression scores (measured using the Hospital Anxiety and Depression 
Scale) (Williamson et al. 2004a).  In contrast, a Japanese study was not able 
to show a correlation between the mNAPSI score and the HAQ (Japanese 
version) (Maejima et al. 2010).  This may reflect the fact the HAQ is not 
specific enough for the impact of nail psoriasis. 
There is currently only one assessment tool designed to measure the effect 
of nail disease on quality of life, the nail psoriasis quality of life scale 
(NPQ10), which was developed and validated in France (Ortonne et al. 
2010).  This awaits further validation in a longitudinal study to assess the 
response to change.  In the development study, members of a French 
psoriasis patient organisation were surveyed.  86% of the patients were 
troubled by their nail disease, 87% felt that it was unsightly and 59% found it 
painful.  The greater the number of involved nails, the more functional, 
aesthetic and pain impact was seen.  Confirming the validity of the score, a 
correlation between the DLQI and the NPQ10 was seen.  Patients with nail 
disease of both the hands and feet had higher NPQ10 scores than those 
with it only affecting either the hands or feet. 
One open label study has shown an improvement in nail related quality of 
life in psoriasis patients treated with ustekinumab (Rigopoulos et al. 2011), 
although this was done using a questionnaire designed for the assessment 
of quality of life in fungal nail disease (Drake et al. 1999).  A study using 
topical ciclosporin found an improvement in the Psoriasis Disability Index 
scores in those patients who had complete resolution of their nail disease 
with treatment (Abe et al. 2011). 
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2.5.4 Clinical assessment  
 
One of the difficulties, as with the assessment of PsA overall, is developing a 
scoring system that does not take too much time, but that includes the 
different facets of nail disease in order to study what potentially may be the 
result of different pathological processes and may respond to treatment in 
different ways. 
Various options have been developed for the clinical assessment of nail 
disease.  While some studies have used self-reported presence of nail 
disease, other simple options include a clinician assessment of the presence 
or absence of nail disease, or the recording of the number of nails affected. 
The first formal scoring system was developed in Bath and adapted by a 
group in Oxford as the psoriasis nail severity score (PNSS), scoring one 
point per finger nail for the presence each of pitting, onycholysis, 
hyperkeratosis and dystrophy, giving a total possible score of 40 (or 80 if 
including the toenails) (Jones et al. 1994; Williamson et al. 2004a).  
The Nail Psoriasis Severity Index (NAPSI) is the most frequently used semi-
objective measure and was developed by dermatologists in 2003 (Rich et al. 
2003).  In this method, each nail is divided into four quadrants and the 
abnormalities scored for each quadrant, with one point for any features of 
nail bed psoriasis (onycholysis, oil drop spots, splinter haemorrhages and 
nail bed hyperkeratosis) and one point for any features of nail matrix 
psoriasis (pitting, leuconychia, red spots in the lunula and nail plate 
crumbling).  This gives a possible score of 2 per quadrant, 8 per nail and 
thus a total possible score of 80 (or if including the toenails also, a maximum 
of 160).  In this method, individual features do not need to be scored, but it 
does allow for differentiation between the presence of nail bed and nail 
matrix features.  Initial assessment among dermatologists showed 
reasonable reproducibility amongst assessors (Rich et al. 2003) and good 
inter-observer agreement was confirmed in another study (Aktan et al. 
2007). The NAPSI has since been used in clinical trials (Kavanaugh et al. 
2009; Van den Bosch et al. 2010; Igarashi et al. 2012).  However, further 
studies have shown low intra-reader reliability when used by untrained 
rheumatologists (Lubrano et al. 2012).  The NAPSI, like all currently 
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available clinical nail severity assessment tools, does not assess quality of 
life.  A target nail NAPSI has also been suggested, where the presence of 
each feature was scored in each quadrant, giving a maximum score of 32 
(Rich et al. 2003).  The target NAPSI, and indeed the NAPSI may not be 
adequately sensitive to change for use in clinical trials as it merely records 
the presence or absence of features in each quadrant (Parrish et al. 2005).  
Even if the number of pits or the extent of onycholysis improves, the score 
will not change unless there is complete resolution within that quadrant. 
A modification to the NAPSI (the modified Nail Psoriasis Severity Index, 
mNAPSI) was then developed (Cassell et al. 2007).  This was developed by 
a group of physicians scoring a set of nail photographs using the NAPSI, 
and then adapting the system to improve aspects that caused variability 
between raters.  The division of the nail into quadrants was removed and 
instead, pitting, crumbling were scored on a scale from 0-3.  Oil drop 
discolouration and onycholysis were also combined, as they were felt to 
represent the same pathology.  In the newly modified method, each 
fingernail is scored for the presence and the severity of pitting, onycholysis 
and nail plate crumbling (score 0-3) and the presence or absence of splinter 
haemorrhages, leuconychia, red spots in the lunula and nail bed 
hyperkeratosis (score 1 for each if present).  This gives a total possible 
score of 140.  Validation as part of the original study found excellent inter-
rater reliability, along with good correlation with a physician nail VAS and 
good intra-rater reliability (Cassell et al. 2007).  A further international 
reliability exercise involving both rheumatologists and dermatologists found 
excellent agreement between raters with the mNAPSI (Chandran et al. 
2009).  The limitation of the mNAPSI is the time it takes to perform, 
particularly in patients with severe nail disease.   
Robert Baran has also proposed a scoring system for nail psoriasis (Baran 
2004).  This was created to include nail features that may account for 
different sites of pathology.  This system scores both the fingernails and 
toenails.  A semiquantitative score (0-3) is recorded each for pitting, Beau’s 
lines (transverse grooves), subungual hyperkeratosis (graded using a 
calliper), onycholysis, trachyonychia, leuconychia and oil drop spots.  
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Splinter haemorrhages and nail loss are not included in the score.  This has 
not been widely used. 
A simple more qualitative scoring system was described by Cannavo as part 
of an RCT (Cannavo et al. 2003).  In this method, a semiquantitative score 
(0-3) is recorded each for pitting, onycholysis, nail plate crumbling, nail bed 
hyperkeratosis and oil drop discolouration.  The overall score is simply the 
average of the score for all diseased nails. 
A study comparing the NAPSI and Cannavo’s scoring system found good 
inter-rater agreement for the NAPSI, and a good correlation between the two 
systems.  The authors did not find agreement between two raters for the 
scores in the toenails, which may be more subject to trauma or fungal 
disease. 
  
2.5.5 Imaging of nails in psoriatic disease (psoriatic arthritis and 
psoriasis)  
 
2.5.5.1 Magnetic resonance imaging 
 
While conventional radiographs are a useful way to assess the bony 
structures of the hand, they are limited by the two dimensional nature of the 
technology, as well as their inability to assess the soft tissues.  MRI has 
therefore been receiving increasing interest as a way to image the nail and 
the surrounding structures.  It allows the study of inflammation within the soft 
tissues and bone, as well as detecting disease at an earlier stage than is 
seen on radiographs.  High field machines may require uncomfortable 
positions to be held for some time, and therefore low field extremity 
machines have been developed which may offer some advantages, but 
perhaps with loss of some image quality (Soscia et al. 2009). 
A series of papers were published by Tan describing the findings on MRI of 
the finger joints in patients with PsA, OA and healthy controls.  In one study 
of patients with osteoarthritis, either the DIP or PIP joint was imaged (Tan et 
al. 2005).  Cartilage loss, synovitis, osteophytosis and bone marrow oedema 
were seen.  Thickening of the collateral ligaments was noted in every case, 
but milder changes in the collateral ligaments were also seen in older normal 
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controls, and in asymptomatic joints in patients with OA elsewhere.  In a 
study comparing DIP joints in OA and PsA patients, the PsA patients 
generally had a pattern of extracapular changes, entheseal disease, 
enhancement of the ligaments and more diffuse bone oedema (Tan et al. 
2006a).  The OA patients did have changes within the ligaments and 
entheses, but with less inflammation.  The diffuse inflammation seen in the 
PsA patients extended to involve the nail bed.  The close association 
between the nail and the DIP entheses was then examined using cadaveric 
histological sections, and compared to MRI findings in patients (Tan et al. 
2007).  Fibres were seen extending from the extensor tendon towards the 
nail bed on MR.  The nail thickness as seen on MR was greater in PsA 
patients than OA or controls.   Using the histological sections, it was 
confirmed that some fibres from the extensor tendon do continue up to and 
surround the nail root and matrix.  Some fibres from the flexor tendon also 
anchor the nail root and matrix at the outer aspects.  Thereby the diffuse 
inflammation seen in these areas in PsA may potentially explain the links 
with nail disease.  A previous dissection study had found close links between 
the collateral ligaments and the lunula and nail matrix (Guero et al. 1994). 
Scarpa described methodology to assess the nail and the DIP joint using 
MRI, with a 1.5 Tesla scanner, a surface coil and with Vaseline applied to 
the outer surface of the nail in order to visualise the nail thickness (Scarpa et 
al. 2006b).  Twenty three PsA patients with a median NAPSI score of 5 were 
scanned.  Thickening of the nail, with surface irregularity in some, was seen 
in 95.7% of the patients (100% of those with nail disease) and they recorded 
a higher MRI nail involvement score in those with nail disease than those 
without.  They did not detect abnormalities in the controls.  Within the distal 
phalanx, 95.7% PsA patients had abnormalities, which were more marked in 
those patients with clinical nail disease (of whom 100% had abnormailities).  
Only one control had evidence of bone resorption.  Involvement of the DIP 
joint was again more common in patients with nail disease.  No cases had 
isolated DIP joint involvement without bony changes in the distal phalanx, 
and the authors suggest that therefore DIP joint involvement is secondary to 
nail and distal phalanx disease. 
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McQueen’s group have used MRI to assess a cohort of 34 PsA patients with 
a baseline clinical asessment and MRI, followed by a clinical assessment in 
20 patients one year later (Dalbeth et al. 2012).  The MRI scan was 
performed of the dominant wrist and hand, using a 1.5 Tesla scanner with a 
dedicated wrist coil.  At baseline, nail pitting was not associated with MRI 
changes in the distal phalanx, but onycholysis and hyperkeratosis were.  
Bone marrow oedema on the baseline MRI was associated with the 
development of new onycholysis and hyperkeratosis at the one year visit.  
No comment was made on the nail appearances by MRI.  This study is 
interesting as the results conflict with the traditional thoughts that 
onycholysis and hyperkeratosis are nail bed lesions and therefore perhaps 
due to localised psoriasis in the nail bed rather than underlying bone or 
entheseal disease. 
No studies have yet been published describing the MRI findings of nail 




Two observational studies have studied the ability of ultrasound to image the 
nails in psoriasis.  Gutierrez et al. scanned the skin and nails of 30 psoriasis 
patients and 15 healthy controls and demonstrated structural changes in the 
nail and nail bed (focal hyperechoic deposits in the ventral nail plate, loss of 
definition of the nail plate, a wavy deformity of the nail plate, thickening of 
the nail bed and increased blood flow seen with power Doppler) (Gutierrez et 
al. 2009).  However, another observational study measuring nail volumes 
and matrix volumes was unable to detect a difference between healthy 
controls and patients with psoriatic nail disease (Wollina et al. 2001).   
In a cohort of psoriasis and PsA patients, an increased thickness of the nail 
plate and nail bed was seen in the psoriasis patients with nail disease, 
compared to healthy controls (Gisondi et al. 2012).  A correlation was also 
seen between the NAPSI score and the nail thickness.  Even in the psoriasis 
patients with clinically normal nails, an increased thickness of the nail plate 
and nail bed was also seen, when compared to controls. 
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Gutierrez found abnormalities of the nail plate and bed by ultrasound in PsA 
patients, with loss of definition of the ventral nail plate in early or mild nail 
disease and loss of the complete trilaminar appearance in later stages 
(Gutierrez et al. 2010).  Thickening of the nail bed was also seen, as was 
abnormally increased blood flow in the nail bed in the presence of nail 
disease.  In another study, Gutierrez demonstrated reductions in PD scores 
in the nail bed with TNF inhibitor treatment (Gutierrez et al. 2012). 
 
2.5.5.3 Optical coherence tomography  
 
Optical coherence tomography (OCT) is a newer imaging technique finding 
increasing use in the dermatology setting (Welzel et al. 1997).  OCT uses 
infrared light in the same manner that ultrasound uses acoustic waves.  The 
reflections of the light are detected and processed by a computer, 
generating an image.  The axial resolution is 1 – 2mm, and is determined by 
the bandwidth of the light source.  It is therefore only suitable for the 
assessment of very superficial structures.  Within dermatology, it has found 
use in the assessment of skin cancer, and in opthalmology for retinal 
assessment (Sakata et al. 2009; Geitzenauer et al. 2011; Pomerantz et al. 
2011; Coleman et al. 2013).  Initial reports in the assessment of nail 
diseases using OCT have shown an ability to objectively measure the nail 
thickness, and demonstrate abnormalities within the nail plate in leuconychia 
(Mogensen et al. 2007; Abuzahra et al. 2010; Sattler et al. 2012)).  Our 
group has demonstrated the ability of OCT to detect psoriatic nail disease in 
one case (Aydin et al. 2011) and work is ongoing in a larger cohort.   
 
2.5.6 The response of nail disease to treatment 
  
Historically, the treatment of psoriatic nail disease has been difficult.  
Research into efficacy may also previously have been hampered by the lack 
of validated outcome measures. 
Topical treatments are commonly used, but require frequent applications for 
a prolonged period of time, and with little available evidence to support their 
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efficacy.  Most frequently used are glucocorticoids and vitamin D3 
analogues, both of which have more data available to support their 
effectiveness on the skin than the nails.  A comparison study of calcipotriol 
and betamethasone topical treatments for nail psoriasis found around 50% 
reductions in subungual hyperkeratosis with either treatment (Tosti et al. 
1998).  Small studies are also available for topical fluorouracil, 5-FU, 
anthralin, ciclosporin and tazarotene (Jiaravuthisan et al. 2007).   
Glucocorticoid injections may also be used, injecting the steroid into or 
around the nail matrix.  Again only small studies are available, with variable 
results.  Injections appear more effective in the treatment of nail matrix 
lesions (pitting, nail crumbling) than nail bed lesions (such as onycholysis) 
(Jiaravuthisan et al. 2007).  Repeated injections may be needed, the 
injections can be fiddly, and they may also be painful.   
Only two studies have been published describing the effects of PUVA 
(psoralen plus ultraviolet A light phototherapy) in nail psoriasis.  Greater 
responses were seen for onycholysis than for pitting  (Marx et al. 1980; 
Handfield-Jones et al. 1987). 
Two open label studies have demonstrated improvements in nail psoriasis 
with oral ciclosporin, which is commonly used for skin psoriasis (Mahrle et al. 
1995; Feliciani et al. 2004).  An open label study comparing methotrexate 
and ciclosporin found mean reductions in the NAPSI score of 43% and 37% 
respectively (Gumusel et al. 2011).  Acitretin has shown some promise in an 
open label study of psoriasis patients treated for six months (Tosti et al. 
2009).  The mean NAPSI was seen to reduce by 41% with treatment, and 
the mean mNAPSI by 50%.  Improvements in the nail disease were seen in 
83% patients. 
With the advent of the biological treatments for psoriasis and PsA came the 
realisation that nail disease also improved.  Efficacy has been shown for 
adalimumab, etanercept, golimumab, infliximab, ustekinumab and variably 
for alefacept (which has since been withdrawn).  Initial publications were in 
the form of case reports and small case series but subsequently as RCTs 
(although generally as secondary outcome measures and thus without 
statistical power). 
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An open label uncontrolled study of adalimumab in PsA included 442 
patients, of whom 259 (59%) had nail disease at baseline (Van den Bosch et 
al. 2010).  When assessing the 164 patients with a baseline NAPSI of ≥10, 
54% had a ≥50% improvement in the NAPSI at week 12.  A small open label 
study of patients with nail disease and either psoriasis or PsA found a 
reduction in the mean NAPSI for the fingernails with adalimumab from 10.57 
to 1.57 for the psoriasis patients (n=7) and 23.86 to 3.23 for the PsA patients 
(n=14) (Rigopoulos et al. 2010). 
An open label study in patients with nail psoriasis compared etanercept 
50mg twice a week to etanercept 50mg once a week for 12 weeks, followed 
by 12 weeks where both groups received treatment once a week (Ortonne et 
al. 2013).  No significant difference in efficacy was seen between the two 
groups, with a mean target finger NAPSI score reduction at 24 weeks of 4.3 
in the twice a week group, and 4.4 in the once a week group.  With baseline 
mean target nail NAPSI scores of 6.0 and 5.8, the reductions seen are 
impressive.  A large randomised open label study treated psoriasis patients 
either continuously or intermittently (treated until target reached and then 
discontinued until flare) with etanercept (Luger et al. 2009).  The study 
included 564 patients with nail psoriasis, with a mean target finger NAPSI of 
4.64 at baseline.  At 12 weeks, the mean target finger NAPSI was 3.30, at 
week 54 it was 2.26, with 30% patients having complete clearance in the 
target nail.     
A phase III RCT of golimumab in PsA found significant reductions in the 
severity of nail disease at both 14 and 24 weeks with golimumab using the 
physician global assessment of nail disease and the target nail NAPSI 
(Kavanaugh et al. 2009). 
A phase III study of infliximab in psoriasis found statistically significant mean 
reductions in the NAPSI compared to placebo at as early as ten weeks, with 
a mean 56% improvement in the NAPSI by 24 weeks (Reich et al. 2005).  A 
further phase III study in psoriasis found complete nail disease clearance in 
the target nail in 26% patients on infliximab at week 24 (compared to 5% 
patients on placebo) and in 45% at one year (Rich et al. 2008).  
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Improvements were seen in both nail bed and nail matrix features of 
psoriasis 
An open label study of 27 psoriasis patients treated with ustekinumab found 
significant reductions in the NAPSI score at as early as four weeks, and 
maintained up to 40 weeks (Rigopoulos et al. 2011).  A small open label 
study (n=8) with alefacept showed variable results, with improvement in 
some patients but worsening in others (Korver et al. 2006). 
These studies confirm good responses of nail disease to treatment with an 
TNF inhibitor, but of course these treatments are expensive and have 
potential side effects.  Treatment guidelines do not currently recommend 
biologic treatment purely for psoriatic nail disease in the absence of 
significant skin psoriasis or arthritis (Ritchlin et al. 2009; Gossec et al. 2012). 
 
2.6 Treatment of psoriatic arthritis  
 
Many of the treatments used for psoriatic arthritis are taken from those used 
for RA.  Traditional treatments include non-steroidal anti-inflammatory drugs 
and a range of ‘disease modifying drugs’ including methotrexate, 
sulphasalazine, leflunomide and ciclosporin.  However, there are very little 
good quality RCT data available to provide an evidence base in support of 
these treatments (Ash et al. 2012a). 
 
 
2.6.1 Treatment of psoriatic arthritis with biological agents 
 
A systematic literature review and meta-analysis on the pharmacologic 
treatment of PsA was performed to inform a European League Against 
Rheumatism (EULAR) taskforce producing new management guidelines 
(Gossec et al. 2012).  The previous guidelines published on the 
management of PsA were produced by GRAPPA, based on literature 
reviews performed in 2005 (Ritchlin et al. 2009).  Given a significant body of 
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new data available since then, it was felt appropriate to produce new 
guidelines.    
Systematic literature searches covering the period between 1962 to January 
2010 were performed using PubMed MEDLINE, EMBASE and COCHRANE 
databases, to identify all articles reporting the efficacy and safety of 
biological agents in PsA (Ash et al. 2012a). 
The taskforce was responsible for outlining the scope of the literature 
search, specifying research questions designed to facilitate the formulation 
of the guidelines and evaluating the results of the systematic literature 
search.  
Inclusion criteria for this review were: (1) systematic reviews and meta-
analyses; (2) double-blind randomised controlled trials (RCTs); (3) patients 
with PsA; (4) studies involving biological agents; (5) studies recruiting at 
least five patients; (6) publications in English, French, German, Italian or 
Spanish.  With regard to biological agents, data on safety and efficacy were 
extracted from all studies, but only double-blind RCTs were included in the 
meta-analysis.  Data were extracted from the articles independently by two 
reviewers. Discrepancies were resolved by discussion.  
Where possible (in particular for biologics), efficacy data were meta-
analysed using Revman V.5.0. software and expressed as RR for 
dichotomous variables or mean differences for continuous variables. 
Random effects were assumed throughout and heterogeneity was assessed 
using the χ2 test and I2 test. Where the heterogeneity test was significant at 
p<0.1, data were not pooled. Toxicity data from RCTs were meta-analysed 
using generic inverse variance analysis of the natural log of the rate ratio (of 
events per 100 patient years, random effects assumed).  
 
2.6.1.1 The efficacy of biological treatments 
Of 1974 articles screened, 132 articles and 33 abstracts were included in the 
final review.  These included 11 RCTs used for the efficacy meta-analysis on 
adalimumab, alefacept, efalizumab, etanercept, golimumab, infliximab and 
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ustekinumab.  Results are summarised according to questions formulated by 
the EULAR taskforce. 
 
a) In patients with PsA, is treatment with biological agents efficacious 
compared to placebo or active comparator? 
 
All TNF inhibitors (adalimumab, etanercept, golimumab and infliximab) 
showed efficacy at 12 – 16 weeks for Psoriatic Arthritis Response Criteria 
(PsARC) response, American College of Rheumatology (ACR) 20, 50 and 
70 response criteria and Psoriasis Area and Severity Index (PASI) (Mease et 
al. 2000; Mease et al. 2004; Antoni et al. 2005a; Antoni et al. 2005b; Mease 
et al. 2005; Genovese et al. 2007; Vander Cruyssen et al. 2007; Kavanaugh 
et al. 2009) (Figure 6).  Efalizumab was not superior to placebo for PsARC 
response or ACR 20, 50 and 70 responses (Papp et al. 2007).  Ustekinumab 
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Figure 6.  Efficacy of biological drugs in PsA 
Risk ratios for PsARC response at 12 - 14 weeks comparing the use of a 
biological disease modifying antirheumatic drug versus placebo in 




Improvements in Health Assessment Questionnaire (HAQ) were greater with 
adalimumab (Mease et al. 2005; Genovese et al. 2007), infliximab (Antoni et 
al. 2005a; Antoni et al. 2005b), ustekinumab (Gottlieb et al. 2008) and 
alefacept (Mease et al. 2006a) than placebo at 12 weeks, and with 
adalimumab (Mease et al. 2005), etanercept (Mease et al. 2004), golimumab 
(Kavanaugh et al. 2009) and infliximab (Antoni et al. 2005a) at 24 weeks, but 
not with alefacept (Mease et al. 2006a) at 24 weeks. Radiographic 
progression as measured by the modified total Sharp or PsA modified van 
der Heijde Sharp scoring method was lower for patients treated with 
etanercept (Mease et al. 2004), golimumab (Kavanaugh et al. 2012a) and 
infliximab (van der Heijde et al. 2007) at 12 months compared to placebo. 
Data for adalimumab (Gladman et al. 2007b) and infliximab (Kavanaugh et 
al. 2006) showed significant differences compared to placebo at 24 weeks. 




b) Is there a different efficacy of biological agents in PsA subtypes of 
articular involvement (monoarthritis, oligoarthritis, polyarthritis, axial disease, 
dactylitis, enthesitis)? 
 
For peripheral joint disease, no RCTs reported results separately for the 
different subtypes of PsA.  With regards to spinal disease, only one 
observational study (Olivieri et al. 2008) was found reporting on spinal 
disease associated with PsA although final results were pooled for patients 
with and without spinal disease.   
For dactylitis and enthesitis, six RCTs reported data (between 12 - 16 
weeks) (Antoni et al. 2005a; Antoni et al. 2005b; Genovese et al. 2007; 
Gottlieb et al. 2009; Kavanaugh et al. 2009; Sterry et al. 2010) showing 
significant benefits with golimumab, infliximab and ustekinumab.  However 
both (dactylitis and enthesitis) were reported as secondary outcomes with no 
prior power calculations having been performed.  Studies used different 
outcome measures with only a proportion of patients having documented 
baseline dactylitis or enthesitis. 
 
c) Is there efficacy of biological agents on the extra-articular manifestations 
of PsA (ie: skin and nail involvement)? 
 
Skin disease:  Nine RCTs reported data for PASI responses.  Treatment with 
all TNF inhibitors was better than placebo at reducing the PASI score at both 
12 and 24 weeks (Mease et al. 2000; Mease et al. 2004; Antoni et al. 2005a; 
Antoni et al. 2005b; Mease et al. 2005; Kavanaugh et al. 2008) (Figure 7). 
Efficacy was also demonstrated for alefacept, efalizumab and ustekinumab 
(Papp et al. 2007; Gottlieb et al. 2008; Mease et al. 2009).  
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Figure 7.  Efficacy of biological drugs for psoriasis 
Risk ratios for PASI 50 response at 12 - 16 weeks comparing the use of a 
biological disease modifying antirheumatic drug versus placebo in 




Nail disease: Only one RCT reported on nail disease.  Patients treated with 
golimumab showed a significantly greater percentage change in Nail 
Psoriasis Severity Index (NAPSI) score at both 14 and 24 weeks 
(Kavanaugh et al. 2009).  Two large observational studies with adalimumab 
also showed clear improvements in nail disease (Manger et al. 2008; Van 
den Bosch et al. 2010). 
 
d) In the treatment of PsA, are there differences in efficacy or safety 
between the different biological agents (spine, skin, nail etc.)? 
 
There is evidence for a lower RR for etanercept for a PASI 75 response at 
12 weeks (11.00, 95% CI 0.65, 186.02) when compared to the other anti-
TNF agents.  Efficacy of etanercept is demonstrated at 24 weeks, but with a 
lower RR than adalimumab, golimumab and infliximab. 




e) In TNF-blocker inadequate responders, what evidence is there for efficacy 
of a second biological agent? 
 
While no RCTs are available, data from observational studies were available 
from 8 scientific papers (Gomez-Reino et al. 2006; Conti et al. 2007; 
Descalzo et al. 2007; Papoutsaki et al. 2007; Pitarch et al. 2007; Coates et 
al. 2008b; Mazzotta et al. 2009; Saad et al. 2009) and one abstract 
(Burmester et al. 2008).  Data from the Spanish registry BIOBADASER show 
drug survival of 0.87 (95% CI 0.83 – 0.90) for the first biologic and 0.81 (95% 
CI 0.65 – 0.90) for the second biologic, although numbers are small (Gomez-
Reino et al. 2006). A later publication from BIOBADASER (Descalzo et al. 
2007) reported that 23 of 118 patients had discontinued their second biologic 
(mean follow up 2.18 years), and 2 of 15 patients had discontinued their third 
agent.  A paper from the British Society for Rheumatology Biologics Register 
(BSRBR) (Saad et al. 2009) shows one year drug survival of 0.82 (95% CI 
0.79 – 0.85) for the first biologic and 0.74 (95% CI 0.71 – 0.78) for the 
second.  Four observational studies also documented good response rates 
in patients switching to a second agent (Conti et al. 2007; Papoutsaki et al. 
2007; Coates et al. 2008b; Mazzotta et al. 2009). 
 
f) Is there evidence of greater efficacy or greater risks with combination 
therapy (with DMARDs)? 
 
Data available from RCTs are limited.  Both IMPACT2 and ADEPT showed 
similar response rates comparing biologic monotherapy versus combination 
of a biologic agent with a DMARD (Antoni et al. 2005a; Mease et al. 2005).  
Seven other papers and one abstract were reviewed.  Data from the 
Norwegian DMARD register showed similar response in patients who 
received concomitant methotrexate (MTX) compared to those on 
monotherapy biologic at six months (Heiberg et al. 2007).  However, a 
significantly increased drug survival was seen at one year in those patients 
receiving combination therapy with MTX and a biologic, compared to 
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monotherapy biologic (P=0.02) (Heiberg et al. 2008).   A further analysis of 
440 patients in the NOR-DMARD register found again no difference in 
treatment response, but greater drug survival in those patients also receiving 
methotrexate, and this effect was most marked with infliximab (Fagerli et al. 
2013).  Patients receiving infliximab monotherapy had a greater chance of 
adverse events leading to treatment discontinuation.  Data from the South 
Swedish Arthritis Treatment Group (SSATG) register also described better 
drug survival in those patients on concomitant MTX (Hazard Ratio 0.64, 95% 
CI 0.39 – 0.95, P=0.03), due to fewer drop-outs for adverse events 
(Kristensen et al. 2008).  A further paper published by the same group in 
2009 showed an increased risk of dose escalation of infliximab in patients 
not taking MTX (P=0.03) (Kristensen et al. 2009). 
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2.7 Arthritis mutilans 
 
Psoriatic arthritis is associated with a number of manifestations. One of 
these is the development of a very destructive arthritis of the small joints of 
the hands and feet with extensive dissolution of the bone.  This highly 
osteolytic arthropathy is known as arthritis mutilans and was described by 
Verna Wright as one of the subtypes of PsA (Wright et al. 1976).  Many 
cases have been reported historically, with a description of the ‘opera glass 
hand’ syndrome describing the redundant skin and the ability to manually 
lengthen the digits (Swezey et al. 1972). 
One of the characteristic radiographic features is the pencil-in-cup deformity, 
resulting from destruction blunting the head of the metacarpal or other bone, 
and resorption and new bone formation creating a cup at the base of the 
phalanx (Swezey et al. 1972; Laurent 1985).  Even in the same patient the 
different pathological processes can occur, as is demonstrated in a case 
with severe erosive disease in the peripheral joints and florid new bone 
formation in the spine (Ly et al. 2009).  An MRI study comparing 11 patients 
with arthritis mutilans with 17 patients with other forms of erosive PsA found 
higher MRI erosion, bone proliferation and bone oedema scores in the 
patients with arthritis mutilans (Tan et al. 2009).  The authors suggested that 
bone oedema could reflect a pre-erosive feature, but this would require 
clarification in a longitudinal study. 
Cross-sectional studies have found arthritis mutilans in 2 - 5% of PsA 
patients (Torre Alonso et al. 1991; Jones et al. 1994; Veale et al. 1994; 
Nossent et al. 2009; Reich et al. 2009). One study found no clinical 
predictors of which patients develop arthritis mutilans and found that it could 
occur in any PsA subtype (Kammer et al. 1979).  A study following 73 
patients found a significant association between axial disease and female 
sex with arthritis mutilans (Marsal et al. 1999).  Data from the Classification 
of Psoriatic ARrthritis (CASPAR) study (Taylor et al. 2006) found that 
patients with arthritis mutilans had a longer disease duration, more joints 
involved, were more likely to be ACPA positive, have undergone surgery and 
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have radiographic damage (Helliwell 2009).   A possible definition of arthritis 
mutilans has been proposed, with criteria including polyarticular disease, a 
long disease duration, symmetrical arthritis, ACPA positivity and 
characteristic radiographic features (osteolysis, ankylosis, entheseal 
abnormalities, and spinal involvement) (Helliwell 2009). 
Arthritis mutilans can develop quickly and there is an urgent need to better 
identify it, so that effective but expensive therapies could be promptly 
initiated in this disease subgroup.  
 
2.8 Predictors of radiographic progression in psoriatic 
arthritis 
 
Magnetic resonance imaging of the sacroiliac joint has been used in early 
axial spondyloarthropathy, which is closely related to PsA, to show that 
baseline MRI bone oedema, histologically an osteitis, is associated with the 
development of radiographic destructive changes eight years later (Bennett 
et al. 2008). However much of the pathology in the sacroiliac joint and the 
spine is characterised by new bone formation whereas the hand pathology in 
PsA is typified by joint destruction.  In a prospective longitudinal study, 
inflammation in an individual joint in PsA has been shown to later predict 
clinical damage to that joint (Cresswell et al. 2011).  Radiographic data was 
not presented.  A cross sectional study demonstrated higher levels of bone 
oedema in arthritis mutilans compared to erosive PsA without bone lysis, 
with a correlation seen between bone oedema and current radiographic 
damage (Tan et al. 2009).  A small retrospective study found that patients 
with an increasing swollen joint count developed more radiographic damage 
than those with a stable or reducing number of swollen joints (Simon et al. 
2012).  That study also echoed the results of the RCTs, with less 
radiographic damage occurring in patients receiving TNF inhibitors than in 
patients on DMARDs.  In an analysis of RCT data, achieving the Minimal 
Disease Activity criteria (Coates et al. 2010a) also led to less radiographic 
progression (Coates et al. 2010b), supporting the idea that active disease is 
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a risk factor for ongoing radiographic progression.  Data from an 
adalimumab RCT found the baseline and mean CRP level to be associated 
with radiographic progression, but again with less progression in those 
patients treated with the TNF inhibitor compared to those receiving placebo 
(Gladman et al. 2010).  Similarly, data from the Bath cohort show increased 
radiographic progression with a higher plasma viscosity at baseline (McHugh 
et al. 2003). 
In a cross-sectional study, multivariate analysis found DIP involvement and 
polyarticular disease to be associated with aggressive joint manifestations 
such as radiological erosions or irreversible deformities (Alenius et al. 
2002a).  ACPA antibodies were found to be associated with polyarticular 
disease but not radiographic damage or clinical deformity (Alenius et al. 
2006).  However, another small study found an association between ACPA 
antibodies and erosive disease (Korendowych et al. 2005).  A prospective 
study of 100 PsA patients found an increased risk of destructive arthritis in 
women, and radiographic changes more frequently in patients with 
symmetrical arthritis (Kammer et al. 1979).  A prospective study of patients 
with early PsA in Ireland found significantly more periostitis on follow-up 
radiographs in patients presenting with young onset (age <60) than elderly 
onset PsA (Kane et al. 2003).  Another prospective study comparing young 
and elderly onset PsA found more aggressive disease in the elderly onset 
PsA, with higher inflammatory markers and more radiographic progression 
(Punzi et al. 1999).  In another study, axial disease and a history of swollen 
joints during the follow-up up period were associated with radiographic 
erosions (Marsal et al. 1999).  A retrospective study found an association 
between female sex and erosive disease (Queiro et al. 2001).  A prospective 
study following 71 patients with PsA found only polyarticular onset of 
disease to be an independent predictor of the development of erosive and 
deforming disease, with an odds ratio of 37 (Queiro-Silva et al. 2003).  Initial 
analysis from that study showed the development of erosive disease to be 
more common in females and those with DIP disease and the HLA B27 
genotype.  Contrastingly, one of the original studies by Verna Wright’s group 
found more radiographic damage in men (Roberts et al. 1976). 
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Data from the Toronto PsA cohort which has been ongoing since 1976 has 
found an association between the development of clinically damaged joints 
and a higher number of swollen or inflamed joints, raised inflammatory 
markers, clinically damaged joints at baseline, female sex and the duration 
of PsA (Gladman et al. 1995; Gladman et al. 1999; Siannis et al. 2006).  
Gladman has also reported predictors of radiographic damage to include 
DIP disease, symmetrical polyarthritis, the number of swollen and tender 
joints at the last visit, age, disease duration, baseline ESR and previous 
clinical damage (Gladman et al. 1987a; Bond et al. 2007).  They have also 
noted an increase in radiographic damage in a dactylitic compared to non-
dactylitic digit (Brockbank et al. 2005). 
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2.9 Summary  
 
Enthesitis is a characteristic feature of PsA.  The nail bed and matrix are 
closely associated with the entheses of the ligaments and tendons around 
the DIP joint.  In PsA with active arthritis of the DIP joint, there is diffuse 
inflammation of the bone, soft tissues, and entheses surrounding the nail 
matrix, and this is associated with the presence of nail disease.   
A significant proportion of patients with psoriasis have an underlying 
subclinical enthesitis seen around the large joints, but the significance of 
this is not yet known.  The role of DIP joint enthesitis in the pathogenesis of 
nail disease in psoriasis (without arthritis) is not yet known.  Clinical 
predictors for the presence of subclinical enthesitis have not yet been 
investigated. 
Nail disease is known to improve with TNF inhibitor therapy in both 
psoriasis and PsA.  These treatments are also effective for enthesitis. 
Arthritis mutilans is a rare subtype of PsA and on a cross-sectional basis is 
associated with bone oedema.  Active arthritis predicts later radiographic 
damage in the same joint in PsA.  Imaging features which predict the later 








Aims and objectives 
 
The hypotheses of this work are that: 
 
1.  Nail disease could be a marker for those psoriasis patients who 
have subclinical enthesitis elsewhere, and therefore could be a 
potential predictor for the later development of PsA 
 
2.  Nail disease is due to subclinical or clinical enthesitis around the 
DIP joint in both PsA and psoriasis 
 
3.  The improvement in nail disease seen with anti-tumour necrosis 
factor (TNF) therapy may be due to improvements in enthesitis 
around the DIP joint 
 
4.  DIP joint bone marrow oedema lesions in active PsA are predictive 
of radiographic damage in that joint at a later stage 
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A number of research questions have been formulated based on these hypotheses: 
Table 8.  Research questions addressed in this thesis 





Chapter  Reference 
if published 
Could nail disease be a marker for 
those psoriasis patients who have 
subclinical enthesitis elsewhere, 
and could this be a potential 
predictor for the later development 
of PsA? 
To explore whether nail disease in 
PsA and nail disease in psoriasis but 





MAP * Chapter 4  
 
Chapter 5  
(Ash et al. 
2012b) 
(Aydin et al. 
2013) 
Is nail disease due to clinical or 
subclinical enthesitis around the 
DIP joint in both PsA and 
psoriasis? 
To describe the pattern of enthesitis 
around the DIP joint seen on high field 
magnetic resonance imaging (MRI) in 
patients with psoriasis and PsA, 





MAP * Chapter 6   
 
Chapter 7  
 
 
(Aydin et al. 
2012) 
 
- 126 - 
 
 





Chapter  Reference 
if published 
Is the improvement in nail disease 
seen with anti-tumour necrosis 
factor (TNF) therapy due to 
improvements in enthesitis around 
the DIP joint? 
To describe the changes seen in nail 
disease and DIP enthesitis in patients 
before and after receiving anti-TNF 




NET  Chapter 8   
Are DIP joint bone marrow oedema 
lesions in active PsA predictive of 
radiographic damage in that joint at 
a later stage? 
To investigate the predictive value of 
the bone marrow oedema MRI lesion 
in the DIP joint in PsA in the future 
development of osteolysis 
Long term follow-




Chapter 9   
* MAP: High resolution MRI of the nail and ultrasound of Asymptomatic entheses in patients with Psoriasis 
  NET: High resolution MRI to describe the changes in Nail disease and Enthesitis around the DIP joint in patients with psoriasis and 
psoriatic arthritis receiving biologic Therapy 
῁ PAMPA: The Prognostic value of baseline MRI-determined osteitis in predicting Arthritis Mutilans in Psoriatic Arthritis 








Psoriasis affects approximately 2% of the population and up to 30% of these 
will develop psoriatic arthritis (PsA) (Gelfand et al. 2005b; Radtke et al. 
2009; Reich et al. 2009; Christophers et al. 2010). As dermatologists usually 
see patients with psoriasis before arthritis develops then they are well placed 
to diagnose PsA early.  Now that effective therapies for the suppression of 
PsA exist, the early recognition of PsA has important consequences for 
optimal patient management.   Presently, the conceptual basis for the link 
between psoriasis and nail disease and subsequent PsA is poorly 
understood.   
It has been suggested that enthesitis is the primary lesion that underscores 
the diverse skeletal manifestations of PsA (McGonagle et al. 1998b). It has 
also been demonstrated that subclinical enthesopathy and associated 
osteitis is present in up to 50% of patients with psoriasis with no arthritis 
(Gisondi et al. 2008; McGonagle et al. 2011a). Another stream of research 
has shown that the presence of nail disease is a harbinger for the future 
development of PsA (Wilson et al. 2009a). These findings are noteworthy 
since it has been shown that psoriatic nail disease in PsA is intimately 
associated with enthesopathy of the distal interphalangeal joint and that the 
nail is functionally integrated with the enthesis (Tan et al. 2006a; Tan et al. 
2007; McGonagle et al. 2009a).  
These combined clinical and imaging observations suggest that there may 
be a link between systemic enthesopathy and psoriatic nail disease.  
Therefore, the question is posed here as to whether nail disease in psoriasis 
is linked to a greater degree of systemic enthesopathy compared to 
psoriasis patients without nail disease.   Such a link would offer a novel 
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unifying concept for nail disease, systemic enthesopathy and the future 




The study was carried out in two European populations (Leeds, UK and 
Verona, Italy).  Ethical approval for the study was obtained in both countries. 
 
4.2.1 Patient groups and clinical assessment 
Forty-six patients with psoriasis (31 with nail disease) and 21 healthy 
controls (HC) were included.  Thirty-six patients were recruited in the UK, 10 
patients and the HC were recruited in Italy.  Any patients with PsA according 
to the CASPAR criteria (Taylor et al. 2006), patients with evidence of 
osteoarthritis, and those with arthralgia or articular symptoms were 
excluded. The clinical assessment was performed by a clinician blinded to 
the US data.  The clinical assessment included a PASI and BSA score, 
tender (78) and swollen (76) joint count,  Leeds and SPARCC enthesitis 
indices and a dactylitis count.  Modified NAPSI scores for all fingernails were 
recorded for patients recruited in UK (Cassell et al. 2007).  Patients 
completed questionnaires including the PEST and DLQI and high resolution 
photographs of the nails were taken.  Patients receiving glucocorticoids and 
anti-TNF therapies were excluded from the study, those receiving DMARD 
therapy were recruited if they had active skin disease (inadequate 
responders). 
For HC recruitment, adults aged between 18-64 who were accompanying 
patients were approached in the outpatient clinical waiting area.  People 
without a history of arthritis and psoriasis were recruited. 
 




Ultrasound was performed by three rheumatologists fully trained in 
musculoskeletal US and with a special interest in scanning enthesitis (SZA 
and CC-G in UK, IT in Italy) using a Logiq E9 machine in UK and Logiq 5 
machine in Italy (General Electric, Wauwatosa, Wisconsin USA) both with a 
linear probe at 9–14 MHz. 
Ultrasound of the lower limbs entheses (Achilles, plantar fascia insertion, 
quadriceps insertions, patellar tendon origins and insertions) and common 
extensor tendon origins of the upper limbs was performed blinded to the 
presence of psoriasis or nail disease. To enable blinding, patients were 
asked not to communicate with the ultrasonographer about their disease 
during the US assessment. The sonographer did not perform a physical 
examination, therefore sites other than those involved in the US scan were 
not seen by the sonographer. The room was completely darkened starting 
from the beginning of the US assessment.  The light of the US machine 
alone is not enough for the sonographer to see the nails clearly. 
The patients were placed in a supine position to assess the entheses around 
the knee (extended to assess the presence of Doppler signal and semiflexed 
to 30 degrees to assess the grey-scale (GS) changes) and in a prone 
position with the feet over the end of the examination table for visualization 
of the entheses around the heel. To assess the common extensor tendon, 
patients were placed in a sitting position with the elbow flexed to 90 degrees 
(Table 9).  
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Table 9. Entheseal sites assessed by US, patient and probe positioning  







In supine position with the knee extended 
to assess the presence of Doppler signal 
and semiflexed to 30 degrees to assess 
the grey-scale changes.  






In supine position with the knee extended 
to assess the presence of Doppler signal 
and semiflexed to 30 degrees to assess 





In supine position with the knee extended 
to assess the presence of Doppler signal 
and semiflexed to 30 degrees to assess 
the grey-scale changes. 





In prone position with the feet over the 
end of the examination table in neutral 
position 





In prone position with the feet over the 
end of the examination table in neutral 
position 





In a sitting position and the elbow flexed 
to 90 degrees. 
Lateral elbow 
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The PD settings were standardized with a pulse repetition frequency of 750 
Hz, a colour-mode frequency of 9.1 MHz and low wall filters. The colour gain 
was increased to the maximum level not generating PD signals under the 
bony cortex. All US assessments were performed using a multiplanar 
scanning technique. 
 
4.2.3 Ultrasound image interpretation 
The OMERACT definition of enthesopathy was used to interpret US images: 
“abnormally hypoechoic (loss of normal fibrillar architecture) and/or 
thickened tendon or ligament at its bony attachment (may occasionally 
contain hyperechoic foci consistent with calcification), seen in two 
perpendicular planes that may exhibit Doppler signal and/or bony changes 
including enthesophytes, erosions, or irregularity” (Wakefield et al. 2005). 
Bursal enlargement was also scored.  Thickness measurements and 
erosions were scored quantitatively, except the thickness of the common 
extensor tendon which was assessed semi-quantitatively. The thickness of 
the entheses was measured at the level of insertions in longitudinal scans. 
Normal values for each insertion was accepted as reported in the literature 
(Balint et al. 2002)  and additionally < 1 mm of increase exceeding the 
threshold was scored as grade 1, ≥1 but <2 mm of increase was scored as 
grade 2 and ≥2mm was scored as grade 3. Erosions were also scored 
quantitatively (maximum diameter of the erosion >0, <2 mm: grade 1; ≥2, <3 
mm: grade 3; ≥3 mm: grade 3). The rest of the assessments were done on a 
semiquantitative basis (mild changes grade 1, moderate grade 2 and severe 
grade 3).  
Ultrasound findings were categorized according to the following: 
The GS changes related to inflammation (entheseal hypoechogenicity, 
thickening and bursal enlargement) and the PD scores were added up to 
create an “inflammation score” (range 0-156). The GS changes related to 
chronic findings (calcifications, erosions and enthesophytes) were added up 
to calculate a “chronicity score” (range 0-108).  A total score (by adding up 
all findings) had a possible range of 0-264 (Table 10).  
- 132 - 
 
 
Table 10.  Components of the ultrasound enthesitis score, with the maximum 
possible score per patient 
The two bursa scores are not applicable at the proximal patellar tendon 
insertion or plantar fascia.  Each patient is assessed at 12 entheseal sites 











Calcifications  36  108  
Erosions  36  








36  96  




PD score PD at the 
enthesis 
36  60  
PD in the bursa  24  
Total inflammation score  156  
Total  score 264  
 
4.2.4 Statistics 
Categorical data are expressed as frequencies, and continuous variables 
are given as means (standard deviation) or medians (range) (depending on 
the distribution). The prevalence of each individual lesion by US in patients 
with or without nail disease was compared by using a chi-square test. Mann-
Whitney U test was used in order to compare US scores between groups.  
Correlations between clinical parameters (mNAPSI, PASI, and disease 
duration) and US scores (separately for US scores related to inflammation, 
damage and total) were analysed by Pearson correlation test. Statistical 
analysis was performed using SPSS version 11.5.  
For agreement between sonographers, all investigators agreed on 
definitions and the scoring system prior to the study both on saved images 
and while acquiring sample images. 1020 stored images of 21 patients for 
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grey scale and PD for all entheses included in the study were scored by all 3 




4.3.1 Inter-observer agreement 
A moderate to excellent agreement between both investigator pairs were 
calculated for different US scores: for GS inflammation the ICC values were 
0.91-0.93 (95% CI: 0.79-0.97), for PD inflammation 0.74-0.95 (95% CI:0.45-
0.98), for chronicity scores 0.89-0.93 (95% CI:0.76-0.98) and for total US 
scores 0.92-0.95 (95% CI:0.81-0.98). 
 
4.3.2 Patient characteristics 
The distribution of key characteristics of patients and HCs did not differ 
significantly [for age mean (SD) 44.2 (15.5) vs  50.5 (10) respectively; p=NS] 
[for BMI 26.7 (5.1) vs 24.9 (2.7) respectively; p=NS] (female %: 50% in 
psoriasis vs 52.4 % in HC).  Comparing psoriasis patients with nail disease 
and those with normal nails, again similar values for age and BMI were seen 
[for age mean (SD) 46.7 (15.9) vs 39 (13.8) respectively] [for BMI 27.4 (5.7) 
vs 25.6 (3.6)].  PASI scores of psoriasis patients with [5.6 (4.1)] or without 
nail disease [6.3 (5)] were similar.  They also had similar disease durations 
[19.1 (10) years for nail disease and 14.1 (12.6) years for psoriasis; p=0.06]. 
Nail findings within the nail disease group were as follows: 104/310 nails had 
onycholysis 165/310 had pitting and 41/310 had crumbling.  Although no 
patients reported joint symptoms and none had clinically evident joint 
swelling, 4 cases had mild entheseal tenderness on physical examination (3 
with nail disease, 1 without nail disease). Three of these patients had 
tenderness only at one site (2 lateral epicondyle and 1 patellar ligament 
insertion) and 1 patient had tenderness at multiple sites.    
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4.3.3 Soft tissue changes at insertions 
Patients with psoriasis had higher inflammation scores than HC [med 
(range): 12 (0-34) vs. 5 (0-19), p<0.001]. The inflammation scores of 
psoriasis patients with nail disease [13 (0-34)] were higher than both patients 
without nail disease [8 (2-15); p=0.02] and HC [5 (0-19), p<0.001] (Figure 8 
and 9, Table 11).   Hypoechogenicity and thickening were more frequent in 
patients with nail disease compared to patients without nail disease (Table 
12).   With a Bonferroni correction, only entheseal thickening remains 
significantly more frequent in psoriasis patients with nail disease. 
 
Table 11.  Median ultrasound scores for psoriasis patients and healthy 
controls 
 
 Psoriasis patients 
with nail disease 
Psoriasis patients 




13 8 5 
Chronicity score 10 5 7 
Total US score 23 15 11 
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Figure 8: Relationship between ultrasound enthesopathy scores and nail disease 
Comparison of median US scores related to inflammation and chronicity in psoriasis patients with and without nail disease and healthy 
controls. 
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Figure 9:  Example nail photograph and ultrasound scan 
A.  Photograph of thumb nail of a patient with psoriasis, showing onycholysis and an oil drop spot. B. Longitudinal US scan of the 
proximal insertion of the patellar tendon of the same patient showing severe thickening (white line=0.7 mm), hypoechogenicity (*) 
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Table 12: Total number of US findings at all sites. PD refers to power 
Doppler. 
 Psoriasis with nail 
disease (372 entheses) 
Psoriasis without 
nail disease (180 
entheses) 
p 
n % n % 
Hypoechogenicity 98 26 31 17 0.02 
Thickening 146 39 41 23 0.0001 
PD 3 1 2 1 0.7 
Calcifications 18 5 5 3 0.4 
Bursal 
enlargement 
23 6 20 11 0.06 
PD inside the 
bursa 
1 0.3 2 1 0.3 
Enthesophytes 152 41 57 32 0.04 
Erosions 9 2 6 3 0.4 
 
4.3.4 Bone erosion and spur formation 
Patients with psoriasis had similar chronic changes to HC [8.5 (0-31) vs. 7 
(1-24); p=0.08] (Figure 8).  When patients with nail disease were compared 
separately, the nail disease group had considerably higher enthesopathy 
chronicity scores than HC [10 (0-31) vs. 7 (1-24); p=0.04].  Patients with nail 
disease had more enthesophytes than patients without nail disease (Table 
12). 
 
4.3.5 Total ultrasound scores 
Patients with nail disease had higher total US scores [23 (0-65)] compared 
to patients without nail disease [15 (5-26); p=0.02] and HC [11 (3-39); 
p=0.005]. A detailed list of US findings depending on the site can be seen in 
Table 13. 
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Table 13: Frequency of US abnormalities at the different entheseal sites 
 
 Psoriasis with nail 
disease  
(n=31 patients, 62 
entheses) 
Psoriasis without 
nail disease  
(n=15 patients, 30 
entheses) 
Enthesis Patient Enthesis Patient 
n % n % n % n % 
Achilles Hypoechogenicity 9 15 7 23 0 0 0 0 
Thickening 12 19 8 26 0 0 0 0 
PD 0 0 0 0 0 0 0 0 
Calcifications 2 3 2 7 0 0 0 0 
Bursal 
enlargement 
9 15 6 20 3 10 3 20 
PD inside the 
bursa 
1 2 1 3 0 0 0 0 
Enthesophytes 51 82 28 90 24 80 13 87 
Erosions 
 
1 2 1 3 0 0 0 0 
Quadriceps Hypoechogenicity 20 32 15 49 10 33 7 47 
Thickening 14 23 9 29 5 16 3 20 
PD 1 2 1 3 1 3 1 7 
Calcifications 3 5 2 7 2 7 2 13 
Bursal 
enlargement 
3 5 3 10 2 7 2 13 
PD inside the 
bursa 
0 0 0 0 0 0 0 0 
Enthesophytes 21 34 13 42 13 43 9 60 
Erosions 
 
1 2 1 3 1 3 1 7 
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 Psoriasis with nail 
disease  
(n=31 patients, 62 
entheses) 
Psoriasis without 
nail disease  
(n=15 patients, 30 
entheses) 
Enthesis Patient Enthesis Patient 
n % n % n % n % 
Patellar 
origin 
Hypoechogenicity 19 31 14 45 10 33 7 47 
Thickening 42 68 24 77 15 50 9 60 
PD 0 0 0 0 0 0 0 0 
Calcifications 3 5 3 10 0 0 0 0 
Bursal 
enlargement 
1 2 1 3 0 0 0 0 
PD inside the 
bursa 
0 0 0 0 0 0 0 0 




2 3 2 7 2 7 2 13 
Patellar 
insertion 
Hypoechogenicity 22 36 17 55 6 20 5 33 
Thickening 41 66 15 49 16 53 9 60 
PD 0 0 0 0 1 3 1 7 
Calcifications 3 5 3 10 3 10 2 13 
Bursal 
enlargement 
9 15 7 23 15 50 8 53 
PD inside the 
bursa 
0 0 0 0 2 7 1 7 




1 2 1 3 0 0 0 0 
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 Psoriasis with nail 
disease  
(n=31 patients, 62 
entheses) 
Psoriasis without 
nail disease  
(n=15 patients, 30 
entheses) 
Enthesis Patient Enthesis Patient 
n % n % n % n % 
Plantaris Hypoechogenicity 9 15 8 26 3 10 3 20 
Thickening 15 24 11 36 2 7 1 7 
PD 0 0 0 0 0 0 0 0 
Calcifications 0 0 0 0 0 0 0 0 
Bursal 
enlargement 
0 0 0 0 0 0 0 0 
PD inside the 
bursa 
0 0 0 0 0 0 0 0 
Enthesophytes 24 39 17 55 4 13 3 20 
Erosions 4 7 3 10 2 7 2 13 
CET Hypoechogenicity 19 31 14 45 2 7 2 13 
Thickening 22 36 17 55 3 10 2 13 
PD 2 3 2 7 0 0 0 0 
Calcifications 7 11 6 19 0 0 0 0 
Bursal 
enlargement 
1 2 1 3 0 0 0 0 
PD inside the 
bursa 
0 0 0 0 0 0 0 0 
Enthesophytes 22 36 14 45 9 30 5 33 
Erosions 0 0 0 0 1 3 1 7 
 
 
4.3.6 Link between clinical assessments and ultrasound findings 
The link between the overall burden of nail disease extent and severity was 
explored using the mNAPSI scores in 36 patients.   The severity of nail 
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disease correlated with the inflammation (r2 =0.45, p=0.005) and chronicity 
scores (r2 =0.35, p=0.04).  The duration of psoriasis also tended to correlate 
with entheseal inflammation (r2 =0.29; p=0.05) whereas no link between 
PASI and US scores was evident.  
A further analysis was performed to exclude the effect of tenderness on 
physical examination and compared the US scores by excluding 4 patients 
with mild entheseal tenderness. The US scores showed the same statistical 




Given that nail disease is a predictor for PsA evolution and that the nail is 
functionally integrated with a network of entheses about the distal 
interphalangeal joints, the hypothesis tested was that nail involvement in 
psoriasis was linked to a more extensive subclinical enthesopathy. These 
findings confirm that subclinical enthesopathy was common and was 
specifically related to nail disease.  It was also found that more extensive 
nail involvement correlated with more severe enthesopathy scores.   
Subgroup analysis to look at different patterns of nail disease would be 
interesting but was not possible due to the co-existence of different patterns 
within the same patient, and the small numbers that would be involved. 
What is the pathophysiological basis for these findings?   It has recently 
been shown that nail disease in psoriasis most typically affects the dominant 
hand thumb nail and then other nails that are most associated with hand 
function (Rich et al. 2008). This points towards tissue specific factors rather 
than autoimmunity in general as being key drivers in the psoriatic 
onychopathy process.  Given that Koebnerisation responses in the skin 
occur in the presence of tissue trauma or an aberrant repair response to it, 
then it is possible that much of the nail disease process is linked to joint 
mechanics and / or trauma (Buckley et al. 1959; McGonagle et al. 1999).   
The genetic basis for these changes awaits elucidation.   
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There is also a clear epidemiological link between PsA and joint trauma and, 
perhaps of even greater relevance, is the observation that normal entheses 
have evidence for microscopic damage and associated inflammatory 
changes that likely represent part of the normal healing process (Punzi et al. 
1998; Benjamin et al. 2007b; Pattison et al. 2008).  Therefore, the subclinical 
enthesopathy noted in psoriasis cases with nail disease may point towards 
an aberrant response to tissue micro-damage at diverse sites.   However, it 
may be that the genetic factors that predispose to nail disease may also help 
switch subclinical enthesopathy into a manifesting inflammatory enthesitis.   
At this point, it must be accepted that the actual basis for the link between 
nail disease and distant enthesopathy awaits elucidation and that other 
putative mechanisms may exist.      
In conclusion this study confirms that enthesopathy is common in psoriasis 
patients without clinical arthritis. Moreover subclinical enthesopathy is 
especially associated with nail involvement in a cross sectional analysis. 
These findings suggest that nail disease is in some way linked to the 
expression of enthesitis including subclinical disease.    
  




Comparison of the ultrasound appearances of peripheral 




During the last decade it has emerged that enthesitis and associated osteitis 
are the common denominators underlying the multifaceted skeletal 
manifestations of psoriatic arthritis (PsA) that include axial and appendicular 
disease (McGonagle et al. 1999).  In keeping with the importance of 
enthesitis as the key pathologic lesion in PsA, some studies have shown 
enthesopathy in asymptomatic large insertions of the lower limbs in patients 
with spondyloarthropathies including PsA (Balint et al. 2002).  This is 
reminiscent of studies in inflammatory oligoarthritis where ultrasound 
detected synovitis in joints which were clinically uninvolved (Wakefield et al. 
2004).  Of even greater importance is that several studies have shown 
subclinical enthesopathy or osteitis in up to 50% of psoriasis patients with no 
musculoskeletal symptoms (McGonagle et al. 2011a).    
As detailed in chapter two, ultrasonography (US) is well suited to the 
assessment of entheses.  In recent years, power Doppler (PD) US has been 
increasingly used in rheumatology as it identifies vascular abnormalities 
known to be associated with inflammation.  PD US to some extent provides 
a reflection of the degree of angiogenesis, which is critically related to joint 
damage and therapeutic responses to drugs (Naredo et al. 2008; Aydin et al. 
2010b; Kurosaka et al. 2010; Hammer et al. 2011).   Extra-articular PD 
signal has been demonstrated in both PsA and psoriasis patients (Fournié et 
al. 2006; Gutierrez et al. 2011a; Gutierrez et al. 2011b; Ash et al. 2012b).  
However, there is limited work directly comparing PD changes at the 
insertions between patients with PsA and psoriasis. 
The purpose of this study was to undertake US of symptomatic and 
asymptomatic insertions in cases with PsA and cases with psoriasis, the 
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latter having no clinical arthritis.  The hypothesis tested was that the imaging 
phenotypes might differ between PsA patients and psoriasis cases without 
clinical arthritis.  Specifically, it was hypothesised that the enthesopathy 
associated with PsA would have a greater degree of vascularisation 
compared to that seen in psoriasis without arthritis.  It was also postulated 
that subclinical vascular changes at the entheses might be associated with 
more widespread disease activity in PsA.  Such an imaging biomarker could 
be helpful in understanding and predicting the disease evolution from 




The study was carried out at two European centres - at the Leeds Teaching 
Hospitals (UK) and the University Hospital Department of Verona (Italy).    
Ethical approval for the study was obtained at both sites. 
 
5.2.1 Patient groups and clinical assessment 
One hundred consecutive patients (42 with psoriasis and 58 with PsA) and 
23 healthy controls (HC) were recruited.  Seventy-four patients were 
recruited in the UK, 26 patients and the healthy controls were recruited in 
Italy.  PsA patients were included if they fulfilled the CASPAR criteria (Taylor 
et al. 2006).  Psoriasis patients were excluded if they had a current or 
previous history of arthralgia, arthritis or enthesitis.  The clinical assessment 
was performed by one rheumatologist at each centre, who was blinded to 
the US data.  This assessment included the psoriasis area and severity 
index (PASI), tender and swollen joint counts (TJC, SJC), a dactylitis count 
and the Leeds and SPARCC enthesitis indices in the patients with PsA.  
Patients receiving glucocorticoids and anti-TNF therapies were excluded 
from the study, those receiving DMARD therapy were recruited if they had 
active skin or joint disease (inadequate responders). 




Ultrasound scanning of the peripheral entheses was performed as described 
in chapter four although the common extensor origin was excluded for this 
study. 
 
5.2.2.1 Ultrasound image interpretation 
Ultrasound images were scored according to the system described in 
chapter four.  It is now recognised that the enthesis represents an integrated 
organ comprising the insertion (which is avascular in health) and adjacent 
tendon, fibrocartilages and the immediately adjacent synovium where 
present (Benjamin et al. 2009).  For the PD assessment the sonographers 
therefore looked for PD signal in all the components of the enthesis organ, 
including signals at the insertion and inside the adjacent bursa, wherever 
these were present.  It is not possible to define the margins of the enthesis 
by US, however the entheseal vascularity was assessed when the Doppler 
signal was close to the cortical bone. 
 
5.2.3 Statistics 
Data are expressed either as frequencies, means (standard deviation) or 
medians (range) according to the variability.  The prevalence of each 
individual lesion by US in patients with or without arthritis was compared by 
using a chi-square test.  The Mann-Whitney U test was used to compare US 
scores between groups.  
Correlations between clinical parameters (TJC, SJC, PASI, and disease 
duration) and US scores (separately for US scores related to inflammation, 
damage and total) were analysed using the Pearson correlation test.  
Statistical analysis was performed using SPSS version 11.5.  
To provide agreement between sonographers, all investigators agreed on 
definitions and the scoring system prior to the study both on saved images 
and while acquiring sample images.  Stored images from the first 21 patients 
included in the study (total 1020 images) were scored by all three 
sonographers for grey scale and PD for all entheses.  ICC values were 
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calculated for each pair of investigators and for all type of US scores used in 




5.3.1 Inter-observer agreement on sonography scoring 
A moderate to excellent agreement between both investigator pairs was 
found for different scores: for GS inflammation the ICC values were in the 
range 0.91-0.93 (95% CI: 0.79-0.97), for PD inflammation 0.74-0.95 (95% 
CI: 0.45-0.98), for chronicity scores 0.89-0.93 (95% CI: 0.76-0.98) and for 
total US scores 0.92-0.95 (95% CI: 0.81-0.98). 
 
5.3.2 Patient characteristics 
Patients and HCs were of similar age [46.3 (15) vs. 52.2 (11) respectively; 
p=NS] and body mass index [26.7 (19.3-42.4) vs 24.2 (21-31.3); p=0.08]. 
The gender distribution was also similar in both groups (43% female in the 
psoriasis group and 52% in the HC).  None of the patients with psoriasis had 
clinical enthesitis compared to 51.7 % of the patients with PsA (30/58).  In 
the PsA patients, the median tender joint count was 4 (0-20) and the swollen 
joint count was 4 (0-19).  PASI scores were slightly lower in the patients with 
PsA [3.3 (0-18)] compared to those with psoriasis [4.3 (0-22); p=0.02)].  The 
groups had similar disease durations [19.1 (12.5) years for PsA and 17.5 
(11) years for psoriasis].  In general, hypoechogenicity, thickening and 
enthesophytes were the most frequent US findings for each site, whereas 
PD and erosions were relatively rare (Table 14) (Figure 10).  These findings 
are described in more detail below.  
 
  
- 147 - 
 
 














n (%) n (%) n (%) 
Hypoechogenicity 29 (12.6) 105 (25) 208 (35.9) 0.0003 
Thickening 69 (30) 162 (38.6) 250 (43.1) 0. 15 
PD 0 (0) 2 (0.4) 12 (2.1) 0.05 
Calcifications 22 (9.6) 17 (4.1) 57 (9.8) 0.0005 
Bursal 
enlargement 
3 (1.3) 35 (8.3) 77 (13.3) 0.02 
PD inside the 
bursa 
0 (0) 3 (0.7) 16 (2.8) 0.02 
Enthesophytes 90 (39.1) 180 (42.9) 297 (51.2) 0.01 
Erosions 1 (0.4) 12 (2.9) 29 (5) 0.1 
*: p values are given for comparisons between groups with PsA and 
psoriasis 
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Figure 10.  Ultrasound appearances of enthesitis 
Examples of ultrasound findings of enthesitis in psoriatic arthritis (A) and psoriasis (B).  A: The origin of the patellar tendon with 
moderate thickening (white line), hypoechogenicity (*), a small enthesophytes (e), calcifications (c) and power Doppler signals 
inside the enthesis.  B: The insertion of the patellar tendon with moderate hypoechogenicity (*) and a large enthesophytes (e). 
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5.3.3 Soft tissue changes at insertions 
As expected, patients with psoriasis (with or without arthritis) had higher 
enthesitis scores related to inflammation than HC (for inflammation 
p<0.0001, for total US scores p<0.0001).  The PsA patients had higher US 
scores than both psoriasis patients without arthritis (for inflammation p=0.04, 
for total US scores p=0.02) and HC (for inflammation p<0.0001, for total US 
scores p<0.0001) (Table 14).  Certain findings including hypoechogenicity 
and bursal enlargement were more frequent in PsA compared to psoriasis 
(Table 14).   
 
5.3.4 Power Doppler evaluation 
Doppler positivity in at least one entheseal site was observed more 
frequently in PsA (21/58, 36.2 %) than in psoriasis (4/42, 9.5%; p=0.002).  
Doppler signal was not seen in any healthy controls.  The presence of 
Doppler positivity had a sensitivity of 36% (95%CI: 24-50%) and a specificity 
of 91% (95%CI: 77-97%) with a positive likelihood ratio of 3.8 to discriminate 
PsA and psoriasis.  The most discriminative site for PD positivity was the 
retrocalcaneal bursa (seven PsA vs. one psoriasis patient).   Furthermore, 
six patients had PD signal at more than one site and 5 of these patients had 
PsA.    
 
5.3.5 Bone erosion and spur formation 
Psoriasis patients (with or without arthritis) had more chronic changes 
compared with HC (p=0.02).  The PsA patients had higher chronicity scores 
than both patients with psoriasis (p=0.02) and HC (p=0.003) (Table 14).  
This may reflect previous episodes of inflammation.  Calcification and 
enthesophytes were also more frequent in the entheses of patients with PsA 
compared to the psoriasis group, which may be in keeping with previous 
inflammatory episodes with subsequent tissue remodelling (Table 14).     
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GS score 4 (0 – 15) 9.5 (0 – 30) 11.5 (1 – 44) 12 (2 – 44) 
PD score 0 (0 – 0) 0 (0 – 3) 0 (0 – 7) 0 (0 – 4) 
Total inflammation score 4 (0 – 15) 9.5 (0 – 30) 13 (1 – 46) 12.5 (2 – 46) 
Chronicity score 6 (1 – 22) 8 (0 – 25) 10 (2 – 29) 10 (2 – 24) 
Total ultrasound score 10 (3 – 36) 16 (0 – 55) 21.5 (4 – 69) 23 (4 – 69) 
GS: grey scale, HC: healthy control, PD: power Doppler, PsA: psoriatic arthritis 
Numbers are given as median (range) 
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5.3.6 Clinical assessments and their association with ultrasound 
findings 
When patients with clinical enthesitis were excluded from the PsA group, 
patients with arthritis still had higher PD enthesopathy scores than patients 
with psoriasis (p=0.003), as well as higher chronicity scores (p=0.01) (Table 
15).  The tender joint counts (TJC) (r2 =0.21; p=0.03) and swollen joint 
counts (SJCs) (r2 =0.29; p=0.003) correlated to entheseal Doppler scores.  
Furthermore, the SJC correlated to total US scores (r2 =0.21; p=0.03).   No 




This study showed that the frequency of enthesis-related PD change was 
significantly higher in PsA compared to psoriasis even when only sites of 
asymptomatic enthesopathy were evaluated in PsA.  Moreover, the 
frequency of subclinical enthesopathy was significantly higher in PsA 
compared to psoriasis.  The results of this cross-sectional study suggest that 
there may be a trend towards increased entheseal thickening with 
subsequent vascular changes representing a step in the progression 
towards PsA in psoriasis cases.  This will require confirmation in a 
longitudinal study.   
It is noteworthy that abnormal patterns of vascularity have been reported in 
psoriatic arthritis synovium both by arthroscopic inspection and by 
histological assessment (Reece et al. 1999; Fearon et al. 2003).  Likewise 
prominent vascular changes have been reported in skin disease and at the 
nail matrix in psoriasis (Zaric et al. 1982; Creamer et al. 1997).   
Furthermore, normal entheseal insertions are sites prone to microdamage 
and in the course of physiological tissue repair at such sites prominent 
histological evidence for vascular changes is seen even in healthy subjects 
(Benjamin et al. 2007b).  This study found a high prevalence of 
enthesophytes in the healthy controls.  Enthesophytes are not specific to 
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enthesitis and may be related to mechanical forces.  This finding also 
reflects the high sensitivity of US to detect these changes.   
In this study, no entheseal PD signals were seen in the HC group.  The 
majority of the literature supports the absence of US detectable blood flow in 
normal subjects (Naredo et al. 2011), PD changes have been reported in a 
few cases (de Miguel et al. 2011b).  This raises the possibility of using 
Doppler signals for early diagnosis, although this would need to be 
demonstrated in prospective trials.   
This study was performed in two different European populations by different 
sonographers, which raises issues about its reliability and general 
applicability.  However, both study populations exhibited identical trends in 
patterns of disease.  Likewise the sonographers met and agreed on 
standard sonographic criteria for enthesitis and the inter-observer agreement 
was quite high.    
Taken together these findings now need to be applied in a large inception 
cohort of psoriasis patients to ascertain whether they define the subgroup 
that will be likely to evolve into PsA in the following months and years.  In 
that regard, US has previously been used to show a high frequency of 
subclinical entheseal involvement in patients presenting with psoriasis but 
without clinically evident arthritis (Gisondi et al. 2008).  After following this 
cohort for 3.5 years a link was demonstrated between subclinical 
enthesopathy in patients with psoriasis and the future development of PsA 
(Tinazzi et al. 2011).  
In conclusion, this study shows that the degree of systemic subclinical 
enthesopathy is much greater in PsA compared to psoriasis.  Of particular 
note the difference in vascular changes in PsA compared to psoriasis might 
have implications for determining the likelihood of a given patient 
progressing to PsA.   This will form the basis for future studies. 
  




High resolution magnetic resonance imaging of the distal 




Although PsA was historically considered in relationship to synovial 
inflammation it has emerged that enthesitis and associated osteitis are the 
common denominator at the different sites of skeletal inflammation 
(McGonagle et al. 1998a; McGonagle et al. 1999).  In keeping with the 
importance of enthesopathy in PsA, imaging studies in patients with 
psoriasis without clinical arthritis have also shown a high prevalence of 
subclinical entheseal changes in peripheral large joint entheses such as the 
Achilles tendon (Namey et al. 1976; Offidani et al. 1998; Ozcakar et al. 2005; 
Erdem et al. 2008; Gisondi et al. 2008; Raza et al. 2008; Emad et al. 2010).   
 
Of particular clinical relevance to both rheumatologists and dermatologists is 
that nail disease is more strongly associated with PsA than psoriasis and its 
presence in the latter is a predictive factor for the later development of PsA 
(Wilson et al. 2009a).   Enthesitis in DIP joint disease in PsA is common on 
high resolution MRI in clinically active joints (Tan et al. 2006a).  Furthermore, 
the nail is anchored directly to the skeleton via a network of entheses around 
the DIP joint (Tan et al. 2007).  As shown in chapter four, the presence of 
nail disease in psoriasis is also associated with a greater degree of 
subclinical enthesopathy at distant sites in the lower limbs (Ash et al. 
2012b). 
 
Given the intimate link between the nail and the entheses, this study 
explored the extent of enthesopathy present in psoriasis related nail disease 
and the degree of underlying associated bone changes.  To address this, a 
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spectrum of PsA and psoriasis cases with and without nail involvement were 




Ethical approval was gained from the local ethics committee and all patients 
gave written consent.  Cases were recruited consecutively from the 
dermatology and rheumatology clinics of the Leeds and Harrogate teaching 
hospitals between March 2011 and November 2012.  Psoriasis cases were 
recruited based on a diagnosis of psoriasis confirmed by a dermatologist, 
but were only recruited if they had no current arthralgia or arthritis or history 
suggestive of PsA.  The PsA cases all fulfilled the CASPAR criteria (Taylor 
et al. 2006).  Patients receiving biological therapies were excluded, but those 
on systemic immunosuppression were included if they had persistent active 
disease. 
All patients underwent a clinical assessment including Psoriasis Area and 
Severity Index (PASI), Body Surface Area affected with psoriasis (BSA), 
modified Nail Psoriasis Severity Index (mNAPSI) (Cassell et al. 2007), a 76 
tender and swollen joint count, an assessment for clinical enthesitis (Leeds 
Enthesitis Index [LEI] (Healy et al. 2008b) and Spondyloarthritis Research 
Consortium of Canada enthesitis index  [SPARCC]) (Maksymowych et al. 
2009) and a dactylitis count.  Patients also reported any painful or tender 
nails and completed visual analogue scales for global, psoriasis and arthritis 
disease activity as well as nail pain.  Quality of life was assessed using the 
Dermatology Life Quality Index (DLQI) (Finlay et al. 1994) and psoriasis 
patients also completed the Psoriasis Epidemiology Screening Tool (PEST) 
(Ibrahim et al. 2009). 
A high resolution MRI was performed of one finger using a 3-T Verio 
scanner (Siemens Healthcare, Erlangen, Germany).  The finger to be 
scanned was selected on the basis of the most severely affected nail.  In 
patients with normal nails, the index or middle finger was chosen.  The scan 
included intermediate-weighted sagittal, fat-suppressed proton density axial, 
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T2 coronal and T1 post contrast sequences.  A 4cm loop coil was used to 
image from the finger-tip to the middle phalanx.  Gadolinium contrast was 
given unless contra-indicated, and petroleum jelly was applied to the nail to 
delineate the outer contour, as described by Scarpa et al. (Scarpa et al. 
2006b). 
The MRIs were scored by two experienced musculoskeletal radiologists by 
consensus.  The radiologists were blinded to the diagnosis.  The scoring 
system used has previously been reported (Tan et al. 2006a).  It included 
anatomical structures (cartilage, collateral ligaments, flexor and extensor 
tendons), synovitis post-contrast and bone marrow lesions (BMLs) on proton 
density / T2 weighted fat suppressed spin echo images.  Anatomical 
structures were recorded dichotomously as normal or abnormal.  Synovitis 
and effusion were graded 0-2 on a semi-quantitative basis and BMLs were 
graded from 0-3.  Features of enthesopathy scored included tendon tears, 
tendon thickening, signal change within the tendon, peri-ligamentous high 
signal, BMLs or erosions at the enthesis. 
 
6.2.1 Statistical analysis 
Categorical data are expressed as frequencies (percentages).  Fisher’s 
exact 2-tailed test was used to compare the proportions of patients with 
certain findings between groups, with differences considered significant if the 
P value was less than 0.05. 
 
6.3 Results 
6.3.1 Demographic data 
A total of 57 patients were recruited; 29 patients with PsA and 28 patients 
with psoriasis without arthritis or arthralgia.  The mean patient age was 41 
(range 18 – 83), 47% of the patients were female.   
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6.3.2 Clinical data 
When assessed at baseline, 14 of the PsA patients had clinical nail disease, 
while 15 had normal nails.  Seven out of 29 (24%) of the PsA patients had 
clinically active arthritis (tenderness or swelling) in the DIP joint scanned at 
the time of the assessment.  Of the remaining 22, 3 had current tenderness 
or swelling in another DIP joint (but not the one scanned) and a further four 
had previously had DIP disease but had no current DIP activity.  For the PsA 
patients, the mean swollen joint count was 5, tender joint count 7, LEI 1 and 
SPARCC 3.  Only one patient had dactylitis in the digit that was scanned.   
Among the psoriasis patients, 17 had nail disease and 11 psoriasis patients 
had normal nails.  The mean PASI was 3.0 in the PsA patients and 5.9 for 
psoriasis.  Fifty-two percent of the PsA patients were on disease modifying 
therapies.  Of the psoriasis patients, 11% were not receiving any treatment, 
25% were using topical treatments only, 25% were having phototherapy and 
39% were on systemic immunosuppression (ciclosporin or methotrexate).   
 
6.3.3 Magnetic resonance imaging results 
In keeping with previous data, the PsA cases with active DIP arthritis had 
diffuse inflammation around the DIP joint including BMLs 4/7 (57%), nail bed 
changes, extensor or flexor tendon enthesopathy 4/7 (57%) and synovitis 
5/7 (71%).  Subclinical enthesopathy and BMLs were seen even in 
asymptomatic (non-tender and non-swollen) DIP joints in the PsA patients 
(BMLs in 6/22 (27%), extensor or flexor tendon enthesopathy in 5/22 (23%), 
synovitis in 6/22 (27%)).  As further described below, a proportion of patients 
with psoriasis but no clinical PsA had evidence for enthesopathy, synovitis 
and BMLs (Table 16).  The severity of the changes seen was markedly 
higher in the PsA patients than the psoriasis patients.   
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Table 16.  Frequency of different findings in PsA and psoriasis patients 

























57% 27% 45% 9% 12% 9% 








14% 14% 27% 0% 6% 0% 
 
 
6.3.4 Extensor tendon enthesopathy 
Extensor tendon (ET) enthesopathy (as measured by tendon thickening, 
signal change and BMLs) was seen only in PsA patients and not in psoriasis 
patients (7/29 (24%) vs. 0/28 (0%), p=0.01).  Within the PsA patients, ET 
enthesopathy was seen more frequently in the presence of nail disease 
(5/14 (36%) in patients with nail disease vs. 2/15 (13%) in patients with 
normal nails, p=NS) (Figure 11).  Given the potential link between these 
tendon changes and adjacent nail disease, the frequency of different types 
of nail changes was assessed.  In PsA patients with nail disease, pitting was 
seen in 4/5 (80%) of those with extensor tendon enthesopathy and 6/9 
(67%) of those with normal extensor tendons.  Onycholysis was seen in 5/5 
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(100%) of those with extensor tendon enthesopathy and 6/9 (67%) of those 
with normal extensor tendons. 
 
Figure 11.  Examples of normal and abnormal extensor tendons 
The petroleum jelly appears overlying the nail (asterisk). A: normal extensor 
tendon. B: thickened extensor tendon in a PsA patient (black arrow) 
with osteitis and high signal (white arrow) at the insertion.  
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6.3.5 Flexor tendon enthesopathy 
High signal at the insertion of the DIP flexor tendon (FT) was seen only in 
patients with clinical nail disease (4/14 (29%) in PsA patients with nail 
disease and 1/17 (6%) in psoriasis patients with nail disease).  This 
difference was statistically significant between PsA patients with and without 
nail disease (p=0.04).  No flexor tendon disease was seen in patients with 
normal nails irrespective of the presence of psoriasis or PsA. 
 
6.3.6 Magnetic resonance imaging-determined bone marrow 
lesions 
The prevalence of BMLs of the DIP joint was much greater in PsA compared 
to psoriasis.  BMLs were seen in (4/7) 57% in PsA patients with active DIP 
arthritis compared to 6/22 (27%) in PsA patients with a clinically inactive DIP 
joint p=NS).  In contrast, 2/17 (12%) of psoriasis patients with nail disease 
and 1/11 (9%) of psoriasis with normal nails were noted to have BMLs.   
Moreover, the severity and extent of BMLs varied greatly between PsA and 
psoriasis, with no psoriasis patient demonstrating a BML score of greater 
than grade one (mild) (Figure 12).  Within the PsA patients, in those DIP 
joints that were clinically active (tender or swollen, n=7) 3/7 (43%) had no 
BMLs and 4/7 (57%) had grade 2-3 BMLs.  In PsA patients with clinically 
inactive DIP joints, 16/22 (73%) had no BMLs, 5/22 (23%) had grade one 
and 1/22 (5%) had grade three BMLs. 
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Figure 12.  Examples of BMLs 
Examples of BMLs (white arrows) grade 0, 1, 2 and 3 (scored as the maximum intensity seen within each patient not overall extent) 




In PsA patients with a clinically active DIP joint, MRI synovitis was seen in 
5/7 (71%) patients, in PsA patients with a clinically inactive joint, subclinical 
synovitis was seen in 6/22 (27%).  In psoriasis patients, subclinical Gd-
DTPA enhancement suggestive of synovitis was seen in 3/16 (19%) of those 
with nail disease and 3/10 (30%) of those with normal nails. 
 
6.3.8 Nail bed and nail matrix lesions 
The majority of patients with nail disease had features of both nail bed and 
nail matrix lesions.  Of all nails scanned, eight had only features of nail bed 
psoriasis and six had only features of nail matrix psoriasis.  There were no 
substantive differences in the prevalence of different clinical nail features 
between the PsA and psoriasis patients.  Due to the small numbers no 
analysis was performed to assess differences in underlying soft tissue or 
bony changes between the groups. 
 
6.3.9 Imaging of the nail  
Abnormalities of the nail itself were apparent by MRI in 12/31 (39%) of the 
patients with nail disease, with a specificity of 100%.  These tended to be the 
patients with more severe nail disease (median mNAPSI 24 in those with 
MRI-evident nail disease vs. 16 in those with clinical nail disease that was 
not visible on MRI).  Thickening of the nail bed was also seen in some 
patients with nail disease (Figure 13). 
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Figure 13.  MRI appearances of psoriatic nail disease   
A: MRI of a patient with psoriasis with clinical nail disease showing 
thickening and irregularity of the nail plate (white arrow) and nail bed 
(black arrow).  B: MRI of a patient with PsA and nail disease 
demonstrating nail plate crumbling with loss of half of the nail (white 
arrow) and thickening of the nail bed (black arrow).  The petroleum jelly 
appears bright (asterisk).   
 
 
6.3.10 Collateral ligament enthesopathy 
Collateral ligament enthesopathy was seen in 15/29 (52%) PsA patients and 
12/28 (43%) psoriasis patients.  Collateral ligament enthesopathy was more 
common in subjects over 40 years old (61% vs. 31%, p=0.03), in keeping 
with previous reports describing age related changes in healthy subjects 
(Tan et al. 2005).  Collateral ligament changes therefore seem to be more 
likely to relate to normal age-related changes than psoriatic pathology. 
 




The purpose of this study was to use MRI to explore the link between 
enthesopathy and bone changes with nail disease in PsA and psoriasis.  
Although the magnitude of skeletal changes were substantially less than in 
PsA patients, there was nevertheless evidence for subtle subclinical 
inflammation around the DIP joint in a subgroup of psoriasis patients.  This is 
in keeping with published data finding enthesopathy in a significant 
proportion of psoriasis patients in sites such as the knee, Achilles tendon 
and other large joint areas  (Namey et al. 1976; Offidani et al. 1998; Ozcakar 
et al. 2005; Erdem et al. 2008; Gisondi et al. 2008; Raza et al. 2008; Emad 
et al. 2010).  Subclinical enthesopathy may have implications for the 
development of PsA in psoriasis patients, with one study finding a higher 
rate of PsA development after three years in psoriasis patients with more 
subclinical enthesopathy at baseline (Tinazzi et al. 2011). 
A clear link was shown between MRI determined extensor tendon 
enthesopathy in PsA and nail disease in PsA.  Contrary to the hypothesis, 
these data do not show a relationship between the presence of inflammation 
at sites around the DIP joint and nail disease in psoriasis patients.  These 
findings may reflect the relative lack of sensitivity of MRI to detect the more 
subtle enthesis changes seen in psoriasis subjects. 
An unexpected finding in this study was the association of flexor tendon 
enthesopathy with nail involvement in PsA.   It is noteworthy that on full 
flexion of the DIP joint in gripping or climbing actions, considerable forces 
are likely to be transmitted to the nail.    Moreover, fibrous tissue from the 
flexor tendon merges with fibres from the extensor tendon, forming a lateral 
lamina which attached to the nail root and matrix and likely provides 
anchorage to the lateral aspects of the nail bed, but this has not been 
studied in great detail (Tan et al. 2007).   These findings support  emerging 
data from a positron emission tomography (PET) study showing that the 
nails and bone form a functionally integrated network (Tan et al. 2013). 
The findings of this study are limited by the relatively low numbers in each 
patient group, which prevent analysis of further subgroups.  No control group 
is available for comparison, however given the very low prevalence of 
- 164 - 
 
 
abnormalities in the psoriasis group, this would be unlikely to add much.  A 
number of the patients were receiving systemic treatments for their skin or 
joint disease, and given that these may treat enthesopathy or arthritis this 
may have affected the findings.  This was a pragmatic cohort recruited on 
the basis of active skin or joint disease and thus you would not expect the 
enthesopathy to be fully controlled.  This was a pilot study and the imaging 
scoring used is not a validated system, although it has been used previously 
to study the DIP joint.  The PsAMRIS scoring system for PsA affecting the 
hands was not designed to score ligaments and entheses so was not 
suitable for use in this study (Boyesen et al. 2011).  Finally, whilst the 
radiologists were blinded, in some severe cases the arthritis or nail disease 
was very easily apparent on MRI. 
In conclusion, this the first MRI study to assess the underlying DIP joint 
musculoskeletal changes in psoriasis patients with and without nail disease.  
Some psoriasis patients had subtle subclinical enthesopathy in the same 
sites as is seen in PsA-related nail disease. However the magnitude of the 
associated bone changes, where present, was much less.  Flexor tendon 
entheseal changes were evident in some cases, which are likely to be 
relevant as the nails, bones and tendons are functionally integrated.    
  




Ultrasound imaging of the nail and distal interphalangeal 
joint and nail in psoriasis and psoriatic arthritis 
 
7.1 Introduction 
The importance of nail disease in subjects with psoriasis is being 
increasingly recognised (Baran 2010). Clinically, nail disease is associated 
with pain, functional loss, disfigurement and psychological distress (de Jong 
et al. 1996). From the rheumatological perspective, the presence of nail 
disease is a predictor for the development of PsA (Wilson et al. 2009a). In 
PsA patients, nail disease is associated with arthritis of the DIP joint (Jones 
et al. 1994; Williamson et al. 2004a). The nail is directly anchored to the 
underlying bone by structures including the extensor tendon (Tan et al. 
2006b; Tan et al. 2007; McGonagle et al. 2009a). Enthesopathy is a 
generalised feature of both psoriasis and PsA.  As shown in chapter four, in 
psoriasis patients nail disease is associated with a greater degree of 
systemic enthesopathy (Ash et al. 2012b). 
Presently, assessment of nail disease is difficult given the limited utility of 
clinical assessment tools for the nail, which include the nail psoriasis severity 
index (NAPSI) and the modified NAPSI (mNAPSI) (Rich et al. 2003; Cassell 
et al. 2007). Recently magnetic resonance imaging, ultrasonography (US) 
and optical coherence tomography have been reported as possible tools for 
a more objective assessment of nail disease (Mogensen et al. 2007; 
Gutierrez et al. 2009; Soscia et al. 2009; Aydin et al. 2011). US has wide 
availability in the rheumatology setting, modest costs, a high resolution and 
allows good visualisation of tendons and entheses. With respect to the nail 
matrix region, this study aimed to determine whether US had the capability 
to detect local DIP joint enthesopathy in PsA and psoriasis patients. No US 
based imaging study of the nail has considered the matrix region before. 
Therefore this study assessed the utility of US for the assessment of 
psoriatic nail disease including both the nail plate and nail matrix region. 





7.2.1 Patient groups and clinical assessment 
This study was approved by the Leeds (East) Research Ethics Committee. 
Informed consent was obtained from all participants.  A total of 86 psoriasis 
patients with or without PsA (169 nails) and 20 healthy controls (HC) (40 
nails) were assessed for the purpose of this study. 
Macroscopic nail features were assessed by clinical examination.  
Abnormalities including onycholysis, pits, nail plate crumbling, leuconychia, 
splinter haemorrhages, nail bed hyperkeratosis and red spots in the lunula 
were recorded and scored by using the mNAPSI scoring system (Cassell et 
al. 2007) by a rheumatologist experienced in this assessment. This assessor 
was blinded to the US findings. 
 
7.2.2 Ultrasonography 
An US scan of patients’ nails was performed by a rheumatologist fully 
trained in musculoskeletal US (S.Z.A.), using a Logiq E9 machine (General 
Electric, Wauwatosa, Wisc., USA) and a linear probe at 18–10 MHz. Two 
nails per patient were scanned by US.  The clinician performing the mNAPSI 
selected the most severely involved nail and the corresponding nail on the 
other hand (irrespective of involvement) to be scanned. The 
ultrasonographer was unaware of the presence or absence of nail disease 
and was only informed which finger was to be scanned. The nail plate and 
nail matrix were scanned in every patient. A thick gel layer allowed for 
appropriate transmission of ultrasound without any additional device. 
All US assessments were performed using a multiplanar technique, 
scanning the nail from medial to lateral sites and from the lunula to the distal 
nail in order to provide as complete coverage as possible. Particular 
attention was paid to blind the sonographer from the clinical findings; the 
room was completely darkened during the US assessment and the patients 
and controls were asked not to talk to the sonographer prior to or during the 
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US assessment.  The sonographer did not perform a physical examination, 
therefore sites other than those involved in the US scan were not seen by 
the sonographer. The light of the US machine alone is not enough for the 
sonographer to see the nails clearly. 
 
7.2.3 Nail plate region 
A dorsal longitudinal scan of the distal phalanx at the midline was used for 
thickness measurements. The thickness of the nail was measured as the 
maximum distance between the dorsal and ventral nail plates. The 
sonographic trilaminar appearance of the nail plate was evaluated (Gutierrez 
et al. 2009). The trilaminar structure (two hyperechogenic bands with a 
hypo/anechogenic band in the middle) was documented as either present or 
absent. Pits and irregularities of the nail plate surface were noted as regions 
where the normal convexity of the nail plate was lost (Figure 14). 
 
7.2.4 Nail matrix region 
The skin thickness was measured as the maximum thickness of the 
hyperechoic epidermis and hypoechoic dermis around the level of the DIP 
joint. The thickness of the matrix was measured as the distance between the 
ventral nail plate and the cortex of the distal phalanx at the level of the 
matrix, determined by a line perpendicular to the bone profile (Figure 15).  
With respect to the nail matrix region, the thickness of the extensor tendon at 
the level of insertion was assessed as normal or thickened by comparing it 
to the proximal part of the tendon. The grey-scale settings used for nail 
assessment were: frequency at 14 MHz, gain at 18 dB and a dynamic range 
at 36 dB. 
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Figure 14.  Ultrasound appearances of nail disease 
Longitudinal (A) and transverse (B) scan of the healthy nail demonstrating 
the trilaminar structure as two hyperechoic lines (arrows) surrounding 
an anechoic line.  C: loss of the trilaminar appearance at the ventral 
plate seen as the irregularity and absence of the deeper hyperechoic 
line (arrow).  D: pitting and irregularity of the nail plate (arrows).  NP = 
nail plate, S = skin, DP = distal phalanx, DIPJ = DIP joint. 
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Figure 15.  Thickness measurements of the nail and nail matrix 
Measurements of the thickness and comparison between groups.  a: nail 
thickness: the maximum distance between the dorsal and ventral nail 
plates.  b: nail matrix thickness: the distance between the ventral nail 
plate and the cortex of the distal phalanx at the level of the matrix.  c: 
skin thickness: the maximum thickness of the hyperechoic epidermis 
and hypoechoic dermis around the level of the DIP joint (DIPJ).  np = 




Data are expressed either as frequencies or medians (range).  The 
concordance between US and physical examination was evaluated using 
absolute agreements and kappa analysis and the prevalence of findings was 
compared using the Χ2 test. The measurements of the HC and patients were 
compared using the Mann-Whitney U test. To test the differences between 
subgroups for the presence or absence of nail disease, the Kruskal-Wallis 
test was applied followed by the Mann-Whitney U test. 
To assess reproducibility, the images of randomly chosen 100 extensor 
tendons were reassessed for the presence or absence of thickening by the 
same investigator blinded to the nail plate findings, and this revealed a 
moderate agreement with a kappa value of 0.58. 
Statistical analysis was performed using SPSS version 11.5. 
 




Of the psoriatic patients, 33/86 (38.4%) were female, compared to 11/20 
(55.0%) of the HC. 52 of the psoriatic patients (60.5%) had clinical nail 
disease and 42 patients (48.8%) had arthritis. Median (range) of disease 
duration in patients with psoriasis was 16 (1–55) months and mNAPSI score 
was 15 (1–56) in patients with nail disease.  None of the HC had any known 
clinical nail disease, psoriasis nor arthritis. 
 
7.3.1 Nail plate findings by ultrasound and comparison with 
clinical assessment 
Patients with psoriasis had significantly more US findings of the nail than HC 
(42/86 [48.8%] vs. 2/20 [10.0%], p<0.002). There were more abnormal nail 
US findings in nails with clinical findings (57/101 [56.4%] vs. 6/68 [8.8%], 
p<0.0001). mNAPSI scores were higher in the presence of any nail 
abnormality by US (14 [0–50] vs. 1 [0–56], p<0.0001). 
The absolute agreement between US and clinical assessment in the 169 
nails of the psoriatic patients was 76.3% with a kappa value of 0.52 
(p<0.0001). US detected abnormalities in 10 nails where clinical examination 
was normal. Conversely, US failed to demonstrate any lesions in 30 nails 
despite the presence of a positive clinical finding. These patients had either 
onycholysis or pitting but collectively their nails had milder abnormalities with 
lower mNAPSI scores than nails that were abnormal on US (mNAPSI 10 [1–
56] vs. 17 [1–50], p=0.03).  
Nail thickness was greater in patients in the psoriasis group compared to HC 
(0.56mm [0.3–1.9] vs. 0.5mm [0.3–0.6], p<0.0001). Nail thickness was 
higher in those nails with clinical abnormalities (0.6mm [0.3–1.9] vs. 0.5mm 
[0.3–0.9], p<0.0001). 
 
7.3.2 Nail matrix findings 
Whereas US and clinical examination were broadly similar in the 
assessment of the nail plate, the US assessment of the nail matrix, skin and 
DIP joint region was very revealing. Entheseal thickening of the extensor 
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tendon insertion region was more frequent in patients in whom there was an 
abnormality in the adjacent nail by physical examination (35/83 vs. 15/86, 
p=0.001). When different clinical nail findings were analysed separately, 
onycholysis (26/50 [52.0%] vs. 34/119 [28.6%], p=0.005), pitting (23/50 
[46.0%] vs. 36/119 [30.3%], p=0.05) and nail crumbling (7/50 [14.0%] vs. 
3/119 [2.5%], p=0.008) were found more frequently in patients with extensor 
tendon entheseal thickening. Likewise entheseal thickening of the extensor 
tendon insertion region was more frequent in patients in whom there was an 
abnormality in the adjacent nail by US, but this difference was not 
statistically significant (24/63 [38.1%] vs. 26/106 [24.5%], p=0.08). 
Both sonographically determined nail matrix and skin thickness were higher 
in patients with psoriasis compared to HC (nail matrix thickness: 1.9mm 
[1.1–3.9] in psoriasis vs. 1.8mm [1.2–2.2] in HC, p=0.003; skin thickness: 
1.1mm [0.7–1.9] in psoriasis vs. 1mm [0.6–1.6] in HC, p<0.0001). Of note, 
skin thickness in psoriasis was not higher in those with clinical nail disease 
compared to those without nail disease (Table 17). The thickness of the 
matrix was higher if there was clinical nail disease (2mm [1.2–3.9] vs. 1.8mm 
[1.1–2.5], p<0.0001).   
However, with respect to the extensor tendon insertion region it was noted 
that tendon enthesopathy was often associated with thickening of the 
adjacent epidermis and oedema of the dermis (skin thickness in patients 
with entheseal thickening 1.2mm [0.7–1.9] compared to those without 
entheseal thickening 1.02 m [0.7–1.9], p=0.009) (Figure 16). 
To ascertain whether the extensor tendon thickening was related to clinical 
DIP arthropathy or whether it could be linked to psoriasis and nail disease 
without clinical arthropathy, both groups were assessed separately. Patients 
with or without PsA had similar thicknesses of the skin, nail and matrix. 
Similarly, the relationship between extensor tendon thickening and clinical 
nail disease was seen in both psoriasis and PsA (Table 17). 
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Figure 16.  Entheseal thickening with associated skin thickening 
An example of different entheseal and skin thickness (blue line) in a HC (A) 
and in a patient with psoriasis (B).  The thickening of the extensor 
tendon (red line) and enthesis is seen in addition to hypoechogenicity 
(*) and an enthesophyte (e) (B) as well as the increased thickness of 
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Table 17.  Comparison of extensor tendon thickening, skin, nail and nail matrix thickness between different disease groups 
 
 Psoriasis Psoriatic Arthritis Healthy 
controls 
Nail disease Normal nails Nail disease Normal nails 
Extensor tendon thickening, 
frequency (%) 
17 / 45 (38) 7 / 43 (16) 18 / 38 (47) 8 / 43 (19) 0 / 40 (0) 
Median skin thickness, mm (range) 1.1 (0.8 – 1.9) 1.05 (0.7 – 1.7) 1.07 (0.7 – 1.7) 1.1 (0.7 – 1.9) 1 (0.6 – 1.6) 
Median matrix thickness, mm (range) 1.9 (1.2 – 3.9) 1.8 (1.2 – 2.4) 2 (1.5 – 3.5) 1.7 (1.1 – 2.5) 1.8 (1.2 – 2.2) 
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In patients with clinical DIP disease (with tenderness or swelling), extensor 
tendon thickening was more frequent (11/18 [61.1%] in active DIP joints vs. 
39/151 [25.8%] in non-active DIP joints, p=0.005). The thickness of the skin 
(1.3mm [0.8–1.9] vs. 1.1mm [0.7–1.9], p=0.04) and the matrix (2.1mm [1.4–
2.9] vs. 1.9mm [1.1–3.9], p=0.05) were higher in those with clinical DIP 
disease whereas nail thicknesses were similar (0.55mm [0.3–0.9] vs. 
0.56mm [0.3–0.9], p=0.8). 
 
7.4 Discussion 
This is the first study using US to assess the entire nail apparatus including 
the nail plate and nail matrix region, where it is now known that the nail is 
integrated with the skeleton (McGonagle et al. 2009a). Both US and clinical 
examination were broadly similar for the assessment of the nail plate region.  
In the evaluation of the nail matrix region an association was noted between 
extensor tendon enthesopathy and nail disease. This enthesopathy was 
specifically associated with nail disease but not clinical PsA.  In contrast, 
MRI was not able to demonstrate this relationship between nail disease and 
extensor tendon enthesopathy in psoriasis patients (Chapter 6).  This likely 
reflects the higher resolution of ultrasound and consequently the greater 
ability of ultrasound to demonstrate the subtle changes seen in psoriasis 
patients.  These findings are relevant for the development of US for the 
assessment of the nail disease and also point towards the importance of the 
enthesis in nail involvement. 
These findings have implications for a better understanding of nail disease in 
psoriasis. The link between enthesopathy on US and clinical nail disease 
was not confined to pitting, a recognised matrix-specific abnormality, but was 
also seen with onycholysis (thought to be a nail plate lesion) which therefore 
would not be expected to be related to extensor tendon disease. These 
findings raise the possibility that nail pain and loss of function seen in the 
dermatological setting may in part be related to microenthesopathy-related 
pain. The relevance of these changes for the development of PsA and their 
relevance for the prognosis of nail disease awaits further study. 
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Another noteworthy finding of the present study was that the DIP 
enthesopathy was associated with both epidermal thickening and dermal 
oedema. This is interesting since it suggests a very close link between the 
pathology in the skin and the adjacent enthesis and to the best of our 
knowledge has not being recognised before. Perhaps the skin changes may 
be secondary to extension of the inflammatory processes to the adjacent 
dermis with secondary epidermal changes, or they may reflect common 
mechanical stretching responses to the skin and enthesis during finger 
flexion.  
There are some potential limitations to this study. As with all US studies on 
psoriasis, it is not technically possible to be completely blinded to the skin 
findings if the patient has very severe disease. To attempt to prevent this 
situation, conversation between the patient and the ultrasonographer about 
their disease was avoided and the room was completely darkened from the 
beginning of the assessment. 
In conclusion, this study confirms that US is helpful to objectively assess 
psoriatic nail disease and compares favourably with clinical assessment. 
Given that only superficial changes can be detected by physical 
examination, US proved to be informative in the nail matrix and adjacent 
extensor tendon region. In particular the US findings in this study showed a 
link between extensor tendon enthesopathy and nail disease. This supports 
the concept that nail disease in psoriasis is more than skin deep, and is 
linked to enthesopathy. This has broad implications for further studies into 
nail disease in psoriasis. 
 
  








Nail involvement is part of the clinical spectrum of psoriatic disease.  
Intimate microanatomical connections have been demonstrated between the 
nail and the entheses around the DIP joint that might help explain the link 
between nail disease and arthritis (Jones et al. 1994; Tan et al. 2007).   
Limited efficacy has been seen with most traditional treatments for nail 
psoriasis (Reich 2009).  The introduction of TNF inhibitors has revolutionised 
the management of psoriasis and PsA, showing efficacy for psoriasis, 
arthritis, enthesitis and dactylitis (Ash et al. 2012a).  The TNF inhibitors have 
also shown striking improvements in nail disease (Kavanaugh et al. 2009; 
Reich et al. 2010; Van den Bosch et al. 2010).   Given the suggested 
contribution of inflammation at the adjacent entheses and bones in the 
pathogenesis of nail disease, it might be expected that improvements in nail 
disease with such therapies would be associated with dramatic resolution of 
the underlying arthropathic features.     
Thus far the effects of anti-TNF therapies on the DIP joint in relationship to 
nail disease improvement have not been investigated.   This study used high 
resolution MRI and ultrasound to investigate whether improvements in 
psoriasis-related nail disease correlated with improvements in underlying 
associated DIP joint enthesitis, bone marrow oedema like lesions 
(henceforth referred to as BMO), synovitis and enthesitis during TNF 
inhibitor therapy. 
 




Ethical approval was gained from the local ethics committee and all 
participants gave written consent.  Suitable cases were recruited 
consecutively from dermatology and rheumatology clinics.  PsA cases all 
fulfilled the CASPAR criteria (Taylor et al. 2006).  All patients were TNF 
inhibitor naive, but were due to commence treatment with a TNF inhibitor for 
either active psoriasis or PsA.  To be included in this study, patients were 
required to have psoriatic nail disease.   A full clinical and imaging 
assessment was performed at baseline and repeated after six months TNF 
inhibitor therapy.   
 
8.2.1 Clinical assessment 
Clinical assessment included the Psoriasis Area and Severity Index (PASI), 
Body Surface Area affected with psoriasis (BSA), modified Nail Psoriasis 
Severity Index (mNAPSI), 78/76 tender and swollen joint count, 
Spondyloarthritis Research Consortium of Canada enthesitis index 
(SPARCC) and a dactylitis count.  Patients also reported any painful or 
tender nails and completed a visual analogue scale for nail pain.  Quality of 
life was assessed using the Dermatology Life Quality Index (DLQI) (Finlay et 
al. 1994) and psoriasis patients also completed the Psoriasis Epidemiology 
Screening Tool (PEST) (Ibrahim et al. 2009).  The target finger for imaging 
was selected on the basis of current nail disease, in addition to clinically 
active arthritis in that DIP joint in PsA patients. 
 
8.2.2 Magnetic resonance imaging assessment 
A high resolution MRI was performed of one finger using a 3-T Verio 
scanner (Siemens Healthcare, Germany).  This was performed at baseline 
and six months.  A 4cm loop coil was used to scan from the finger-tip to the 
middle phalanx.  Gadolinium contrast was given, and Vaseline was applied 
to the nail to delineate the outer contour, as described by Scarpa (Scarpa et 
al. 2006b).  Sequences performed were as described in chapter six. 
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The MRIs were scored by blinded paired analysis by consensus by two 
experienced musculoskeletal radiologists.  The scoring system used has 
previously been reported (Tan et al. 2006a).  It included anatomical 
structures (cartilage, collateral ligaments, flexor and extensor tendons), 
synovitis post-contrast and BMO on proton density / T2 weighted fat-
suppressed spin echo images.  Anatomical structures were recorded 
dichotomously as normal or abnormal.  Synovitis and effusion were graded 
0-2 on a semi-quantitative basis.  BMO was graded from 0-3. 
 
8.2.3 Dynamic contrast-enhanced magnetic resonance imaging 
Dynamic enhancement curves were generated from regions of interest 
within MR images of DIP joints. DCE-MRI images were processed using a 
combination of in-house programmes and commercial image analysis 
software (Analyze10.0, Inc., Lenexa, KS).  Colour-coded maps were created 
which reflected the temporal changes in signal intensity (Radjenovic et al. 
2008; McGonagle et al. 2011b) and were used to assist the identification of 
regions of soft-tissue enhancement (Figure 17A). Exact regions of interest 
(ROIs) were manually delineated by a single investigator using these colour-
coded maps (Figure 17B).  
For each patient, the nail bed was observed as a high signal-enhancing, C-
shaped region. Soft-tissue ROIs were selected to include the entire C-
shaped region and were chosen in the most proximal slice at which this area 
could be seen. The median number of pixels for these ROIs was 284 (range 
229–461).  
Dynamic enhancement curves of signal intensity versus time were created 
for each ROI and quantified in terms of maximal enhancement (ME) and 
initial rate of enhancement (IRE) (Figure 17C) (Radjenovic et al. 2008). 
Owing to the small number of data (n = 4) in this preliminary study, statistical 
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Figure 17.  Dynamic MRI images and plots 
A colour-coded map for a dynamic MRI dataset of the most proximal slice at 
which a highly-enhanced (yellow region), C-shaped nail bed region can 
be seen (A). Here the ROI is outlined. The corresponding MR grey-
scale image with the selected ROI superimposed (B). Note that in B, 
the high-signal region above the ROI is that of the Vaseline. A typical 
dynamic-enhancement curve; the slope represents the maximum rate 
of enhancement (IRE) and maximum relative enhancement (ME) is 
indicated as a red cross (C). Plots showing ME and IRE for all patients 
pre- and post treatment are shown in D and E respectively. The mean 
ME was 2.19 (0.65) for patients prior to treatment and 1.88 (0.48) for 
patients following treatment. The mean IRE was 0.035 (0.018) s-1 prior 
to treatment and 0.030 (0.010) s-1 following treatment. 
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8.2.4 Ultrasound assessment 
Ultrasound of the peripheral entheses (Achilles, plantar fascia insertion, 
quadriceps insertions, patellar tendon origins and insertions and common 
extensor origins of the upper limbs) was performed and scored as described 
in chapters four and five (Ash et al. 2012b) with features scored according to 
inflammatory and chronic findings.  Ultrasound of the target finger and the 
corresponding finger on the other hand was also performed as  described in 
chapter seven (Aydin et al. 2012).  This scan included the nail, extensor 
tendon, DIP joint and surrounding soft tissues. 
Ultrasound scans were performed in a darkened room by a sonographer 
blinded to disease state.  Patients were asked not to communicate with the 
sonographer about their diagnosis.  The light from the ultrasound machine is 
not sufficient to see details of the skin or nails.  The sonographer was asked 
to scan the same finger on each hand without being aware which the target 
finger was.  Data on inter-observer reliability between the sonographers is 
described in chapter four (Ash et al. 2012b). 
 
8.2.5 Statistical analysis 
Results are presented as mean (SD) or median (range) depending on the 
distribution.  Categorical data are expressed as frequencies.  P values were 
not calculated due to the small sample size. 
 
8.3 Results 
8.3.1 Demographic data 
Nine patients were recruited, with a mean patient age of 39, 7/9 patients 
were male.  The mean duration of skin psoriasis was 19 years.  Seven 
patients had co-existent PsA, of whom all had both tenderness and swelling 
of the target finger DIP joint at baseline. 
 




All patients had previously failed disease modifying therapies, as per the 
National Institute for health and Care Excellence (NICE) guidelines.  TNF 
inhibitor prescription was made according to NICE guidelines and according 
to the choice of the treating physician.  Five patients received etanercept 
(50mg once a week) and four patients adalimumab (40mg once a fortnight), 
administered subcutaneously. One psoriasis patient was withdrawn at five 
months due to skin non-response and was not able to attend for a repeat 
MRI scan.  The results are presented here for the eight patients who 
completed the study. 
 
8.3.3 Clinical data 
Marked improvements were seen in clinical parameters (Table 18). At six 
months, no patients had residual clinical swelling in the target finger DIP joint 
and only one had persistent tenderness.  Onycholysis and pitting were the 
most frequent abnormalities seen in the target nail at baseline (in seven and 
five patients respectively).  The majority of patients had more than one type 
of nail abnormality.  Three of the eight patients had completely normal nails 
in the target finger at six months.  There was no difference in clinical nail 
clearance between nail matrix features (pitting or nail bed crumbling) 
compared to nail bed abnormalities (onycholysis, splinter haemorrhages or 
nail bed hyperkeratosis).  Onycholysis resolved in 4/7 patients and pitting 
resolved in 3/5 patients.  The median visual analogue score for nail pain 
reduced from 15/100mm to 0/100mm when excluding one patient whose 
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Table 18.  Clinical and laboratory assessments.   
Arthritis outcome measures reported for PsA patients only. 
 Baseline Six months 
PASI  
Median (range) (n=8) 
3 (0.2 – 22.2) 0.4 (0 – 1.9) 
Swollen joint count 
Mean (SD) (n=7) 
11 (6) 1 (1) 
Tender joint count 
Mean (SD) (n=7) 
12 (7) 1 (1) 
SPARCC enthesitis index  
Mean (SD) (n=7) 
3.4 (2) 0.4 (1) 
mNAPSI 
Mean (SD) (n=8) 
26 (15) 9 (6) 
mNAPSI in the target finger   
Median (range) (n=8) 
3 (2-5) 1 (0-2) 
Visual analogue score for nail 
pain  
Median (range) (n=8) 
15 (0-60) 0.5 (0-46) 
Visual analogue score for 
global disease activity 
Mean (SD) (n=8) 
60 (19) 7 (9) 
DLQI 
Median (range) (n=8) 
3.5 (1-29) 0 (0-3) 
C-reactive protein (mg/L) 
Median (range) (n=8) 
<5 in 3/8 patients 
7.1 (6.4-46) in 
remaining patients 
<5 in 7/8 
patients   
5.4 in remaining 
patient 




8.3.4 Magnetic resonance imaging appearances 
Baseline MRI scans showed evidence of DIP enthesitis, BMO or synovitis in 
all PsA patients (86%, 71% and 100% respectively).  Collateral ligament 
enthesopathy was seen in 86%, flexor tendon enthesopathy in 71% and 
extensor tendon enthesopathy in 86%.  The psoriasis patient had a normal 
MRI scan at both timepoints.   The three patients with purely nail bed 
features of nail disease at baseline also had marked underlying BMO, 
synovitis and enthesitis on the baseline MRI. 
Follow-up MRI scans surprisingly showed persistent inflammatory changes 
in the DIP joint, distal phalanx and the soft tissues around the nail. (Figure 
18 and Table 19).  No patient with baseline BMO showed complete 
resolution of this, and four of the five had no change in BMO score.  All 
seven PsA patients had synovitis at baseline; this resolved in two, improved 
in one, was unchanged in three and worsened in one patient.  High signal at 
the flexor tendon insertion was present in 5/7 patients at baseline and 2/7 
patients at six months.  No patient had complete resolution of extensor 
tendon abnormalities; BMO at the insertion resolved in two patients but was 
present ‘de novo’ in another at six months, peri-tendinous enhancement was 
present in 4/7 at baseline and resolved in two.  Extensor tendon thickening 
as expected persisted in all patients in whom it was seen at baseline.  
Collateral ligament abnormalities were largely unchanged, although BMO at 
the proximal insertions resolved more frequently than at the distal insertions 
(5/6 sites resolved compared to 1/8 sites respectively). 
No relationship was seen between the MRI changes and the clinical 
response to treatment, either in terms of the overall TJC, SJC, mNAPSI, 
PASI or the nail disease clearance in the target finger.  
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Figure 18.  Nail photographs and MRI scans of a patient with PsA.   
Improvements in the nail appearances are seen on the photograph. Vaseline 
(asterix) is seen overlying the nail on the MRI.  At baseline, a large 
enthesophyte (periosteal new bone formation at the insertion) is seen 
at the extensor tendon enthesis (white arrow) with diffuse bone marrow 
changes (black arrow).  After six months treatment with etanercept, 
persistent bone marrow changes are seen (black arrow), with a greater 
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Table 19: MRI changes at baseline and follow-up for each individual patient. 
 
 Age  Diagnosis  
Baseline → follow-up 
 Comment BMO score  
(0 – 3)  
Synovitis score  
(0 – 2)  
26  PsA  0 → 0  1 → 0  No enthesitis.  Synovitis resolved at F/U  
49  PsA  2 → 2  2 → 2  Marked changes on both scans but overall felt to have improved.  
38  PsA  3 → 3  1 → 2  Effusion resolved but more synovitis at F/U.  Severe BMO on both scans  
40  PsA  2 → 1  2 → 0  BMO improved but still present.  Flexor tendon changes and synovitis resolved  
22  Psoriasis  0 → 0  0 → 0  Normal scans  
47  PsA  0 → 0  1 → 1  Persistent enthesopathy collateral ligaments and extensor tendon  
54  PsA  2 → 2  2 → 2  Overall improvement on F/U scan despite persistent BMO  
30  PsA  1 → 1  2 → 1  Marked improvement in collateral ligaments  
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8.3.5 Dynamic contrast-enhanced magnetic resonance imaging 
findings 
Baseline and follow-up images suitable for analysis were available for only 
four PsA patients.  The ROIs prior to, and following treatment, were 
analysed. ME values for all four patients were lower post-treatment, whilst 
IRE decreased for 3/4 patients (Figure 17D-E).  These trends suggest that 
anti-TNF was associated with a diminution in interstitial oedema (~ME) and 
vascular permeability (~IRE) in the nail bed.  IRE, in particular, has 
previously been shown to correlate with the degree of angiogenesis 
(Radjenovic et al. 2008).  
 
8.3.6 Ultrasound appearances 
A reduction was seen in overall ultrasound scores for peripheral 
enthesopathy with improvements, but not normalisation, of both 
inflammation and chronic change scores (Table 20).   
The normal trilaminar appearance of the nail was absent in 5/8 patients at 
baseline, of whom four patients had recovered a trilaminar appearance at 
follow-up (Figure 19).  Pitting was seen on ultrasound in 2/8 patients at 
baseline and had resolved in one at follow-up, but one other patient with no 
pitting at baseline had pitting seen on the follow-up scan.  Nail bed 
vascularity scores (graded 0-3 where higher values are thought to be 
normal) increased between baseline and follow-up in 5/8 patients, were 
stable in two patients and reduced in the other.  Power Doppler synovitis of 
the DIP joint was seen in only one patient at baseline, and had resolved on 
the follow-up scan.  Extensor tendon thickening was seen in 5/7 (71%) 
patients at baseline (not reported in one patient) and in 4/8 (50%) patients at 
six months.  
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Table 20.  Peripheral entheseal ultrasound assessment scores 
 Baseline Six months 
Total ultrasound peripheral enthesopathy score 27.1 21.6 
Inflammation score related to power Doppler changes 1.1 0.1 
Chronic enthesopathy score 11.6 9.4 
 
Figure 19.  Ultrasound appearances of the nail at baseline and after six months treatment with a TNF inhibitor 
These show loss of the normal trilaminar appearance of the nail plate at baseline(arrows) with recovery of the trilaminar appearance 
at six months. 
 




Previous imaging studies have shown conflicting data regarding the 
resolution of inflammation with TNF inhibitors.  In RA patients in remission 
on treatment, ultrasound has shown persistent subclinical synovitis (Saleem 
et al. 2009).  In PsA, some studies have shown significant improvements or 
complete resolution of BMO with TNF inhibitors (Antoni et al. 2002; Bongartz 
et al. 2005; Marzo-Ortega et al. 2007a).  In contrast, other studies have seen 
persistent BMO and synovitis after six months (Anandarajah et al. 2008; 
Anandarajah et al. 2010).  One report described a patient with greater 
reductions in BMO volume at 18 months compared to six months 
(Anandarajah et al. 2008).  In scoring the peripheral entheseal ultrasound 
scans, we divided findings into those related to inflammation and those due 
to chronic damage.  This categorisation was affirmed by a recent study 
finding reductions in PD, bursitis and morphologic abnormality 
(hypoechogenicity and thickening) scores with TNF inhibitor treatment, but 
an increase in the calcific deposit and cortical abnormality scores (Naredo et 
al. 2010). 
These data are limited by the small numbers of patients and, similar to other 
studies, the short duration of follow-up.  Perhaps if the imaging had been 
repeated after a longer duration of treatment, a greater suppression of 
inflammation may have been seen.  The persistent inflammation seen could 
relate to the high sensitivity of the imaging techniques used, although a 
previous high resolution MRI study of the DIP described minimal findings in 
healthy controls (Tan et al. 2005).  Given the age of the patients and the 
disease duration, some of the persistent MRI changes may also relate to 
damage.  In order to study the soft tissues around the DIP joint in detail, the 
scoring system previously used by Tan and Grainger was chosen in place of 
the PsAMRIS.   
In conclusion, this pilot study assessing response to TNF inhibitors in 
psoriatic nail disease demonstrated persistent subclinical musculoskeletal 
inflammation on MRI despite good clinical response.  The next step would 
be repeated imaging of a larger cohort of PsA patients with a longer duration 
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of follow-up, to demonstrate both the natural history of inflammatory lesions 
and whether they do indeed improve with more prolonged treatment.




An assessment of high resolution magnetic resonance 
imaging of distal interphalangeal joint psoriatic arthritis for 
predicting radiographic joint destruction at nine years 
 
9.1 Introduction 
Psoriatic arthritis encompasses a diverse spectrum of phenotypes and 
manifestations.  Pathological skeletal changes include joint ankylosis, 
periostitis, bone sclerosis and entheseal new bone formation, all of which 
can lead to disability.  In the small joints of the hands and feet, PsA can also 
be associated with the propensity for severe osteolysis and progressive 
shortening of the digits, termed arthritis mutilans.  Arthritis mutilans is one of 
the rarer subtypes of PsA, occurring in 2 – 5% of PsA patients (Torre Alonso 
et al. 1991; Jones et al. 1994; Veale et al. 1994).  Whilst rare, it may cause 
major disability and thus identification of patients with arthritis mutilans at an 
early stage would be desirable in order to facilitate treatment.  
Preliminary MRI studies have shown bone marrow oedema (BMO) (which 
histologically represents an osteitis (Bollow et al. 2000)) in patients with 
arthritis mutilans as well as other PsA subtypes (Tan et al. 2006a) (Tan et al. 
2009).  High resolution MRI has been used to explore the microanatomical 
basis for distal interphalangeal joint (DIPJ) PsA in subjects with recent onset 
symptoms (Tan et al. 2006a).  Many of these patients had MRI-determined 
BMO.  This study asked the question as to whether such baseline changes 
were associated with the evolution of destructive or disabling arthropathy at 
a mean follow-up duration of nine years. 
9.2 Methods 
The 43 patients (23 PsA as well as 10 OA and 10 healthy controls) who had 
participated in two previous studies (Tan et al. 2006a)(other cohort 
unpublished) were invited to return for a single study visit.  The study was 
approved by the local ethics committee and all patients gave written 
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consent.  Data were collected on the current diagnosis and current treatment 
as well as treatment since the previous study.  Entry to the previous studies 
required clinician-diagnosed PsA or OA.   
 
9.2.1 Clinical assessment 
A full clinical assessment was performed, including a 78/76 tender and 
swollen joint count, an assessment for dactylitis and enthesitis (Leeds and 
SPARCCC enthesitis indices).  Psoriasis was assessed using the BSA and 
PASI and nail disease using the mNAPSI.  Inflammatory markers were 
measured (ESR and CRP).  High resolution photographs were taken of the 
finger nails.  Patients also completed questionnaires including visual 
analogue scales (VAS) for global disease activity, joint and skin disease 
activity and a measure of physical functioning (HAQ).  For the healthy 
controls, in the absence of any symptoms of arthritis, only demographic data 
was collected and a radiograph performed. 
 
9.2.2 Imaging assessment and analysis 
One AP radiograph was taken on all patients, to include both hands.  This 
was scored independently by two rheumatologists with an interest in the 
imaging of psoriatic arthritis, who were blinded to the clinical data and 
diagnosis.  Features consistent with PsA were scored using the PsA van der 
Heijde modified Sharp score (van der Heijde et al. 2005).  This gave a 
maximum possible score for the DIPJ of 9.  Features consistent with 
osteoarthritis were scored using the Kellgren-Lawrence Grading Scale 
(Kellgren et al. 1957).  The likely diagnosis was also recorded based on the 
radiographic abnormalities.  Where substantive disagreement was seen 
between raters, these radiographs were re-scored by consensus. 
The MRI scans performed as part of the previous studies were high 
resolution 1.5 Tesla MRI scans of one target finger.  The details of the 
sequences have been previously reported (Tan et al. 2006a).  The MRI 
scans were re-scored separately by two rheumatologists.  The middle and 
distal phalanx were each divided into four quadrants and each quadrant was 
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scored on a semi-quantitative basis (0 – 3) for BMO.  In the same quadrants, 
soft tissue inflammation was also scored from 0 – 3.  As baseline 
radiographs were not available for the majority of patients, evidence of joint 
damage at baseline was scored from the T1 MRI sequences, recording 
features as per the radiographic scoring system (erosions, joint space 
narrowing, gross osteolysis and ankylosis). 
 
9.2.3 Statistical analysis 
 
To calculate the agreement between the raters for the MRI scoring, 
intraclass correlation coefficients were calculated for the various features 
using SPSS version 19.  To calculate agreement for the radiographic 
scoring, category-specific proportions of agreement were calculated, in 
addition to quadratic-weighted, prevalence-adjusted, bias-adjusted Kappa 
(PABAK) given the non-normal distribution.  This was performed using 
WinPEPI. Bivariate analysis with Spearman’s correlation was used to 
correlate the baseline BMO scores with the follow-up radiographic scores.  
For this, the mean of the two raters scores was used. 
9.3 Results 
9.3.1 Demographic data 
Of the original 43 patients, 18 (42%) responded to the invitation and were 
recruited to the study; 11/23 (48%) with PsA, 4/10 (40%) with OA and 3/10 
(30%) of the healthy controls (HC).  One patient originally labelled as PsA 
would currently be classified instead as peripheral SpA (no history of 
psoriasis).  This patient has been included in the PsA group for the purposes 
of analysis. 
For one PsA patient, all imaging (baseline MRI as well as baseline and 
follow-up radiographs) showed severe damage.  Given the severe damage 
at baseline and difficulties in scoring the imaging due to multiple deformities, 
this patient has been removed from analysis and thus results for 10 PsA 
patients are presented henceforth.  
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The mean ages were 53 (PsA), 69 (OA) and 41 (HC).  Of the PsA patients, 
70% were male compared to none of the OA patients and 67% of the HC.  
The mean time elapsed since the baseline MRI scan was 9 years. 
For the original MRI, in 10/17 patients the index finger was scanned, in 4/17 
the middle finger was used and in 3/17 the ring finger was selected.  The 
joint scanned was selected on the basis of active arthritis with a recent onset 
of symptoms. 
 
9.3.2 Clinical data 
All of the PsA (but not the SpA) patients fulfilled the CASPAR criteria (Taylor 
et al. 2006).  8/10 (80%) PsA patients had current psoriatic nail disease.   
At the time of the visit, 7/10 (70%) of the PsA patients were taking a TNF 
inhibitor, 1/10 was taking NSAIDs and two were not receiving treatment for 
the arthritis due to inactive disease.  Three of the OA patients were on no 
relevant medications, one was taking NSAIDs. 
Prior treatment for the PsA patients had included DMARDs in 7/10 (70%), 
steroids in 2/10 (20%) and one each had been on a prior TNF inhibitor, 
NSAIDs or acitretin.  One of the OA patients had previously tried 
sulphasalazine and one had received steroids. 
For clinical features, laboratory results and patient reported outcomes see 
Table 21.  The PsA patients generally had fairly inactive disease, which is 
likely to relate to the high percentage on TNF inhibitors.  A high number of 
clinically damaged joints was seen, in keeping with the long disease 
duration. 
Of the 10 PsA patients, two patients had arthritis mutilans clinically (only one 
in the joint that was scanned originally).  One had complete bony ankylosis 
and one a flail joint in the joint scanned. 
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Tender joint count 0 (0-5) 1.5 (0-5) 
Swollen joint count 0 (0-11) 1.5 (0-2) 
Damaged joint count * 5 (1-13) 12 (1-21) 
SPARCC enthesitis count 0 (0-4) 0 (0) 
Leeds enthesitis count 0 (0-3) 0 (0) 
Number of patients with dactylitis 4 / 10 0 / 4 
Duration of early morning 
stiffness, mins 
0 (0-30) 30 (0-30) 
PASI 1.2 (0-4.2) NC 
mNAPSI 8 (0-14) NC 
CRP (mg/L) <5 in 8/10 
Mean 14 in other two 
<5 in all 
ESR (mm/hour) 6 (2-43) 7 (6-18) 
VAS global 18.5 (0-68) NC 
VAS skin 3 (0-76) NC 
VAS joints 3 (0-92) 76 (10-100) 
HAQ 0.31 (0-2) 0.5 (0.5 – 
0.75) 
All presented as median (range).  * damaged joints = bony swelling or 
deformity, ankylosis or arthritis mutilans.  NC:  not completed. 
 
9.3.3 Imaging agreement 
The ICC between the two raters for BMO scores was 0.65 (95% CI 0.27-
0.85).  For the soft tissue score the ICC was 0.65 (0.28-0.86). 
Category-specific proportions of agreement for the radiographic scores were 
82%, 71% and 59% for the erosion, joint space narrowing (JSN) and total 
scores respectively.  Agreement analysis with PABAK for the weighted 
Kappa gave scores of 0.85, 0.94 and 0.92 for the erosion, JSN and total 
scores, respectively. 
- 195 - 
 
 
For the scoring of damage from the baseline MRI scans, category-specific 
proportions of agreement were 76%, 59% and 53% for the erosion, JSN and 
total scores, respectively.  PABAK for the weighted Kappa values were 0.89, 
0.69 and 0.87 respectively. 
 
9.3.4 Magnetic resonance imaging findings 
On the baseline MRI scans, all PsA and OA patients had both BMO and soft 
tissue inflammation.  Virtually all of the PsA patients had diffuse BMO that 
involved the distal phalanx sometimes in its entirety.  BMO scores were 
higher in the PsA and OA patients than in the HC, as expected (Table 22).  
A greater degree of soft tissue inflammation was seen in PsA than in either 
OA or the HC.  Some mild changes (soft tissue or BMO) were seen in all the 
HC, suggesting that the imaging scoring may be a little too sensitive. 
 
Table 22.   Mean MRI scores for BMO and soft tissue inflammation 
 PsA OA HC 
BMO score 
Mean (SD) 




14 (4) 6 (3) 4 (3) 
 
There was relatively little evidence of damage in the PsA patients on the 
baseline MRI scans.  Seven out of 10 were either normal or had minimal 
JSN only, one had both erosions and JSN (this patient progressed into 
clinical arthritis mutilans at the time of follow-up), two had moderate to 
severe JSN. 
Baseline MRI scans for the healthy controls showed no damage.  For the OA 
patients, all had both erosions and joint space narrowing seen on the 
baseline MRI scans. 
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9.3.5 Radiographic findings 
Four PsA patients had baseline radiographs available for comparison, 
although this was not included as part of the original studies.  Two were 
normal, one showed minimal joint space narrowing and one showed joint 
space narrowing, erosions and new bone formation. 
On the radiographs taken as part of the current study on PsA patients, two 
patients had complete DIPJ ankylosis.  One out of 10 patients had DIPJ 
erosions and 8/10 had joint space narrowing.  No patients had complete 
erosion both sides of the joint (as per the Marsal definition of arthritis 
mutilans (Marsal et al. 1999)).  One PsA patient had completely normal 
radiographs.  One had normal films apart from some terminal tuft new bone 
formation.   
The radiographs for the OA patients all showed either grade 3 or grade 4 
changes on the Kellgren-Lawrence score.  The scorers were able to identify 
correctly the features as consistent with OA in all cases.  The radiographs 
for the healthy controls were entirely normal in two and showed minimal joint 
space narrowing in one slightly older subject. 
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Figure 20.  Examples of different radiographic findings 
Digital shortening can be seen with folds of redundant skin (black 
arrow).  Example images presented here may not be the joint that was 
scanned as part of the MRI study. 
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9.3.6 Association between bone marrow oedema and arthritis 
mutilans 
The three patients with clinical arthritis mutilans, flail joint or ankylosis in the 
joint scanned all had severely abnormal current radiographs (Table 23). 
 
Table 23.  Imaging results for patients with severe radiographic 
abnormalities 
 PsA with arthritis mutilans, flail 







BMO score at baseline 
Mean (SD) 
17.8 (1) 12.1 (6) 
MRI erosion score at 
baseline 
Mean (SD) 
1 (2) 0 (0) 
MRI JSN score at 
baseline 
Mean (SD) 
0.7 (1) 0.8 (1) 
Total radiographic 
score at follow-up 
Mean (SD) 
3.7 (1) 1.4 (1) 
 
A moderate degree of correlation was seen between the baseline BMO 
score and the follow-up total radiographic score in PsA patients; correlation 
co-efficient 0.519 (p=0.125) (Figure 21) 
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Figure 21.  Correlation of baseline BMO score and follow-up radiographic 
score for PsA patients 
Note that one patient is excluded as detailed in the results, section 9.3.1. 
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Table 24.  Radiographic findings for the PsA patients 
Age Baseline x-ray 
features (where 
available) 
Baseline MRI * Current PsA 
treatment 


































43 - 2 16 0 0 Etanercept 3 years Normal Minimal JSN 




60 Normal 11 7.5 0 0 Etanercept 7 years Normal Normal 
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Age Baseline x-ray 
features (where 
available) 
Baseline MRI * Current PsA 
treatment 

















36 - 19 16 0 0.5 Etanercept 7 years Ankylosis Ankylosis 
44 Normal 13 15 0 0 Indomethacin 
Had one year 
of etanercept,  
2 years after 
MRI 
Normal Normal 
55 - 16.5 18 0 0 Adalimumab 7 years  Flail joint Ankylosis 
*For the baseline MRI mean scores for the two raters are given.  




This is the first long-term follow-up of PsA DIP joint cases with a baseline 
MRI scan available.  These findings did not show a definite link between 
baseline bone oedema status and subsequent joint damage.  This may be 
due to the fact that all the cases had bone oedema at baseline.  It was not 
possible to follow the progress of a single BMO lesion due to the diffuse 
nature of the BMO seen at baseline.   
A high proportion of the patients were receiving treatment with a TNF 
inhibitor at the time of follow-up.  Bone oedema has been shown to resolve 
rapidly with TNF inhibitor treatment (Bongartz et al. 2005) and in PsA TNF 
inhibitors are known to be potent suppressors of radiographic progression.  
It was interesting to note that baseline bone oedema was associated with a 
disparate group of radiographic outcomes nine years later which included 
both osteolysis and new bone formation.  Joint space narrowing was the 
most common feature overall, which may relate to secondary osteoarthritis 
due to the time since the previous imaging and the age of the study 
participants. 
A significant limitation of this study is the low recruitment rate and small 
number of patients.  The follow-on study was not planned at the outset and 
therefore patients were not expecting to be recalled.  Recruitment may also 
have been limited by the fact that some patients from the original cohorts 
were recruited and seen at a rural hospital 23 miles away from the inner city 
hospital where the follow-up visits took place and thus patients may not have 
been keen to travel for the study visit.  Some time had also elapsed and thus 
patients may have been limited by health problems or infirmity. 
In an ideal setting, this study would have a much larger number of 
participants with complete follow-up data available.  A treatment-naive 
population would be studied in order to not influence the radiographic 
progression.  Furthermore, interval data on clinical course in terms of 
episodes of swelling would be recorded as this is known to predict damage. 
On balance these preliminary findings do not support the use of MRI in 
prognostication as the outcomes were variable in the presence of severe 
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baseline bone oedema.  This may have been due to the efficacy of treatment 
but this is not something that can be addressed, as it would be unethical to 
withhold treatment from subjects with early arthritis purely to define the 
disease natural history.  Despite the fact that patients were treated there was 
still a surprising degree of radiographic progression in this small cohort. 
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Figure 22.  Both ankylosis (*) and osteolysis (arrows) in the same PsA 
patient 
  




Discussion and future directions 
 
In a time of evolving new biologic treatments targeting different parts of the 
immune system, an understanding of the underlying pathogenesis of a 
disease as varied as PsA is vital.  This enables physicians to target 
treatments appropriately both in terms of predictors of disease severity but 
also for different disease subtypes. 
The work in this thesis expands on and proceeds from previous work 
performed in Leeds, focussing on the role of enthesitis in the pathogenesis 
of psoriatic nail disease. 
 
10.1 Enthesitis in psoriasis patients 
It has been known for some time that nail disease is more common in PsA 
than in psoriasis, and that in fact nail disease predicts the future 
development of PsA amongst psoriasis patients (Wilson et al. 2009a).  The 
results in chapter 4 show that psoriasis patients with nail disease do have a 
greater degree of enthesitis at the peripheral entheses than psoriasis 
patients with normal nails.  These results suggest that nail disease may be a 
clinical marker for underlying subclinical musculoskeletal inflammation, and 
may henceforth explain why it is a predictor for PsA development.  Following 
on from here, it raises the question as to whether the presence of nail 
disease may be used to sub-select a population at higher risk of developing 
PsA, and the use of ultrasound in this cohort may again allow a greater 
predictive value.  Preliminary data from a group in Italy does suggest that a 
higher GUESS score in psoriasis patients predicts the development of PsA, 
but this requires further study in a larger cohort for confirmation (Tinazzi et 
al. 2011).  
Our findings also echo those of other groups, finding that minor entheseal 
abnormalities are common even in healthy controls, and one of the key 
challenges of ongoing research in this field is to differentiate between 
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‘normal’ findings and those which are truly pathological, without reducing the 
sensitivity excessively. 
Even then, some of these chronic findings were more common in psoriasis 
patients than healthy controls, suggesting that even asymptomatic psoriasis 
patients without arthritis may have aberrant healing responses to mechanical 
stress at the entheses. 
As an alternative approach, a number of screening questionnaires have 
been developed for the identification of undiagnosed PsA amongst psoriasis 
patients.  The CONTEST study has now compared three of these in a head 
to head study; PEST, PASE and ToPAS (Coates et al. 2013).  The 
sensitivity and specificity for each questionnaire was lower than in their 
original validation studies.  Each questionnaire gave a sensitivity of around 
75%, but with a specificity of 30 – 39%.  The low specificity reflects a high 
number of ‘false positive’ results with the questionnaires, largely due to 
osteoarthritis. 
A separate study assessed the same screening questionnaires again in a 
secondary care population but with some differences in study design 
(Haroon et al. 2013).  Contrasting results were found, with all questionnaires 
showing a low sensitivity (24 – 41%) and a high specificity (90 – 98%).  It 
was notable that the screening questionnaires performed better in identifying 
polyarticular PsA than axial, oligoarticular or entheseal disease.  These 
questionnaires therefore may be useful in helping dermatologists identify 
patients who may have PsA in order to refer for rheumatological 
assessment.  However, their use will be limited by the lower sensitivity in 
non-polyarticular PsA and the low specificity, meaning that they will identify a 
number of patients with other musculoskeletal conditions such as OA. 
 
10.2 Differences in enthesitis between psoriatic arthritis and 
psoriasis patients 
In chapter 5 differences between the enthesitis in PsA and in psoriasis are 
described.  The presence of power Doppler was much more frequent in PsA 
than psoriasis, as were other inflammatory features of enthesopathy 
(hypoechogenicity, entheseal thickening and bursal enlargement).  This 
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suggests that the nature of enthesopathy may differ between psoriasis and 
PsA. 
In our study, PD signal at the enthesis was seen in 9.5% psoriasis patients 
but not in the control subjects.  In keeping with this, in a study recently 
published by Naredo et al. (Naredo et al. 2011), PD was seen in or around 
the enthesis in 11% psoriasis patients and no healthy controls.  The authors 
analysed demographic and clinical factors between those psoriasis patients 
with and without entheseal PD signal and found a higher mean age in those 
with PD but no difference in the severity of the psoriasis or other 
demographic or clinical factors.  A further study in 45 psoriasis patients and 
45 healthy controls also found no PD signal in healthy controls, but found PD 
in 0.9% of the entheses assessed (Gutierrez et al. 2011a).  
This raises the question as to whether when assessing the predictive value 
of entheseal ultrasound in psoriasis patients, some features may be of more 
value (such as power Doppler) while other findings (such as enthesophytes 
and calcifications) may lack specificity.  Thus it may better to use certain 
features in place of a total score.  Another factor to bear in mind is that 
entheseal ultrasound scores have been shown to be higher in males than 
females and therefore a single cut-off score would not be appropriate for 
both groups (de Miguel et al. 2011b). 
 
10.3 Imaging of the nail and distal interphalangeal joint in 
psoriasis patients 
With MRI in chapter 6 we were able to reproduce the relationship previously 
seen between nail disease and extensor tendon enthesitis in PsA patients.  
However, we were not able to demonstrate an association between DIPJ 
enthesopathy and nail disease in psoriasis patients.  Subtle evidence of 
inflammation was seen, but not frequently, and without any real relationship 
with nail disease.  The data also suggest that there may be a relationship 
also between flexor tendon inflammation and nail disease in PsA, which is 
plausible as fibres from the flexor tendon do wrap around the distal phalanx 
to anchor in the vicinity of the nail bed.  A recent study using positron 
emission tomography (PET) found diffusely increased update in the distal 
- 208 - 
 
 
phalanx in PsA patients, but with particular uptake noted at the entheses, 
periosteum and tufts (Tan et al. 2013).  This fits with previous research 
showing that fibres from the extensor and flexor tendons merge with the 
periosteum (Tan et al. 2007).  This relationship bears further study.  Using 
the high resolution finger coil, good images of psoriatic nail disease were 
obtained, also demonstrating thickening of the nail bed in some patients with 
severe nail disease. 
Using ultrasound in chapter 7 however, a relationship between nail disease 
and extensor tendon thickening was demonstrated in psoriasis patients.  The 
resolution of the ultrasound probe was higher than with the MRI scan and 
thus it may be that the MRI is not sufficiently sensitive to detect the subtle 
inflammation seen in psoriasis patients.  High resolution ultrasound is able to 
assess entheseal fibrocartilage, which is only 0.5mm thick, while the slice 
thicknesses for the MRI scans used in the study were 1.3 – 1.5mm, with a 
resolution of 512x358 pixels on the sagittal images. 
The results also show that ultrasound is a feasible alternative way to assess 
psoriatic nail disease, being able to demonstrate a number of features 
including pitting, nail bed hyperkeratosis and nail thickening.  The finding of 
thickening of the overlying dermis and epidermis in subjects with extensor 
tendon enthesopathy was not expected.  Further study of this may be better 
performed using OCT, where objective measurements of nail thickness are 
possible, including responsiveness to change (Sattler et al. 2012).  Our 
group has also recently reported a case of psoriatic nail disease assessed 
using OCT (Aydin et al. 2011).  The OCT gives a far higher resolution than 
ultrasound and thus the ability to study abnormalities within and beneath the 
nail plate as well as measuring the skin thickness accurately. 
Looking at PsA-related nail disease, a study has been reported on 34 
patients with PsA (Dalbeth et al. 2012).  All underwent a baseline clinical 
assessment and MRI examination of the dominant wrist and fingers.  At 
baseline, an association was seen between onycholysis and hyperkeratosis 
and MRI evidence of bone erosion and proliferation.  One year later, twenty 
patients had a repeat clinical assessment.  The study found that nails which 
developed hyperkeratosis or onycholysis by the time of follow-up were more 
likely to have had bone marrow oedema on the baseline MRI.  This is 
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counter to what would be expected, as both of these features are 
traditionally thought to be nail bed related, most likely due to psoriatic 
plaques under the nail.  The numbers are small, with only four nails 
developing each feature.  The study does support the idea of underlying 
musculoskeletal inflammation being important in the pathogenesis of 
psoriatic nail disease, but is limited by the small numbers. 
 
10.4 Response of nail disease and underlying 
musculoskeletal inflammation to biologic therapies 
The efficacy of TNF inhibitors in treating psoriasis, psoriatic arthritis and 
associated nail disease is already proven.  The study described in chapter 8 
aimed to assess instead the underlying DIPJ bone and soft tissue changes 
in patients undergoing such treatment.  The results are limited by the small 
numbers, but the presence of persistent imaging-detected inflammation at 
both the entheses and the joint after six months treatment is surprising in the 
context of good clinical response. 
These results are however similar to a recent study assessing the response 
to adalimumab in PsA patients using MRI scanning of a symptomatic wrist or 
knee (Anandarajah et al. 2010).  Baseline and follow-up scans were 
available for 11 patients.  The BMO and joint effusion scores showed 
marked improvements, but the joint erosion score increased during 
treatment.  Persistent BMO was seen in the majority of patients after six 
months treatment and the overall synovitis score did not change.  Does this 
persistent imaging evidence of inflammation matter?  This remains to be 
seen, in view of the fact that TNF inhibitors are known to inhibit radiographic 
progression effectively.  It may be that the imaging response lags behind 
clinical response and will resolve fully with further time on treatment. 
Dynamic contrast-enhanced MRI is an emerging technique for the 
assessment of vascularity in tissues.  As this was incorporated into the study 
only partway through, results were available for only four patients but these 
do show some promise and suggest that it may be a useful technique for 
assessing angiogenesis in these areas. 
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The findings in the peripheral entheses seen with ultrasound also show 
persistence.  Unsurprisingly the inflammation score improves more than the 
chronic enthesopathy score, which would not be expected to improve as 
much with treatment (Naredo et al. 2010).  In contrast, a recent longitudinal 
study in early SpA found that a number of erosions at the Achilles enthesis 
had disappeared by the time of follow-up ultrasound scans (de Miguel et al. 
2011a), suggesting that these are not necessarily permanent structural 
lesions.  One possibility raised by the authors is that new bone formation 
occurs with time, and this may be responsible for the resolution of the 
erosions. 
We found an increase in nail bed vascularity during treatment and with an 
improvement in clinical nail disease.  Using the nailfold resistance index to 
study the vascularity of the proximal third of the nailbed, it has recently been 
suggested that psoriatic nail disease is associated with a pathologically 
decreased blood flow in the nail bed (Husein El-Ahmed et al. 2012).  The 
authors postulate that this may relate to endothelial cell dysfunction.  This 
then might be expected to improve with treatment, as the results in chapter 8 
suggest.  This may therefore have significant implications for microvascular 
disease elsewhere, which is important in patients who are known to be at 
increased risk of accelerated vascular disease. 
10.5 Long term outcomes of distal interphalangeal joint bone 
marrow oedema in psoriatic arthritis 
In the long-term follow-up of two cohorts of PsA patients with DIPJ arthritis 
(chapter 9), a high proportion of these patients with BMO at baseline were 
on TNF inhibitors at follow-up.  This clearly influences radiographic 
progression, but despite this the majority of patients had joint space loss and 
some had developed arthritis mutilans or ankylosis in one or more digits.  
This is a limitation of observational studies in that many other confounding 
factors may alter the findings.  It is still unknown as to why new bone 
formation occurs in one joint while osteolysis occurs in another within the 
same patient.   
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Given the efficacy of TNF inhibitors, these are likely to be given more readily 
by clinicians to patients with severe disease and the prevalence of arthritis 
mutilans may well reduce over the next ten years. 
 
10.6 Future directions 
One of the most important questions is the predictive value of subclinical 
ultrasound enthesitis in the later development of PsA.   If this can be 
established, then the next stages are to consider whether screening should 
be performed and whether treatment is indicated at this stage.  This echoes  
ongoing research in RA, where family and population studies show that 
patients with a positive ACPA (anti-citrullinated protein antibody) can be 
identified at a pre-clinical stage.  In RA, early treatment may be beneficial 
both for preventing structural damage and as there is a far greater chance of 
achieving remission (Emery et al. 2012). 
Larger studies with a longer duration of follow-up are needed to perform 
ultrasound scans on asymptomatic psoriasis patients without arthritis, to 
clarify whether ultrasound evidence of enthesopathy does predict the later 
development of arthritis, and if it does, to identify any other predictive 
features and to develop a model with the best predictive value.  The patients 
in our study most frequently had plaque psoriasis (the most common 
phenotype) but it would also be important to establish whether subclinical 
enthesopathy is also seen to the same degree in palmar-plantar, flexural, 
guttate and pustular psoriasis.  The location of psoriatic plaques may also be 
relevant, as suggested by the article by Wilson et al. finding an increased 
risk with scalp and inter-gluteal psoriasis (Wilson et al. 2009a). 
Identifying patients at risk of PsA would aid both in closer monitoring but also 
potentially in helping dermatologists choose appropriate treatments which 
help the joints as well as the skin (for example methotrexate rather than 
acitretin or UVB).  There are currently no data available on the efficacy of 
TNF inhibitors or other biological drugs in treating asymptomatic enthesitis in 
psoriasis patients but it may be that effective treatment at this stage alters 
the disease course and averts the development of arthritis.  Certainly 
treatment at an early stage may help prevent joint damage forming.  
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However, it is a fine balance between the benefits of treatment and the risks 
of screening causing psychological morbidity and the risk of unnecessary 
treatment if the predictive model does not allow accurate prediction of those 
who will develop PsA.  In the mean time, we should focus on better 
identification of psoriasis patients with undiagnosed PsA using one of the 
number of questionnaires available for this. 
The validation of ultrasound against clinical examination for the assessment 
of psoriatic nail disease opens doors for further use in studies.  However, 
clinical examination is likely to remain the main tool for use in clinical trials 
due to its better feasibility.  Ultrasound does however seem more effective at 
imaging the extensor tendon than MRI.  The research in this thesis still does 
not answer the questions as to whether DIPJ enthesopathy plays a role in 
the pathogenesis of nail disease in psoriasis patients (without arthritis).  
Ultrasound may be the best tool to further study this.  One other potential 
aspect for study is whether the different types of psoriatic nail disease are of 
different pathogenesis.  In the study in chapter 7 it was difficult to tease this 
out, largely because the majority of patients had both ‘matrix’ and ‘nail bed’ 
types of nail lesion.  A larger study recruiting patients with purely one type of 
nail lesion (only pitting or only onycholysis) may be better able to answer 
such questions, but recruitment may be difficult. 
Optical coherence tomography (OCT) is a new technique that is showing 
promise in the assessment of nail disease amongst other areas.  Using 
OCT, accurate measurements of the nail thickness may be recorded, which 
appear sensitive to change and thus may allow a more objective tool for 
future use in research (Sattler et al. 2012). 
The preliminary work done in assessing underlying musculoskeletal 
inflammation and the response of this to TNF inhibitors in patients with 
psoriatic nail disease is limited by the very small numbers.  A future study 
would need to be larger, with a more pure patient population of only patients 
with PsA.  Different drugs may also have different efficacies (as seen with 
the TNF inhibitors and their varying efficacy on skin psoriasis).  A longer 
duration of follow-up would allow evaluation for whether the persistent 
inflammation seen at six months is simply slow to resolve or whether this 
persists in the longer term. 
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Studies assessing patients with arthritis mutilans and other severe 
phenotypes are difficult due to the rarity of these patients.  Perhaps the most 
important research currently is in predictive factors for the onset of arthritis 
mutilans and in demonstrating the efficacy of treatment in these patients, in 
order to facilitate greater access to treatments for patients such as this with 
severe disease. 
 
10.7 Review of hypotheses 
Nail disease could be a marker for those psoriasis patients who have 
subclinical enthesitis elsewhere, and therefore could be a potential 
predictor for the later development of PsA. 
The results presented in chapter four show that psoriasis patients with nail 
disease do indeed have a higher median ultrasound enthesitis score than 
psoriasis patients without nail disease.  This would lend support to this 
hypothesis; that nail disease may be associated with a greater degree of 
subclinical enthesopathy.  Further prospective studies are still needed to 
fully establish the relationship between subclinical enthesitis in psoriasis 
patients and future arthritis development.  Ultrasound evidence of 
enthesopathy was very common (including in healthy controls) and one of 
the challenges for the future is therefore to assess which ultrasound findings 
may be the most predictive for future arthritis development.   
 
Nail disease is due to subclinical or clinical enthesitis around the DIP 
joint in both PsA and psoriasis. 
The relationship between nail disease and DIP joint arthritis and enthesitis in 
PsA patients was again seen in the studies presented in chapters six and 
seven.  In psoriasis patients, although subtle evidence of DIP joint 
enthesopathy was seen with MRI, no relationship was found between this 
enthesitis and the presence of nail disease.  Ultrasound scans were better 
able to visualise the extensor tendon insertion and using ultrasound, an 
association was seen between nail disease and extensor tendon thickening 
in both psoriasis and PsA.  Given that different patterns of nail disease may 
represent different pathological processes, this still requires further 
evaluation, ideally in cohorts of patients with sub-group analyses for the 
pattern of clinical nail disease. 




The improvement in nail disease seen with anti-tumour necrosis factor 
(TNF) therapy may be due to improvements in enthesitis around the 
DIP joint. 
This hypothesis was not confirmed by the results presented in chapter eight.  
Improvements in clinical nail disease were seen, along with good efficacy for 
psoriasis and arthritis clinically.  With ultrasound scans looking at 
enthesopathy at the heel, knee and elbow, residual findings were mainly the 
chronic features of enthesopathy. MRI scans of the DIP joint however 
showed persistent inflammation within the joint and surrounding entheses.  
Data from other studies support the fact that imaging evidence of 
inflammation may persist despite clinical improvement.  It is currently unclear 
whether this persistent inflammation should be a cause for concern; whether 
it may lead to more long term joint damage or is there simply a time lag 
between clinical and imaging improvement. 
 
DIP joint bone marrow oedema lesions in active PsA are predictive of 
radiographic damage in that joint at a later stage. 
This hypothesis could not be tested using the available data in chapter nine 
largely because bone marrow oedema was such a common and widespread 
feature in the baseline MRIs.  It was therefore not possible to either follow 
the progress of a single bone marrow lesion or compare joints with and joints 
without bone marrow oedema.  The majority of patients were receiving anti-
TNF agents at the time of follow-up, which have a significant effect on 
reducing radiographic progression and will have altered the results of the 
study.  Joint space narrowing was the most common feature seen at the 









This thesis aimed to provide an explanation for the predictive value of clinical 
nail disease in psoriasis for the later development of PsA.    
Limited data were found to support the concept that nail disease in psoriasis 
is due to subclinical DIPJ enthesitis.  This may relate to different nail 
phenotypes having different pathological causes. 
Nail disease does however appear to be a marker for subclinical enthesitis 
globally.  A combination of the presence of clinical nail disease and 
ultrasound scans of the entheses may offer potential for better identification 
of psoriasis patients at high risk for developing PsA. 
Nail disease clearly does respond to TNF inhibitors, but persistent 
inflammation is seen in and around the DIPJ in PsA patients, suggesting that 
imaging improvements may take longer to occur than clinical response. 
A small cohort of patients with active DIPJ arthritis with diffuse bone marrow 
oedema on a baseline MRI scan did show radiographic damage including 
joint space loss after nine years follow-up, but the assessment of this is 
complicated by confounders including treatment. 
Identifying patients with PsA at an early stage remains a challenge, but 
increasing awareness amongst dermatologists, the development of 
screening questionnaires and further validation of ultrasound in these 
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